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resumo 
 
 
O trabalho apresentado nesta tese teve como principal objetivo investigar o 
impacto da gravidez saudável e algumas doenças pré-natais no metaboloma e 
lipidoma de plasma sanguíneo materno, com vista à definição de novos 
biomarcadores para a previsão e diagnóstico não invasivos daquelas doenças. 
O Capítulo 1 descreve a perspectiva atual e os desafios das doenças pré-
natais mais relevantes, assim como a estratégia metabolómica e estado da 
arte na investigação pré-natal. Todos os detalhes experimentais do trabalho 
realizado estão descritos no Capítulo 2, incluindo as condições de 
amostragem, recolha e preparação das amostras, bem como os protocolos de 
aquisição e análise dos dados. 
No Capítulo 3 descreve-se o metaboloma e lipidoma de plasma detectados por 
RMN 1D e 2D. Neste capítulo, a utilização de espectroscopia de RMN de 
quantum-múltiplo foi explorada, pela primeira vez, para caracterização de 
misturas lipídicas complexas. 
O Capítulo 4 contribui para colmatar algumas falhas no conhecimento sobre a 
degradibilidade do plasma humano durante o manuseamento da amostra e 
armazenamento, e a importância de condições de colheita como o jejum. A 
utilização de tubos de colheita com heparina não mostrou interferência do 
polissacarídeo nos espectros conservando-se toda a informação espectral, 
enquanto que os tubos com EDTA deram origem a sinais interferentes 
provenientes do EDTA livre e complexado com Ca
2+
/Mg
2+
, cujo impacto na 
análise metabolómica é discutido. Relativamente à estabilidade do plasma à 
temperatura ambiente, foram observadas alterações nas lipoproteínas e 
compostos de colina a partir de 2.5 horas, enquanto que o armazenamento a -
20ºC mostrou ser adequado até 7 dias, sendo o armazenamento a -80ºC 
aconselhado, particularmente para períodos de tempo longos (pelo menos até 
2.5 anos). Relativamente aos ciclos de congelação-descongelação, não se 
aconselham mais de 3 ciclos consecutivos, enquanto que o efeito da colheita 
das amostras em não-jejum (em vez de jejum) foi considerado aceitável. 
O Capítulo 5 apresenta o primeiro estudo de metabolómica por RMN do 
plasma materno ao longo da gravidez, incluindo correlação entre plasma e 
urina. Algumas das alterações metabólicas observadas confirmaram efeitos 
metabólicos conhecidos, tendo outras sido observadas pela primeira vez 
sugerindo alterações no metabolismo energético, na microflora bacteriana 
(citrato, lactato e dimetil sulfona) e na taxa de filtração glomerular (creatina e 
creatinina). Os estudos de correlação revelaram aspetos metabólicos 
específicos das lipoproteínas/proteínas com impacto no metaboloma 
excretado. 
No Capítulo 6 descreve-se o impacto das doenças cromossómicas (CD), 
incluindo Trissomia 21 (T21) no metaboloma e lipidoma de plasma materno. 
  
 Obtiveram-se elevadas taxas de classificação para CD (88-89%) e T21 (85-
92%) no 1º e 2º trimestres baseadas na seleção de variáveis dos dados de 
RMN. A correlação de plasma e urina revelou novos desvios metabólicos, 
nomeadamente no metabolismo das lipoproteínas de baixa densidade e de 
muito baixa densidade (LDL+VLDL), dos açúcares e da microflora bacteriana. 
As alterações observadas no perfil de fosfolípidos do plasma, nomeadamente 
das fosfatidilcolinas, foram confirmadas e caracterizadas por  cromatografia 
liquida hidrofílica acoplada a espetrometria de massa (HILIC-LC/MS). 
No Capítulo 7 apresentam-se os resultados obtidos na prospecção de 
biomarcadores metabólicos de diabetes mellitus gestacional (GDM) pré- e pós-
diagnóstico por metabolómica de RMN de plasma materno do 2º trimestre. 
Observaram-se alterações metabólicas com poder de previsão de GDM, 
nomeadamente um aumento no colesterol, ácidos gordos, triglicerídeos e 
pequenas variações metabólicas na glucose, aminoácidos, betaína, ureia, 
creatina e metabolitos relacionados com a microflora bacteriana. O grupo de 
GDM pós-diagnóstico foi bem classificado utilizando como biomarcador um 
conjunto de 26 ressonâncias do espectro de plasma correspondendo a lípidos 
e 10 metabolitos de baixo peso molecular, sugerindo-se a possibilidade de 
usar este marcador conjunto na gestão clínica da GDM. 
O Capítulo 8 descreve os resultados obtidos para as doenças pré-natais que 
mostraram ter um menor impacto no metaboloma de plasma materno, 
nomeadamente as malformações fetais (FM), e os estados de pré-diagnóstico 
da rutura prematura das membranas (PROM), parto pré-termo (PTD) e pré-
eclampsia. 
Finalmente, no Capítulo 9 são descritas as conclusões gerais e perspetivas 
futuras no contexto desta tese, realçando-se como este trabalho contribui para 
o novo conhecimento dos mecanismos das doenças pré-natais e possíveis 
biomarcadores para a sua previsão e diagnóstico. 
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abstract 
 
The work presented in this thesis aimed to investigate the impact of healthy 
pregnancy and selected prenatal disorders on the metabolome and lipidome of 
maternal blood plasma, in order to define new potential biomarkers for non-
invasive prediction and diagnosis. 
Chapter 1 describes the present status and challenges of the clinically relevant 
prenatal disorders, along with a presentation of the metabolomics strategy 
applied and the state of the art of metabolomics in prenatal research. All 
experimental details are described in Chapter 2, comprising sample metadata, 
sample collection and preparation, data acquisition protocols and data analysis 
procedures.  
The plasma metabolome and lipidome viewed by 1D and 2D NMR experiments 
are presented in Chapter 3. In this chapter, the use of Multiple Quantum NMR 
spectroscopy was explored, for the first time, for assignment of complex lipid 
mixtures. Chapter 4 contributes to filling in some existing gaps regarding 
human plasma degradability during handling and storage, as well as the 
importance of fasting conditions at collection. The use of heparin collection 
tubes resulted in no interference of the polysaccharide and full conservation of 
spectral information, while EDTA tubes produced a number of interfering 
signals from free and Ca
2+
/Mg
2+
 complexed EDTA, the impact of which on 
metabolomic analysis is discussed. Regarding temperature stability, large 
changes in lipoproteins and choline compounds were observed in plasma kept 
at room temperature for  2.5 hours, whereas short-term storage at -20ºC was 
found suitable up to 7 days, with storage at -80ºC being recommended, 
particularly for long-term periods (at least up to 2.5 years). Regarding freeze-
thaw cycles, no more than 3 consecutive cycles were found advisable, while 
the use of non-fasting conditions (instead of fasting) was found acceptable. 
Chapter 5 presents the first NMR metabolomics study of maternal plasma 
throughout pregnancy, including correlation between plasma and urine 
metabolites. Some of the metabolic alterations observed confirmed known 
metabolic effects, while novel changes were observed, suggesting adjustments 
in energy and gut microflora metabolisms (citrate, lactate and dimethyl sulfone) 
and alterations in glomerular filtration rate (creatine and creatinine). 
Correlations studies unveiled specific lipoprotein/protein metabolic aspects of 
healthy pregnancy with impact on the excreted metabolome, providing further 
understanding of pregnancy metabolism.   
In Chapter 6, the impact of prenatal disorders on maternal plasma metabolome 
and lipidome is described for fetal chromosomal disorders (CD), including 
Trisomy 21 (T21). High classification rates were obtained for CD (88-89%) and 
T21 (85-92%) in 1
st
 and 2
nd
 trimesters, based on variable selection of NMR 
data. In addition, novel metabolic deviations were found through plasma/urine 
correlations, namely in low density and very low density lipoproteins  
  
 (LDL+VLDL), sugar and gut microflora metabolisms. Changes in plasma 
phospholipid profile, namely in phosphatidylcholines, were further confirmed 
and characterised by hydrophilic interaction liquid chromatography-mass 
spectrometry (HILIC-LC/MS). 
In Chapter 7, metabolic biomarkers of pre- and post-diagnosis GDM were 
sought by NMR metabolomics of whole maternal plasma and plasma lipid 
profile in the 2
nd
 trimester. Metabolic alterations found to be predictive of GDM 
comprised increases in cholesterol, fatty acids, triglycerides and small 
metabolites changes in glucose, amino acids, betaine, urea, creatine and 
metabolites related with gut microflora. Post-diagnosis GDM was successfully 
classified using a 26-resonance plasma biomarker corresponding to 10 
metabolites and lipids, advancing the possibility of using a multi-metabolite 
biomarker as a complementary tool in the clinical management of GDM. 
Chapter 8 describes the results obtained for prenatal disorders shown to have 
lower impact on maternal plasma metabolome, namely diagnosed fetal 
malformations and pre-diagnosis premature rupture of membranes, preterm 
delivery and preeclampsia.  
Finally, Chapter 9 describes the general conclusions and future perspectives in 
the context of this thesis, highlighting how this work contributes with new 
knowledge on prenatal disease mechanisms and possible biomarkers for 
prenatal diagnosis and prediction methods. 
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1.1. Pregnancy and fetal development 
A human full-term pregnancy can range from 37 to 42 gestational weeks (g.w.), 
counting from the first day of the last normal menstrual period (Creasy et al., 2009). 
Gestational weeks are grouped into three trimesters, each one characterized by 
specific hallmarks of fetal development. The first trimester (1st T) corresponds to the 
period from fertilization until 14 g.w., during which the most important steps of fetal 
organogenesis occur constituting the period of greatest risk for birth defects. At this 
stage, important fetal-maternal structures become completely differentiated (e.g. 
chorionic villi and capillary system which form the placenta and umbilical cord, 
respectively) forming the definitive annexes that support fetal growth as well as 
maintenance, regulatory and endocrine functions. The following trimester (2nd T) is 
defined by the period from 14 to 28 g.w., mainly characterized by organ maturation and 
fetal growth. The third trimester starts on the 28th week and extends to the end of 
pregnancy and it is during this time that fetal growth is enhanced and the fetus 
becomes able to synthesize its own body fat. By the 37th week, fetal maturation is 
complete and pregnancy is at term, although labour can occur up to 41 or 42 weeks. 
During the time course of pregnancy, important maternal-placental-fetal metabolic 
interactions occur in order to 1) ensure adequate growth and development of the fetus, 
2) provide the fetus with adequate energy stores and substrates needed after birth, 3) 
ensure maternal needs for the increased physiological demands of pregnancy and 4) 
provide the mother with sufficient energy stores and substrates required for labour and 
lactation (Hadden and McLaughlin, 2009). The transfer of nutrients and other 
substances between fetal and maternal circulations, in both directions, is illustrated in 
Figure 1.1. The placenta is the primary site of nutrient and gas exchange between the 
mother and fetus presenting three main functions: ensuring fetal metabolism (e.g. 
synthesis of glycogen), transport of gases and nutrients and endocrine excretion. Only 
selected nutrients from the maternal blood are able to cross the placenta, glucose 
being the main nutrient transported and a primary source of energy to the fetus. 
Glucose is responsible for maintenance of basal metabolism, energy storage in form of 
glycogen and in adipose tissues, as well as providing energy for protein synthesis and 
growth. In addition, the active transfer of amino acids from maternal circulation ensures 
the structural basis for protein synthesis, essential for fetal growth, and provides the 
oxidative substrates for energy production, mainly when glucose levels are low. Lipids 
cross the placenta with difficulty, although essential fatty acids and long-chain 
polyunsaturated fatty acids cross from maternal circulation to fetus (Herrera and 
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Ortega, 2008; Moore and Persaud, 2008). Harmful substances also have the ability to 
cross the placenta comprising drugs, chemicals and infection agents.  
 
 
Figure 1.1. Transfer processes taking place between maternal, placental and fetal 
environments. [Adapted from (Moore and Persaud, 2008)] 
 
The transfer of nutrients from mother to fetus leads to several metabolic 
adaptations that take place in maternal metabolism to satisfy both maternal and fetal 
needs. These metabolic changes include hyperinsulinemia, insulin resistance, relative 
fasting hypoglycemia, increased circulating plasma lipids and hypoaminoacidemia 
(Creasy et al., 2009). Although the precise mechanism of insulin resistance is not 
entirely clear, hormonal alterations throughout gestation have been attributed to the 
reduced insulin sensitivity. Hypoglycemia is a result of the high rate of placental 
transfer of glucose, despite of enhanced gluconeogenesis and reduced consumption of 
glucose. Total plasma lipids increase significantly and progressively after 24 g.w., with 
increases in triglycerides, cholesterol and free fatty acids being most marked. 
Hypoaminoacidemia occurs due the above mentioned increased placental uptake of 
amino acids leading to diminished maternal circulating levels (Butte, 2000; Herrera and 
Ortega, 2008; Creasy et al., 2009).  
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1.2. Prenatal disorders and diagnostic procedures: present status and 
challenges 
Despite all metabolic and physiological alterations occurring throughout gestation, 
disruptions may occur and cause maternal and fetal health complications. Prenatal 
disorders comprise maternal and fetal disorders, although most of them affect both 
mother and fetus to some extent. The main pathologies are listed in Table 1.1, in 
decreasing order of prevalence. 
The work described in this thesis entailed the study of prenatal disorders with 
higher prevalence, namely maternal disorders such as preterm delivery (PTD), 
gestational diabetes mellitus (GDM), preeclampsia, and premature rupture of the 
membranes (PROM), and fetal disorders such as chromosomal disorders (CD) and 
fetal malformations (FM). For other prenatal disorders such as intrauterine growth 
restriction (IUGR), small for gestational age (SGA) and large for gestational age (LGA), 
it was not possible to gather sufficient number of samples. A brief overview (i.e., 
pathophysiology, diagnostic procedures and management) of each of these conditions 
is presented throughout this section.  
Table 1.1. Most common maternal and fetal disorders with corresponding prevalence. 
Prenatal disorder Prevalence Reference 
Maternal   
Preterm delivery (PTD) 11.1% of all live births (Blencowe et al., 2013) 
Gestational Diabetes Mellitus (GDM) 9.2% of all pregnancies (DeSisto et al., 2014) 
Preeclampsia 3-8% of all pregnancies (Uzan J et al., 2011) 
Premature rupture of the membranes 
(PROM) 
8% of all pregnancies (Hannah et al., 1996) 
Fetal   
Intrauterine growth restriction (IUGR) 7-15% of all pregnancies (Cetin and Alvino, 2009) 
Small for gestational age (SGA) <10% of all live births (Horgan et al., 2010) 
Chromosomal disorders (CD) 3-4% of all pregnancies (Creasy et al., 2009) 
Fetal malformations (FM) 2-3% of all live births (Creasy et al., 2009) 
 
1.2.1. Preterm delivery 
Preterm delivery (PTD), also referred to as preterm birth, is defined by the World 
Health Organization as any births occurring before 37 completed weeks of gestation or 
fewer than 259 days since the first day of a wom  ’s l s  me s  u l pe   d (Blencowe 
et al., 2013). PTD occurs in 11.1% of all live births and is the major cause of neonatal 
mortality and morbidity. Long-term adverse consequences for children who are born 
prematurely include cerebral palsy, sensory deficits, learning disabilities and respiratory 
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illnesses compared with children born at term (Beck et al., 2010; Blencowe et al., 
2013). PTD can be further subdivided based on gestational age: extremely preterm 
(<28 g.w.), very preterm (28 - <32 g.w.) and moderate preterm (32 - <37 completed 
g.w.). Lower gestational age at birth has been associated with greater risks. (Blencowe 
et al., 2013). 
The causes of PTD can be classified into two broad subtypes: 1) spontaneous PTD 
defined as spontaneous onset of labour or following prelabour premature rupture of 
membranes (pPROM), and 2) provider-initiated preterm delivery defined as induction of 
labour or elective caesarean birth before 37 completed g.w. for maternal or fetal 
indication (e.g., placenta accrete) (Blencowe et al., 2013). Risk factors for spontaneous 
PTD are higher maternal age, multiple pregnancy, infection, underlying maternal 
chronic medical conditions, nutritional, lifestyle/work related, maternal psychological 
health, genetic among others.  
PTD diagnosis remains a challenge due to the incompletely understood sequence 
and timing of events that precede preterm labour. Standard criteria for diagnosis is 
based on the measurement of uterine contractions (>4 per 20 minutes or 8 per 60 
minutes) accompanied by cervical change (cervical effacement of 80% or cervical 
dilatation of 2 cm or more), but it lacks precision. The result is a false-positive diagnosis 
in 40% of women and enrolment of women who are not in labour into trials of agents to 
arrest PTD (Hacker et al., 2004; Creasy et al., 2009). Due the high rates of neonatal 
morbidity and mortality and the later in life health complications of children born 
preterm, early detection preceding the onset of PTD is a recognised requirement. The 
identification of high risk women might allow the initiation of specific pre-treatment care 
and provide important insight into the mechanisms leading to preterm birth. 
 
1.2.2. Gestational diabetes mellitus 
 es       l d  be es mell  us (  M)  s def  ed  s “  c  b hyd   e     lerance of 
v  y  g deg ees  f seve   y w  h   se     f  s   ec g       du   g p eg   cy”   d  s 
usually diagnosed in the 2nd T between 24 and 28 weeks of gestation (Creasy et al., 
2009). In most instances, the underlying pathophysiology of GDM is similar to that 
observed in type 2 diabetes characterized by an inability to maintain an adequate 
insulin response due the significant decreases in insulin sensitivity with advanced 
gestation. This condition often occurs in subjects with no history of diabetes, and 
factors such as age (older than 35 to 40 years), obesity (body mass index (BMI) >30), 
history of previous GDM or large for gestational age (LGA) infant, and genetic 
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background contribute to the severity of the disease (Creasy et al., 2009). Clinically 
recognition of GDM is important since therapy can reduce pregnancy complications 
and potentially reduce long-term sequelae in the offspring. General literature have 
documented an increased risk of GDM mothers and babies for the development of 
other prenatal complications such as preeclampsia, metabolic syndrome, birth trauma, 
fetal hyperinsulinemia, macrosomia, stillbirth, newborn hypoglycemia and 
hyperbilirubinemia, among others (Creasy et al., 2009; Pridjian and Benjamin, 2010).  
Currently, GDM diagnosis involves two discrete temporal phases: a) measurement 
of fasting plasma glucose (FPG) performed at the first prenatal visit and b) oral glucose 
tolerance test (OGTT) performed at 24-28 g.w. of gestation (Metzger et al., 2010). In 
the first prenatal visit, FPG results are interpreted according three thresholds: 1) if FPG 
is ≥126 mg/dL (7.0 mmol/L), treatment and follow-up as for pre-existing diabetes is 
applied, 2) if FPG ≥92 mg/dL (5.1 mmol/L) but <126 mg/dL (7.0 mmol/L), the GDM 
diagnosis is made, and 3) if FPG <92 mg/dL (5.1 mmol/L), a new test for GDM is 
performed at 24-28 g.w. with a 75 g OGTT. The GDM diagnosis at 24-28 g.w. is 
established if one or more values of the 75 g OGTT equals or exceeds the thresholds 
indicated in Table 1.2 (Metzger et al., 2010; George, 2011). 
 
 
Table 1.2. Threshold values for diagnosis of GDM. 
[Adapted from (Metzger et al., 2010; George, 2011)]  
Glucose 
measurement 
75 g OGTT 
mg/dL mmol/L 
Fasting ≥92 ≥5.1 
1 hour ≥180 ≥10 0 
2 hours ≥153 ≥8 5 
 
 
GDM management includes dietary therapy, exercise, and medical treatment 
(Pridjian and Benjamin, 2010). In dietary therapy, GDM patients are advised to have 
five meals a day and the daily calorie requirement is calculated according to the 
standard of 1900-2400 kcal per day with carbohydrate restriction to 35-40% of calories. 
If dietary control is carried out strictly, most patients do not need medical treatment like 
insulin therapy. Physical exercise may increase the sensitivity of peripheral tissues to 
insulin, thus being able to help to control glucose level of GDM patients.  
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1.2.3. Preeclampsia  
Preeclampsia is a disorder that occurs only during pregnancy, characterized by the 
new onset of hypertension, proteinuria and generalized edema, usually after the 20th 
week of gestation, with an unpredictable course that affects both mother and fetus 
(Creasy et al., 2009). There are numerous risk factors for development of 
preeclampsia, including genetic factors, nulliparity, a new partner, demographic factors 
(e.g. maternal age >35 years), factors related to the pregnancy (e.g., multiple 
pregnancy, congenital or chromosome anomalies, urinary infection), factors associated 
with maternal disease (e.g. chronic hypertension, kidney disease, obesity, insulin 
resistance, diabetes), and environmental factors (e.g., living at a high altitude and 
stress) (Uzan J et al., 2011). The placenta plays a key role in the underlying 
mechanisms leading to the development of preeclampsia including inadequate 
placental cytotrophoblast invasion, followed by widespread maternal endothelial 
dysfunction. In addition, excessive oxidative stress, inflammation, immune 
maladaptation, and genetic susceptibility may all contribute to the pathogenesis of 
preeclampsia (Young et al., 2010). 
Preeclampsia has been characterized by some researchers into two different 
disease entities: early-onset and late-onset preeclampsia. Early-onset preeclampsia is 
usually defined as preeclampsia that develops before 34 weeks of gestation, and has 
severe maternal and fetal consequences including IUGR, PTD, low- or very-low birth 
weight (LBW or VLBW), increased perinatal morbidity and mortality and a high 
incidence of the life-threatening HELLP syndrome (hemolysis, elevated liver enzymes, 
and low platelets) (Raymond and Peterson, 2011; Than et al., 2012). On the other 
hand, late-onset preeclampsia develops at or after 34 weeks of gestation and its 
clinical presentation is frequently mild, resulting mainly in maternal consequences. 
The diagnosis of preeclampia is defined by an increase in maternal blood pressure 
and high levels of protein in urine (proteinuria) with onset beyond the 20th week of 
gestation (Creasy et al., 2009; Uzan J et al., 2011). The threshold values for diagnosis 
are 24 hour proteinuria ≥300 mg/day, and a systolic blood pressure >140 mmHg or 
diastolic blood pressure ≥90 mmHg. When the diagnosis is made, the only cure still 
known is immediate delivery, which results in high number of babies born prematurely. 
Accurate prediction of preeclampsia would enable early and optimal management of 
women at high risk. Several predictive markers have been investigated, such as 
maternal mean arterial pressure, uterine artery Doppler pulsatility index, and 1st T 
maternal serum markers (e.g., placental growth factor, pregnancy-associated plasma 
protein A (PAPP-A) and free β-human chorionic gonadotrophin (β-hCG)), but these 
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lack reliable detection and have high false-positive rates (80.8-93% detection rates with 
5-10% false-positive rates) (Kane et al., 2014).  
 
1.2.4. Premature rupture of membranes  
Premature rupture of the membranes (PROM) is defined as the spontaneous 
rupture of membranes (or amniotic sac) at term before the onset of contractions. 
Rupture of fetal membranes is an integral part of the normal parturition process at term 
and usually occurs as a result of a physiologic process of progressive membrane 
weakening (Creasy et al., 2009). PROM affects approximately 8% of pregnancies at 
term, and 95% of these women deliver within 28 hours of membrane rupture. The 
expeditious delivery of the PROM patient can reduce the risk of perinatal infections 
without increasing the likelihood of operative delivery (Hannah et al., 1996; Creasy et 
al., 2009).  
PROM diagnosis is based on the history of vaginal loss of fluid and confirmation of 
amniotic fluid in the vagina. PROM diagnosis is made by 1) testing of the fluid with 
Nitrazine paper, which will turn in blue in the presence of alkaline amniotic fluid (pH of 
7.1 to 7.3), and 2) microscopic inspection for the presence of arborized crystals (i.e., 
ferning, an indication of the presence of estrogen) in an air-dried sample collected from 
the vaginal side walls or pooled vaginal fluid. False-positive nitrazine test results occur 
in the presence of alkaline urine, blood, or cervical mucus (Hacker et al., 2004; Creasy 
et al., 2009). 
 
1.2.5. Fetal growth anomalies  
Intrauterine growth restriction (IUGR) and small for gestational age (SGA) are fetal 
disorders with high occurrence in pregnancy, 7-15% and <10%, respectively (Cetin and 
Alvino, 2009; Horgan et al., 2010). Although some overlap occurs among these two 
disorders, they are differently defined. IUGR is defined as a fetus that does not reach 
its growth potential and is characterized at birth by a weight or a BMI below normal 
values for the corresponding number of gestational weeks. On the other hand, SGA 
defines an infant that has a birth weight below the 10th percentile for specific 
gestational age. It is important to note that not all SGA infants identified at birth are 
patients with IUGR, and that, on the other hand, infants with IUGR are not necessarily 
classified as SGA (Dessì et al., 2013). There are several factors contributing to these 
disorders such as genetic factors, disturbances in the ability of the mother to provide 
sufficient nutrients or in the ability of the placenta to transfer nutrients, intrauterine 
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hormones, and growth factors (Pallotto and Kilbride, 2006). Both conditions are known 
as key risk factors for increased perinatal mortality, birth adaptation complications, 
including perinatal acidosis, hypoglycaemia, hypothermia, coagulation abnormalities, 
and selected immunologic deficiencies. In addition, IUGR infants also have greater risk 
for complications of prematurity (e.g., chronic lung disease) and increased risk for short 
stature, cognitive delays and neurologic disorders in childhood (Pallotto and Kilbride, 
2006). In contrast, large for gestational age (LGA) or macrosomia is defined as a 
neonate with a birth weight above the 90th centile for gestational age. The major risk 
factors for macrosomia are maternal diabetes, obesity and excessive nutrition/weight 
gain during pregnancy. The LGA baby often undergoes hypoglycaemia caused by 
chronic fetal hyperglycaemia which continues even after birth (Dessì et al., 2013). 
Abnormal fetal growth is detected with the clinical suspicion of a subnormal uterine 
size and the diagnosis is usually made by ultrasound. However, there is a high 
percentage of error in this and fetal growth complications are undetected in about 30% 
of routinely scanned cases and incorrectly detected in 50% of cases (Bamfo and 
Odibo, 2011).  
 
1.2.6. Chromosomal disorders 
Chromosomal disorders (CD) are defined as changes resulting in a visible 
alteration of the chromosomes produced by specific chromosomal mechanisms (Moore 
and Persaud, 2008). Figure 1.2 shows an example of the normal human karyotype 
comprising 22 pairs of chromosomes (autosomes), and a pair of sex chromosomes (XX 
in females and XY in males). The common chromosome aberrations in humans are 
abnormalities in chromosome number and alterations of chromosome structure (Moore 
and Persaud, 2008; Creasy et al., 2009). Table 1.3 shows the main characteristics of 
each type of chromosomal disorder along with some examples. Numerical 
abnormalities represent either aneuploidy or polyploidy. Aneuploidy occurs during both 
meiosis and mitosis and is characterized by a number of chromosomes that is not an 
exact multiple of the haploid number of 23 (e.g., 45 or 47). Polyploidy is characterized 
by a chromosome number that is a multiple of the haploid number of 23 other than the 
diploid number (e.g., 69). Aneuploidy is the most frequently seen chromosome 
abnormality in clinical cytogenetics (3% to 4% of clinically recognized pregnancies), 
including the autosomal trisomies, as well as sex chromosomal aneuploidies (Table 
1.3). Trisomy 21 (T21), trisomy 18 (T18) and Trisomy 13 (T13) are the most common 
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autossomal numerical disorders in liveborn humans with an approximate incidence of 
1/830, 1/7500 and 1/22700, respectively (Moore and Persaud, 2008). 
 
 
 
Figure 1.2. The human karyotype comprising 22 pairs of chromosomes and a pair 
of sex chromosomes (XX    fem les   d XY    m les)  Rep  duced f  m “T lk  g 
 l ss  y  f  e e  c Te ms” (h  p://www ge  me g v/gl ss  y/  dex cfm? d=114)  
 
 
Most of the structural chromosomal abnormalities result from chromosome 
breakage followed by reconstitution in an abnormal combination (Moore and Persaud, 
2008; Creasy et al., 2009). Chromosome breakage may be induced by various 
environment factors such as radiation, drugs, chemicals and viruses. Structural 
abnormalities are balanced if there is no net loss or gain of chromosomal material, or 
unbalanced if there is an abnormal genetic complement. The resulting type of structural 
chromosomal abnormality depends on what happens to the broken pieces and can be 
subdivided into deletions, duplications, insertions, inversions, translocations and 
isochromosomes as described in Table 1.3. 
Depending on the type, chromosome abnormalities may range from small 
phenotypic alterations to more severe developmental impairment such as mental 
deficiency and malformations. For instance, the phenotypic changes of individuals born 
with T21 are mental deficiency, brachycephaly, flat nasal bridge, upward slant to 
palpebral fissues, protruding tongue, simian crease, clinodactyly of fifth digit, congenital 
heart defects and gastrointestinal tract anomalies (Moore and Persaud, 2008). 
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Table 1.3. Some of the most common chromosomal abnormalities. [Adapted from (Moore and 
Persaud, 2008; Creasy et al., 2009)] 
Abnormality Characteristics 
Numerical Aneuploidy:  
 Monosomy – presence of only one chromosome from a pair 
Example: Turner syndrome (45, X) 
 Trisomy – presence of an extra third chromosome 
Examples: Trisomy 21 or Down syndrome (47,XX+21 or 47,XY+21), 
Trisomy 18 or Edwards syndrome (47,XX+18 or 47,XY+18), Trisomy 
13 or Patau syndrome (47,XX+13 or 47,XY+13), Kleinfelter syndrome 
(47,XXY), Triple X syndrome (47,XXX) and 47,XYY syndrome 
Polyploidy: 
Example: 48,XXXX, 48,XXXY, 48,XXYY and 49,XXXXY 
Structural Deletions: loss of a chromosome segment  
Duplications: duplication of chromosome segments 
Insertions: insertion of a chromosome segment into a nonhomologous 
chromosome 
Inversions: a segment of a chromosome is reversed 
Translocations: transfer of chromosomal material between chromosomes 
 Reciprocal translocation – exchange of segments from two different 
chromosomes 
 Robertsonian translocation – attachment of an entire chromosome to 
another at the centromere 
Isochromosomes: one arm of a chromosome is lost and the other arm is 
duplicated 
 
 
Non-invasive screening tests for fetal chromosomal disorders may be offered in the 
1st and 2nd trimesters by ultrasound and maternal serum concentrations of various 
fetoplacental products, such as free β-hCG, PAPP-A, alpha-fetoprotein (AFP), 
unconjugated estriol (uE3) and inhibin A (Nicolaides, 2011). In Table 1.4, common 
screening and diagnostic tests are listed including timing of procedures, detection rate 
and false-positive rates. Earlier effective screening for chromosomal abnormalities may 
be provided at 11-14 g.w. by a combination of maternal age, fetal nuchal translucency 
 h ck ess   d m  e   l se um m  ke s   clud  g f ee β-hCG and PAPP-A. This method 
allows the early screening of T21 and other aneuploidies with a detection rate of 85-
95% with 5% false-positive rate, and >90% with 1% false-positive rate, respectively 
(Table 1.4) (Nicolaides, 2004, 2011). In the 2nd T, different combinations of maternal 
age with maternal serum markers can be offered for screening for aneuploidies. As 
shown in Table 1.4, the quadruple test based on the combination of maternal age with 
serum AF   f ee β-hCG, uE3 and inhibin A provides a higher detection rate than 
d uble (m  e   l  ge w  h se um AF   f ee β-hCG) and triple (maternal age with serum 
Introduction 
 
13 
AF   f ee β-hCG, uE3) tests for T21 (Nicolaides, 2011). Detection of chromosomal 
abnormalities by ultrasound alone will depend on whether there are associated 
physical malformations. For instance, the detection rate for T21 in 2nd T have been 
79.9% with a false-positive rate of 6.7% (Benn et al., 2002; Collins and Impey, 2012). 
 
Table 1.4. Common prenatal screening and diagnostic procedures for chromosomal disorders. 
a
C mb  ed  es : c mb         f m  e   l  ge   uch l     sluce cy  f ee β-hCG and PAPP-A; 
b
Trisomies 18 and 13, Turner syndrome, and triploidy; 
c
Double test: combination of maternal 
 ge w  h se um AF    d f ee β-hCG; 
d
Triple test: combination of maternal age with serum AFP, 
f ee β-hCG and uE3; 
e
Qu d uple  es : c mb         f m  e   l  ge w  h se um AF   f ee β-
hCG, uE3 and inhibin A. T21: Trisomy 21 
Procedure (time 
for results) 
Timing of 
procedures 
Detection /false-positive rates References 
Screening    
1
st
 T maternal 
serum markers 
(2-3 days) 
11-14 g.w. Combined test
a
: 
T21: 85-95% /5% 
Others
b
: >90% /1% 
(Nicolaides, 2004, 
2011) 
2
nd
 T maternal 
serum markers 
(2-3 days) 
15-20 g.w. Double test
c
: T21: 60-65% /5% 
Triple test
d
: T21: 65-70% /5% 
Quadruple test
e
: T21: 70-75% /5% 
(Nicolaides, 2011) 
Diagnosis    
Ultrasound 
(immediately) 
11-14 g.w. & 
18-22 g.w. 
T21: 79.9% /6.7% (at 18-22 g.w.) (Benn et al., 2002) 
Chorionic villus 
sampling (CVS) 
(up to 2 weeks) 
10-13 g.w. T21 and others
b
: 97.5–99.6%  (Hahnemann and 
Vejerslev, 1997) 
Amniocentesis 
(up to 2 weeks) 
15-20 g.w. T21 and others
b
: 99.4–99.8% (Hahnemann and 
Vejerslev, 1997) 
Cordocentesis 
(3 days) 
>18 g.w. -  (Moore and 
Persaud, 2008) 
 
Invasive prenatal diagnosis is offered to women who screen above a set risk cut-off 
level on non-  v s ve sc ee   g       p eg     w me  wh ’s pe s   l   bs e   c l     
family history places them at increased risk of having an offspring with chromosomal 
abnormalities (Creasy et al., 2009). The main invasive diagnostic tests used for 
chromosomal anomalies detection are chorionic villus sampling (CVS, performed in the 
1st T), amniocentesis (performed in 2nd T) or cordocentesis (percutaneous umbilical 
blood sampling performed after 18 g.w.) (Keeling and Khong, 2007). These methods 
are very invasive representing a percentage of risk for mother and fetus due the 
associated complications including vaginal spotting, amniotic fluid leakage, fetal needle 
injury and fetal loss. The fetal loss rate associated with amniocentesis and CVS is often 
reported to be 0.5-1%, while for cordocentesis is 3.2% (Tongsong et al., 2000; Tabor 
and Alfirevic, 2010). Another disadvantage is the typically high length of time required 
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for the results of amniocentesis and CVS diagnostic procedures to become available 
(1-2 weeks).  
Recently, analysis of cell-free fetal DNA (cffDNA) in maternal blood has been 
shown to have higher detection rates than the currently available screening tests for 
fetal autosomal aneuploidies. Results of studies using 1st T cffDNA have been shown 
to detection rates of 98.6-100%, 100% and 91.7% for T21, T18 and T13, respectively, 
with false-positive rates < 1% (Walsh and Goldberg, 2013). However, cffDNA cannot 
currently replace either CVS or amniocentesis due the lower detection rate obtained for 
T13 and high costs (ranging from about $500 to $1500 per test). In addition, 
karyotyping can provide information about other conditions (e.g., open neural tube 
defects) besides fetal aneuploidy, whereas cffDNA can not (Benn et al., 2013; Walsh 
and Goldberg, 2013). Despite the clinical usefulness of these screening and diagnostic 
procedures, the development of reliable tests with higher detection rate and lower 
false-positive rates is still required. In addition, the development of cost-effective and 
easy to perform genetic screening tests would extend to the less-developed countries. 
 
1.2.7. Fetal malformations  
Fetal malformations (FM), also referred as congenital anatomic anomalies, 
congenital malformations or birth defects, are defined as a structural abnormality of any 
type that is present at birth (Moore and Persaud, 2008). FM may be single or multiple 
and of minor or major clinical significance. Usually, abnormalities of the organ systems 
occur during fetal development and these comprise neural tube defects, ventricular 
septal defects, cleft lip, cleft palate, low-set malformed ears, and deafness, among 
others. Some of these structural anomalies occur early in the main embryonic period 
(3-8 g.w) when organ systems are formed, but also later during the growth and 
maturation of the fetus (9-38 g.w.), when organs such as the cerebral cortex, the 
gastrointestinal tract and the renal glomeruli continue to differentiate and develop 
(Moore and Persaud, 2008). Table 1.5 lists the major fetal malformations occurring in 
human organs at birth with corresponding prevalence per 10 000 births in Europe 
(EUROCAT Working Group, 2012). The European surveillance of congenital anomalies 
(EUROCAT) reported highest prevalence for congenital anomalies of cardiovascular 
system from 2008 to 2012, followed by limb and urinary systems. Within cardiovascular 
system defects, the most common have been ventricular septal defect (31.0 per 10 000 
live births) and atrial septal defect (19.4 per 10 000 live births). Some anomalies (e.g. 
renal agenesis, anencephaly) are always lethal, with death occurring either in utero or 
in the early neonatal period. Other anomalies are compatible with limited survival but 
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associated with very severe neurologic disabilities (e.g., hydrencephaly), for which 
early pregnancy termination is the usual management. For most anomalies, the 
prognosis is good but uncertain (e.g., mild severe ventriculomegaly) with outcomes 
ranging from severe physical limitation (e.g., spina bifida) or uncertain mental faculties. 
(e.g., agenesis of the corpus callosum) (Creasy et al., 2009). 
 
Table 1.5. Major malformations occurring in human organs at birth with corresponding 
prevalence per 10 000 live births in Europe from 2008 to 2012. [Adapted from (EUROCAT 
Working Group, 2012)] 
Organ system 
Prevalence 
per 10 000 
live births 
Types of fetal malformations 
Central nervous 
system (CNS)  
22.2 Neural tube defects, spina bifida, encephalocele, anencephaly, 
hydrocephaly, microcephaly, holoprosencephaly 
Eye  3.6 Anophtalmia/microphtalmia, congenital cataract, congenital 
glaucoma 
Cardiovascular 71.9 Common arterial truncus, transposition of great vessels, 
ventricular septal defect, atrial septal defect, tetralogy of 
Fallop, hypoplastic left heart, pulmonary valve stenosis, 
pulmonary valve atresia 
Respiratory 3.8 Choanal atresia, cystic adenomatous malformation of lung 
Oro-facial 12.7 Cleft palate, cleft lip 
Digestive 16.6 Oesophageal atresia, duodenal atresia or stenosis, ano-rectal 
atresia and stenosis, diaphragmatic hernia, abdominal wall 
defects, gastroschisis, omphalocele 
Urinary 32.7 Multicystic renal dysplasia, congenital hydronephrosis, 
bilateral renal agenesis 
Genital 21.6 Hypospadias 
Limb 37.9 Limb reduction defects, club foot, hip dislocation and/or 
dysplasia, polydactyly, syndactyly 
 
 
Currently, two-dimensional ultrasound, performed in the 1st (11-14 g.w.) and 2nd 
(18-22 g.w.) T, is the primary method for detection of fetal structural defects, and other 
methods such as amniocentesis (15-20 g.w.), are reserved for specific or confirmatory 
circumstances (Creasy et al., 2009). The sensitivity of ultrasound for detection of major 
anomalies is variable but in general surprisingly low, with reported detection rates from 
22% to 55%. Ultrasound detection rates are dependent on fetal anomaly type, 
gestational age, risk factors and imaging method and quality. The best detection rates 
by ultrasound are obtained for major CNS anomalies such as anencephaly (94-100%), 
with major fetal cardiac defects in the mid range (25-60%) and clefts tending to be 
lower (Creasy et al., 2009). Amniocentesis is performed in order to measure the alpha-
fetoprotein (AFP) concentration in the amniotic fluid. Amniotic fluid AFP concentration 
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is high in pregnancies whose fetuses have severe anomalies of CNS and ventral 
abdominal wall, and when combined with ultrasound scanning, enables the diagnosis 
of approximately 99% of fetuses with these severe anomalies. In addition, when a fetus 
has an open neural tube defect (NTD), the concentration of AFP in maternal serum is 
higher than normal due the rapidly diffusion of this protein from fetal tissues into 
maternal serum via fetal urine (Moore and Persaud, 2008). However, maternal serum 
AFP measured at 11-13 g.w. has provided detection rates for NTDs ranging from 
37.5% to 50% with false positive rates of 10% and 5%, respectively (Bredaki et al., 
2012). 
 
 
 1.3. Metabolomics and lipidomics methods applied in disease diagnosis 
and prognosis 
1.3.1. Concept and strategy 
Novel approaches have emerged to allow the qualitative and quantitative 
measurements of complex interactions in biological systems, namely genomics (the 
study of genes), transcriptomics (the study of gene expression), proteomics (the study 
of protein expression), metabolomics and lipidomics, referred globally  s “ m c” 
technologies (Figure 1.3). Metabolomics, a term today often used interchangeably with 
 he  e m “me  b   m cs”  relates to an analytical strategy that entails the 
comprehensive analysis of all metabolites involved in the metabolic networks of living 
organisms and their response to pathophysiological or other stimuli (Nicholson et al., 
1999). Lipidomics can be viewed as a sub-discipline of metabolomics and is defined as 
the comprehensive identification and quantification of all lipid molecular species in a 
biological system (Wenk, 2005; Griffiths and Wang, 2009). It is thus an extension of 
lipid profiling but put on a qu        ve sc le   d pe f  med       “ m c” m   e  (  e   
analysis of multiple samples in a high throughput setting).  
The general steps performed in metabolomic and lipidomic studies are illustrated in 
Figure 1.4. Both metabolomics and lipidomics use a variety of biological samples, such 
as biofluids, tissues and cells, with the aim to investigate their composition and find 
differences in the nature or amounts of metabolites that characterize phenotypes and 
biochemical responses to perturbations (e.g., diseases, pharmacological treatment). In 
metabolomic studies, biological samples are subjected to a minimal sample preparation 
protocol in order to detect as much metabolites as possible. In lipidomics, a lipid 
extraction step is usually indispensable before analysis, in order to remove interfering 
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agents, such as proteins, saccharides, or other small molecules. Several lipid 
extraction methods have been used, taking advantages of the utilization of solid-liquid 
or liquid-liquid extractions, such as chloroform/methanol methods (e.g., Folch, Bligh & 
Dyer), hexane/isopropanol, methyl tert-butyl ether (MTBE)/methanol and solid phase 
extraction (SPE) (Li et al., 2014).  
 
 
 
Figure 1.3.  chem   c  ep ese         f  he “ m c”  ech  l g es  [Ad p ed f  m (Wenk, 2005)] 
 
The analysis of complex biological samples involves the use of advanced 
metabolite profiling techniques, such as Nuclear Magnetic Resonance (NMR) 
spectroscopy and Mass spectrometry (MS). While NMR is commonly applied for global 
metabolic profiling, MS is applied for both global and targeted profiling, although the 
latter is still a more common approach. Global metabolic profiling (untargeted) studies 
are focused on the investigation of all the metabolites detectable in a sample capturing 
as much information as possible. On the other hand, targeted profiling is focused on a 
small number of metabolites (e.g., phospholipids), commonly requiring a prior isolation 
step followed by separation using chromatographic methods (gas chromatography 
(GC) or liquid chromatography (LC)), or using specific and targeted technological 
approaches such as neutral loss scan or parent ion scan modes in MS analysis. The 
use of both NMR and MS techniques is often necessary for full molecular 
characterization in global metabolite profiling (Collino et al., 2009). On the other hand, 
lipidomics analysis is mainly focused in MS techniques (mainly LC-MS). The benefits, 
drawbacks and costs of the NMR and MS techniques are summarized in Table 1.6. 
Other analytical techniques less commonly used in metabolomics are Raman and 
Infrared spectroscopies (Ellis and Goodacre, 2006). 
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Figure 1.4. Illustrative scheme of a typical metabolomics flowchart. 
 
Table 1.6. Comparison between the analytical techniques commonly used in metabolomics. 
NMR: nuclear magnetic resonance spectroscopy, GC-MS: gas chromatography-mass 
spectrometry, LC-MS: liquid chromatography-mass spectrometry. [Adapted from (Mussap et al., 
2013)] 
Technique Benefits Drawbacks 
NMR - Results in a fast and single experiment 
(ca. 10-30 min for 1D 
1
H NMR) 
- Various nuclei (
1
H, 
13
C, 
31
P) 
- Liquid and solid matrices 
- Very high accuracy and repeatability 
- Quantitative 
- Minimal sample preparation and sample 
recovery 
- Molecular dynamics information 
- Needs very skilled technicians 
- Limitations in sensitivity (sub-
mM) 
- NMR spectrometers are very 
expensive 
 
GC-MS - Very small amount of sample 
- High discrimination of molecules with a 
very similar structure 
- Very high sensitivity (< M) 
- Extensive sample preparation, 
including derivatization 
- Destructive 
- Limitations to volatile 
compounds 
LC-MS - Suitable for measuring lipids, di- and 
tripeptides and other macromolecules 
- Very high sensitivity (< M) 
- Extensive sample preparation 
- Destructive 
- Long analytical time (20-60 
min per sample) 
 
NMR
Statistical analysis
Biomarkers identification
Biochemical interpretation
MS
Univariate
Data pre-processing
Multivariate
Biofluids
Tissues
Cells
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Both NMR and MS datasets of biological complex samples are usually vast, 
requiring the use of pre-processing and data mining methodologies based on 
multivariate analysis (MVA), for their handling and interpretation in terms of potential 
metabolite biomarkers (Rousseau et al., 2008). In parallel with MVA, the potential 
biomarkers are commonly inspected using univariate statistical analysis, followed by 
validation tools to check their accuracy. Biomarker identification is a very challenging 
step due the molecular complexity of biological samples. For NMR data, metabolite 
identification is achieved using databases of standard compounds and 2D NMR 
spectra. Metabolite identification in MS data is difficult due the lack of databases, and 
often extra experiments are needed such as tandem MS. At the end, the metabolite 
alterations are interpreted in terms of disturbed metabolic pathways (Lindon and 
Nicholson, 2008; Lämmerhofer and Weckwerth, 2013). 
 
1.3.2. Brief state of the art of metabolomics 
Regarding metabolomics studies, the most initial application was in drug toxicology, 
studying the effects of drugs on animal models by the measurement of alterations in 
the metabolic profile of biofluids (e.g., plasma and urine) over time, in relation to drug 
exposure (Nicholson et al., 2002). In this respect, metabolic nuances and biomarkers 
can be identified by characteristic changes in the pattern of concentrations of 
endogenous metabolites that relate to the site and mechanisms of toxicity.  
The metabolomics strategy has also been applied in nutrition research focused on 
the study of the metabolic effects of nutrients or dietary patterns (e.g., chocolate intake) 
or nutrition-related diseases (e.g., obesity) on the metabolism (Rezzi et al., 2013). In 
addition, the number of publications of metabolomics applied to human disease 
research has been increasing in the last ten years, with the aim to derive new 
biochemically based assays and identify combination biomarkers for disease diagnosis, 
prognosis and management. For instance, there is a great need for sensitive and 
objective testing methods for cancer within the asymptomatic population, hence much 
research has been carried out in relation to colorectal, breast and lung cancers, among 
others (Duarte and Gil, 2012; Duarte et al., 2013). Cardiovascular diseases have also 
been investigated due to their high incidence of mortality in developed countries (Shah 
et al., 2012), as well as associated risk factors such as hypertension, type 2 diabetes 
and dyslipidemia (Rankin et al., 2014). Both NMR- and MS-based metabolomics have 
been used to comparable extents in disease research using mainly human samples. 
The study of prenatal disorders by NMR- and MS-based metabolomics has been 
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extensively addressed and a review of the main results reported so far is presented in 
the subchapter 1.4.  
 
 
In relation to lipidomics, over the years, an increasing number of disorders have 
been linked with disturbances in lipid metabolism, thus lipidomics has been used to 
search for biomarkers, obtain knowledge on disease mechanisms and monitor the 
efficacy of therapeutic intervention (Vaz et al., 2015). Lipids have been broadly defined 
as hydrophobic or amphipathic small molecules that originate entirely or in part by 
carbanion-based condensations of thioesters and/or by carbocation-based 
condensations of isoprene units (Fahy et al., 2009). In blood plasma/serum, lipids are 
generally packed in particles called lipoproteins formed by an envelope containing 
apolipoproteins and amphipathic lipids (phospholipids and free cholesterol), and a core 
composed mainly by triglycerides, cholesteryl esters and small amounts of other lipids 
(Nelson and Cox, 2005).  
In 2010, the human plasma lipidome was qualitatively and quantitatively described 
using several analytical techniques (GC-MS, LC-MS, MS/MS) unveiling six main 
categories (fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterols and 
prenols), overall containing thousands of distinct lipid molecular species 
(Quehenberger et al., 2010). NMR is a less explored technique in lipidomics approach 
due to their broad and highly overlapped resonances, although some work has 
employed this technique to quantify lipoprotein particles in plasma, either using isolated 
fractions (by ultracentrifugation) or whole plasma/serum (Otvos et al., 1992; Jeyarajah 
et al., 2006; Ala-Korpela et al., 2007). The research in this area resulted in the creation 
of the NMR LipoProfile® test (LipoScience, Inc.), a novel NMR clinical application 
currently used in USA for measurement of lipoprotein particles in blood and individual 
lipids (triglycerides, cholesterol). In addition, few studies employed NMR spectroscopy 
to study the plasma/serum lipid profile using total lipid extracts (Willker and Leibfritz, 
1998; Oostendorp et al., 2006; Tukiainen et al., 2008; Srivastava et al., 2010). 
In clinical research, lipidomics has been extensively used in the study of obesity, 
diabetes, cardiovascular diseases, cancer, inflammations (e.g., rheumatoid arthritis), 
dysfunctions (e.g., mitochondrial dysfunction), genetic disorders (e.g., Barth syndrome) 
  d Al he me ’s d se se (Rolim et al., 2014). In prenatal research, a limited number of 
lipidomics studies have been published as will be further described in the subchapter 
1.4.  
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1.3.3. Analytical techniques: Nuclear Magnetic Resonance (NMR) 
Spectroscopy and Mass Spectrometry (MS) 
Principles of NMR spectroscopy 
NMR is a spectroscopic technique based on the magnetic properties of some 
atomic nuclei when placed in a strong magnetic field, and provides extensive 
information on the molecular structure and dynamics of molecules (Hore, 1999). Atomic 
nuclei have a nuclear spin quantum number,  , which may be zero, a positive integer or 
a half integer. Only nuclei with a positive integer or half integer spin quantum number 
are “NMR v s ble”, and these include 1H, 13C, 15N, 19F, 31P (      ; 2H, 14N (   ); or 
17O (     ) (Claridge, 2009). The spinning nuclei possess angular momentum (   
and a magnetic momentum () originating from their rotating movement, the spin. 
When exposed to an external static and homogeneous magnetic field, B0, the magnetic 
moment of the nuclei experiences a torque which forces it into precession around the 
axis of the magnetic field (Figure 1.5a). In the case of 1H (and any other ½ spin 
nucleus), there are two possible spin orientations or two different energy states. It can 
only align parallel (lower energy,  ) or anti-parallel (higher energy,  ) with respect to 
the external field, B0, corresponding to magnetic quantum numbers of         and 
       , respectively (Claridge, 2009). The torque imposed on the magnetic 
momentum due the presence of the static magnetic field (  ) is known as Larmor 
precession, and is given by        (rad s
-1) or           (Hz), where  is the 
magnetogyric ratio of the nucleus ( = 2.674108 radT-1 s-1 for 1H). The difference of 
potential energy between the two spin states is given by      .  
Considering a collection of similar spin ½ nuclei in the applied magnetic field 
(Figure 1.5b), the parallel   orientation has slightly lower energy than the anti-parallel   
orientation originating an excess of nuclei in the   state at equilibrium, as defined by 
the Boltzmann distribution (Equation 1.1), where    represents the number of nuclei in 
the parallel   spin orientation,   represents the number of nuclei in the anti-parallel   
orientation,     the Boltzman constant and   the temperature. 
  
  
         
Equation 1.1 
 
If the magnetic moments of all nuclei present in the sample are added vectorially, 
the difference of populations between   and   states for a nucleus with spin ½ leads to 
a net vector aligned with the +z direction, named bulk magnetization vector,    (Figure 
1.5b). In order to obtain a NMR signal,    is flipped orthogonally to    by use of a 
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radiofrequency (RF) field (90º pulse),   , oscillating at the same Larmor frequency as 
the spin, and applied for a defined time period. Consequently,    is flipped from the   
axis to the x’-y’ plane and precesses with a frequency equal to the Larmor frequency 
(          in Hz). 
 
 
 
Figure 1.5. a) Precession of the magnetic moment   in the presence of an external magnetic 
field   ; b) at equilibrium the excess of spins in the   state places the bulk magnetization vector 
   parallel to the +z axis. [Adapted from (Claridge, 2009)] 
Upon energy absorption, there is an exponential decrease of the magnetization which 
induces a current in the receiver coil that also decays exponentially (Figure 1.6a). This 
process is recorded as a time domain      signal named Free Induction Decay (FID), 
which is then transformed into the frequency domain       by applying a Fourier 
transformation (Figure 1.6b) (Balci, 2005; Lindon et al., 2007).  
 
 
Figure 1.6. a) Scheme of the magnetization vector    precessing on the x’-y’ plane around the 
z axis inducing a current in the receiver coil; b) Fourier transformation of time domain FIDs to 
the corresponding frequency domain spectrum. [Adapted from (Claridge, 2009)]
 
 
The behaviour of the spins during the period of free precession that follows the RF 
pulse is known as relaxation. There are two main types of relaxation processes, 
namely spin-lattice or longitudinal (T1) and spin-spin or transverse (T2) relaxation. The 
a) 
a) b) 
b) 
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T1 is the time constant for the return to equilibrium of the populations of the spin states, 
while T2 is the time constant for the dephasing of coherence between the spin states. 
Hence, the T1 relaxation time characterizes the relaxation of longitudinal components of 
the magnetization    parallel to   , or in the z component of the magnetization (  ), 
described by Equation 1.2. The T2 relaxation time characterizes the relaxation of 
transverse components of the magnetization    perpendicular to   , or in the x-y 
component of magnetization (   ), being given by Equation 1.3. T2 is less than or 
equal to T1, since return of magnetization of the z direction inherently causes loss of 
magnetization in the x-y plane. (Claridge, 2009) 
 
            
      Equation 1.2 
          
      Equation 1.3 
 
The transverse relaxation processes influence the widths of NMR resonances, the 
widths being inversely proportional to T2 relaxation times. Molecules with a short T2 are 
characterized by faster relaxation (fast decaying in FID) and broad resonances, 
whereas those of long T2 originate slower relaxation (longer FIDs) and narrower 
resonances (Figure 1.7).  
 
Figure 1.7. Influence of transverse relaxation (T2) on the observed FID and 
NMR resonance width. [Adapted from (Claridge, 2009)] 
 
Each nucleus is surrounded by electrons creating their own local magnetic field 
(    ) that opposes to the external magnetic field (  ), thus creating a shielding effect in 
the nucleus. The effective field (    ) experienced by the nucleus is given by      
       . Consequently, each nucleus resonates at a different frequency depending on 
the electronic/chemical neighbourhood, leading to different positions in the NMR 
spectrum. The chemical shift ( ) of a spin is always dimensionless and independent of 
  , given by the resonance frequency of a given nucleus ( ), the resonance frequency 
of a standard signal (      ) and the frequency of the spectrometer (     ), as 
described in Equation 1.4, expressed in parts per million (ppm) (Balci, 2005).  
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  Equation 1.4 
 
The most commonly used reference compounds for 1H and 13C are 
tetramethylsilane (TMS) and 3-(trimethylsilyl)propionate (TSP), which are set to zero. 
The range in which most of the 1H NMR absorptions occur is  el   vely      w  δ 0-14 
downfield from the absorption of TMS. The general chemical shift ranges of different 
functional group can be seen in Table 1.7.  
 
Table 1.7. Typical 
1
H and 
13
C chemical shifts of some chemical groups. 
[Adapted from (Fan, 1996)] 
Chemical group δ 
1
H /ppm Chemical group δ 
13
C /ppm 
C-CH3 0.7-1.1 -CH3 (methyl) 8-30 
=C-CH3 1.5-1.8 -CH2 (methylene) 14-55 
COCH3 (acetyl) 2.0-2.5 -CH- (methine) 22-60 
N-CH3 2.5-3.3 -C- (quaternary) 30-40 
O-CH3 3.3-4.3 CH2=C-R 100-150 
C-CH2-C 1.3-2.5 C=C-C=C-R 110-150 
CO-CH2-C 2.5 C=C-R 65-90 
O-CH2-C 4.0-5.0 Heteroaromatic ring 100-165 
C-CH-OH 3.3-4.0 C-OH (alcohol) 44-85 
C-CH-O-ester 4.2-5.3 C-O-C (ether) 55-85 
=CH-C (olefinic) 5.5-8.5 R-COOH (saturated) 165-188 
Aromatic ring 6.0-9.0 R-COO
-
 175-195 
-CHO (aldehyde) 9.0-10.2 R-C=C-COOH 158-174 
-COOH 10.5-13.5 R-C  R’ (s  u   ed) 158-178 
C-OH (alcohol) 1.5-6.0 R-C=C-C  R’ 152-172 
C-OH (phenol) 6.5-18.5 R-CHO (saturated) 196-220 
Primary amines 1.1-1.8 R-C=C-CHO 176-195 
Secondary amines 1.2-2.1 Saturated ketones  
CO-NH- 5.0-6.5 R-CO-NH2 150-178 
N-alkyl amides 6.0-8.2   
 
 
The area of an NMR resonance is proportional to the relative number of nuclei 
giving rise to it, thus enabling quantitative measurements (Claridge, 2009). In order to 
get accurate NMR peak areas for quantification, the relaxation delay should be at least 
5 × T1 for the slowest relaxing 
1H in the sample. Typically, the concentration of a given 
compound is determined against that of a suitable reference compound (e.g., 3-
(trimethylsilyl)propionate (TSP)) added to the sample. However, in some cases, the 
use of an internal chemical reference may impose constraints such as the interaction 
with the sample components (e.g., interactions between TSP and proteins in 
plasma/serum) which leads to overlap with compound resonances in the sample. An 
alternative approach is to introduce a synthetic rf reference signal as in the ERETIC 
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(Electronic Reference To access In Vivo Concentrations) method. In this method, the 
intensity of the synthetic signal is calibrated by a chemical reference solution of known 
concentration, defining the effective concentration of the ERETIC signal (Claridge, 
2009). 
 
One-dimensional (1D) and two-dimensional (2D) NMR spectroscopy in 
metabolomics 
 NMR spectroscopy has the extraordinary ability to provide detailed information on 
molecular structure of both pure compounds and complex mixtures such as foods or 
biofluids. However, the assignment of 1H NMR spectra of a mixture is a complex 
procedure, and usually requires several 1D and 2D NMR methods, as well as, 
comparison with spectra of standard compounds. 1H NMR experiments are largely 
used in metabolomics due the rapid acquisition times (few minutes per sample), 
making it suitable in studies with large sample arrays. Samples like biofluids have a 
high content of water and, hence, the water protons signal dominates the spectrum 
obscuring a large section. Thus, the water signal has to be suitably suppressed which 
is commonly achieved by water suppression pulse sequences such as a standard 
water presaturation, 1D noesy-presat,  WATERGATE (water suppression by gradient-
tailored excitation) or WET (water suppression enhanced through T1 effects) 
sequences (Lindon et al., 2007). Usually, three types of 1D  experiments are acquired 
in metabolomics studies of complex mixtures: (i) a 1D pulse-and-acquire experiment, 
usually referred as standard 1D, in which large and small molecules contribute to the 
spectrum with intensity proportional to their concentration; (ii) a transverse relaxation 
(T2)-edited or Carr-Purcell-Meiboom-Gill (CPMG) experiment, in which signals from 
protons of macromolecules are suppressed resulting in a spectrum which is dominated 
by the smaller molecules; and (iii) a diffusion-edited experiment based on the 
difference in the diffusion coefficients between macromolecules and low molecular 
weight (Mw) metabolites, an approach in which only macromolecules (or bound small 
molecules) contribute to the spectrum (Beckonert et al., 2007; Lindon et al., 2007). The 
standard 1D pulse sequence consists of an RF 90º pulse preceded by a presaturation 
pulse to saturate the water signal. Usually, the standard 1D 1H NMR spectrum of 
complex samples shows resonances of low Mw (e.g., glucose, lactate, amino acids) 
and high Mw metabolites (e.g., proteins, lipids, lipoproteins) heavily overlapped. The 
CPMG experiment uses the differences in T2 relaxation times to attenuate the signals 
from macromolecules, and the resulting spectrum is dominated by small molecules 
(Meiboom and Gill, 1958; Claridge, 2009). Figure 1.8a shows a CPMG pulse 
sequence, where usually water attenuation occurs during relaxation delay, followed by 
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a 90º pulse, and a spin-echo sequence [-180°-]n used to selectively detect sharp 
signals from low Mw molecules. During the spin-echo delay (), the magnetization 
decreases exponentially with the ratio between /T2, enabling the attenuation of 
macromolecules due their shorter relaxation times compared to small molecules (long 
T2). In order to acquire the whole decay process a large number of echos (n) is 
needed. Diffusion-edited experiments are used to detect broad signals from 
macromolecules due their slow diffusion coefficients, attenuating sharp signals from 
small molecules (fast diffusion coefficients). Figure 1.8b shows a stimulated echo 
sequence for diffusion measurement with bipolar gradients, where an initial 90º pulse is 
applied followed by the application of gradients (G1) which diphase magnetization. 
During the diffusion delay ( ), the molecules are allowed to diffuse, after which large 
molecules remain in a fairly constant position contrarily to small ones due the 
differences in the molecular size. The application of a subsequent gradient, opposite to 
the initial, refocuses magnetization of macromolecules and attenuate signals from low 
Mw molecules. Other pulse sequences commonly used for diffusion measurement are 
based in the pulsed field gradient spin-echo (Claridge, 2009). 
 
a) b)  
 
 
Figure 1.8. Pulse sequences of a) Carr-Purcell-Meiboom-Gill (CPMG) and b) diffusion-edited 
experiments. [Adapted from (Claridge, 2009)] 
 
The use of 2D NMR methods is of paramount importance to provide additional 
information to solve overlap problems and allow identification of metabolites that 
otherwise would remain undetected. 2D NMR methods are based on dipolar (through 
space) or scalar (through bond) couplings between magnetic nuclei. 2D NMR 
acquisition has a general scheme with four basic steps (illustrated in Figure 1.9)  
corresponding to: 1) preparation period, spin systems relax and are excited by at least 
one RF pulse; 2) evolution period (t1), when chemical shifts and spin-spin couplings 
evolve (time domain which is incremented in 2D experiments); 3) mixing period, where 
one or several RF pulses are applied and create an observable transverse 
magnetization; and 4) detection period (t2), which corresponds to the acquisition time 
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(Claridge, 2009). Therefore, the acquisition of a 2D spectrum involves repeating a 
pulse sequence for increasing values of t1 and recording a FID as a function of t2 for 
each value of t1 (Keeler, 2002b). The methods more commonly used for assignment 
and spectral simplification purposes in metabolomics are Total Correlation 
Spectroscopy (TOCSY), Heteronuclear Single Quantum Correlation (HSQC) and J-
resolved spectroscopy (J-res), although two other experiments may also be helpful, 
namely Correlation Spectroscopy (COSY) and Heteronuclear Multiple Bond Correlation 
(HMBC) (Lindon et al., 2007). 
The 1H-1H Correlation Spectroscopy (COSY) experiment reveals the network of 
spin-spin couplings (over 3-5 bonds) in each molecule and can provide simultaneously 
the chemical shift and scalar coupling by detecting the off-diagonal cross peaks, which 
are symmetric with respect to the diagonal (Lindon et al., 2007). The Total Correlation 
Spectroscopy (TOCSY) spectra are more information-rich than COSY since they detect 
multiple relayed connectivities, i. e., allow detection of long range 1H-1H spin-spin 
coupling connectivities (>3 bonds), that are usually too weak in COSY spectra (Lindon 
et al., 2007). TOCSY pulse sequence is characterized by an initial 90º pulse, followed 
by the evolution period (t1) and the Malcolm Levitt (MLEV) sequence that allows 
coherence transfer between all coupled nuclei in a spin-system, as illustrated in Figure 
1.9. The MLEV-17 sequence is formed by 16 composite pulses, followed by a regular 
uncompensated 180º pulse (Bax and Davis, 1985; Claridge, 2009).  
In the Heteronuclear Single Quantum Correlation (HSQC) experiment, the chemical 
shift of 13C is correlated via one-bond coupling constant 1JCH to the 
1H chemical shift of 
the directly bond proton (Lindon et al., 2007). The pulse sequence of HSQC, illustrated 
in Figure 1.9, shows a 90º pulse for proton magnetization followed by an insensitive 
nuclei enhancement by polarization transfer (INEPT) sequence, which transfers 
magnetization between the directly attached 1H-13C and also recovers magnetization 
from 13C to 1H before acquisition (Claridge, 2009). The Heteronuclear Multiple Bond 
Correlation (HMBC) experiment gives correlations between the 13C nuclei and 1H that 
are separated by two, three, and sometimes four bonds (Lindon et al., 2007). 
The 1H J-resolved spectroscopy (J-res) allows spectral simplification based on the 
spin-echo pulse sequence (Lindon et al., 2007). It separates J-splitting and chemical 
shifts on to two orthogonal axes: the J-multiplets are displayed along the F1 dimension, 
while the chemical shifts are shown in F2 dimension. This experiment minimizes 
overlap because contributions of substances with short T2 values are suppressed, and 
allows better determination of coupling constants.  
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Figure 1.9. a) TOCSY pulse sequence based on the MLEV-17 mixing scheme. 
b) HSQC pulse sequence. P, preparation; E, evolution; M, mixing; D, detection. 
[Adapted from (Claridge, 2009)] 
 
Other 2D experiment useful for assignment of complex mixtures is the diffusion 
ordered spectroscopy (DOSY). This experiment allows the discrimination of different 
components in a mixture by their translational diffusion coefficient as a consequence of 
their size (Kerssebaum, 2006). Some applications of this technique include 
determination of binding and association constants (Cohen et al., 2005), identification 
of unassigned spectral peaks in biofluids (Smith et al., 2007) and liquid foods (Gil et al., 
2004), and determination of plasma lipoprotein sizes (Mallol et al., 2013). 
 
The 2D NMR experiments described above are based on the excitation and 
detection of single-quantum coherence. A less explored 2D NMR technique in a 
metabolomics context but still explored for assignment of complex mixtures (e.g., poly- 
and monocyclic aromatic hydrocarbons, olive oil, polycyclic aromatic hydrocarbon 
pollutants) (Reddy and Caldarelli, 2010, 2011, 2012) is the Multiple-Quantum (MQ) 
spectroscopy. In MQ experiments, the excitation of MQ coherence is converted and 
detected as single-quantum coherence. The basic pulse sequence used to excite and 
detect MQ coherences is shown in Figure 1.10, where the first three pulses comprise 
the preparation period, and the last pulse is the mixing period. The first part of the 
sequence (90°- /2-180°- /2) is a spin echo which, at time ( ), refocuses any evolution 
of offset frequencies but allows the coupling to evolve and generate anti-phase 
magnetization. The second 90° pulse turns the anti-phase magnetization into MQ 
coherence which, after evolving for time t1, is returned into observable magnetization 
(single-quantum coherence) by the final 90° pulse (Keeler, 2002b).  
a) 
b) 
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The double quantum-single quantum (2Q-1Q) spectra are very similar to that of 1H-
1H COSY enabling the identification of coupled spins without diagonal-peak multiplets. 
Series of MQ-1Q spectra can be acquired increasing the coherence order, thus 
reducing spectral complexity since some molecules are filtered out due to an 
insufficient size of their spin systems. As can be seen in Figure 1.10b, from a total of 11 
compounds with similar molecular structures, only half appear in the 5Q-1Q spectrum. 
The signals observed in this spectrum correspond to the 5-proton molecular structures, 
thus it was possible to assign 6 compounds (phenol, o-terphenyl, dibenzyl, acetanilide, 
biphenyl and benzophenone) based on their fingerprint in 5Q-1Q experiment (Reddy 
and Caldarelli, 2010). In addition, the intensity of maximum quantum (MaxQ) signals 
can be quantified measuring the whole cross-peak 2D integral, thus enabling the 
quantification of molecules with very similar chemical structure (Reddy and Caldarelli, 
2012).  
 
 
Figure 1.10. a) Pulse sequence for excitation and detection of MQ coherence. b) Expansion of 
the relevant aromatic region of the 5Q-1Q spectrum for assignment of phenol, o-terphenyl, 
dibenzyl, acetanilide, biphenyl and benzophenone in a mixture with 11 compounds. [Adapted 
from (Keeler, 2002b; Reddy and Caldarelli, 2010)] 
Principles of MS 
MS analysis consists in separation of gas-phase ions of compounds according to 
their mass-to-charge ratio (m/z). A mass spectrum (MS spectrum) plots m/z values of 
the ions against the relative abundance or ion intensity. Ions observed in the tandem 
mass spectrum (MS/MS spectrum) provide information about the nature and the 
90 x 90 x180 90 
a) 
b) 
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structure of their precursor molecule. So, the first step in MS is the production of gas-
phase ions of the compounds under analysis in the ionization source. Under 
electrospray ionization, one of the most common ionization methods used nowadays, 
the molecule scan ionize as protonated molecules [M+H]+. To gather structural 
information, these ions can be induced to fragmentation generating new ions, called 
product ions, and thus providing structural information about the initial molecule 
(Hoffmann and Stroobant, 2007). 
A mass spectrometer essentially consists of five parts (Figure 1.11): 1) a sample 
inlet, to introduce the compound that is analysed (e.g. gas chromatograph, direct 
insertion probe), 2) an ionization source, to produce ions from the sample, 3) one or 
several mass analysers to separate the various ions according to their m/z, 4) a 
detector, to detect the ions emerging from the last analyser and measure their 
abundance, and 5) a data processing system, to produce the mass spectrum 
(Hoffmann and Stroobant, 2007). 
 
  
Figure 1.11. Main components of a mass spectrometer. 
 
The sample inlet system can be direct (injects directly samples into the ion source), 
or alternatively coupled to a separation system such as GC or LC. General 
characteristics of GC and LC coupled to MS will be described below in the subsection 
MS techniques in metabolomics and lipidomics. A wide variety of ionization sources 
and mass analyzers are available, the choice being dependent on the nature of the 
sample and the type of information required from the analysis. The most common 
ionization sources are electron impact (EI), matrix-assisted laser desorption and 
ionization (MALDI) and electrospray ionization (ESI). Mass analysers include magnetic 
sector analyzers, quadrupole and ion trap analyzers (e.g. quadrupole ion trap (Q-IT)), 
time of flight analyzers (TOF), and Fourier transform ion cyclotron resonance. 
Following, the basic principles of the ESI and linear ion-trap are described, as they 
were the ionization source and analyzer used in this thesis. In ESI source, the sample 
solution is sprayed after passing through a needle and submitted to a high electric field, 
to create charged particles. Then, a flow of warm gas aid in solvent evaporation 
Ionization 
source
Ion 
detector
Sample 
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Mass 
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Data 
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allowing the formation of ions in the gas phase. Since ESI generates ions directly from 
solution, it is easily coupled with LC. Positive and negative single and/or multiply 
charge ions are created by ESI, depending on the nature of the analyte. Typically ESI-
MS spectrum shows only the molecular ions with absence of fragment ions, since it is a 
soft ionization technique (Mishur and Rea, 2011). In the analyser linear ion trap, the 
molecular ions can be fragmented by collision with an inert gas, generating new ions 
that are further analysed and detected in a new MS/MS spectrum (Hoffmann and 
Stroobant, 2007). Linear ion trap is commonly used for analysis of low abundance 
compounds to their high trapping capacity as well as in fragmentation experiments to 
gain additional structural information (Lee et al., 2010). After sample ionization and sort 
by mass in mass analyzer, the detector converts the information to an electric current 
for quantitation and data analysis. A variety of detectors have been applied, the most 
widely used being the electron multiplier (Mishur and Rea, 2011). 
In order to identify the molecular ions present in MS spectra, fragmentation 
experiments, known as tandem MS (MS/MS or MSn), are widely applied enabling the 
comparison of the experimental fragmentation patterns with authentic standards and 
spectral data bases to confirm the molecular structure. In cases where data bases or 
authentic standards are not available, the metabolite identification is achieved using the 
exact mass of the precursor ion (unfragmented), the exact mass of the fragment ions, 
and their corresponding isotopic distributions (Lee et al., 2010). 
 
MS techniques in metabolomics and lipidomics 
Gas chromatography-mass spectrometry (GC-MS) 
Metabolite profiling with GC-MS involves first an extraction step of metabolites from 
the biological sample, followed by derivatization to reduce the polarity and increase the 
thermal stability and volatility of metabolites making them amenable to GC. The 
derivatized molecules are injected into the GC system and subjected to physical 
separation in which the components are selectively distributed between the mobile 
phase (an inert carrier gas) and a stationary phase (thin film of liquid phase bonded to 
the walls). Capillary GC columns operate at very high temperatures and provide 
significantly high chromatography resolution. Chromatographic separation in GC is 
dependent of several factors such as column properties, carrier gas type, carrier gas 
velocity and oven temperature program (Pasikanti et al., 2008). Due the chemical 
derivatization required, GC provides separation of metabolites in a molecular weight 
range of 18 to ~350 Da and includes a range of relatively polar metabolite classes (e.g. 
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amino acids, organic acids, amines, amides, sugars, among others) (Dunn et al., 
2011a). The ionization technique and mass analyzers mostly applied in GC-MS 
metabolite profiling are EI, and TOF or quadrupole analyzers, respectively. EI provides 
high reproducible fragmentation enabling the assignment of unknown metabolites using 
standard reference libraries (Want et al., 2006a; Dunn et al., 2011a). Recently, the 
introduction of comprehensive two-dimensional GC (GC×GC) combined with TOF-MS 
enable the reduction of analysis time as well as the detection of large number of 
metabolites in a single analytical run.  GC×GC/TOFMS uses two capillary columns with 
different separation mechanisms (Dallüge et al., 2003; Pasikanti et al., 2008). 
While in untargeted metabolomics the GC-MS apparatus is used for global 
metabolic profiling to cover all the measurable analytes in a sample (full scan mode), 
the strategy in targeted profiling is to select the ion signals specific to the chosen set of 
metabolites. The selection of specific ions is usually performed by selected ion 
monitoring (SIM). SIM is exclusively used to quantifying data on known targeted 
compounds providing increased sensitivity over full scan spectral acquisition used in 
untargeted profiling. In SIM mode, the mass spectrometer continuously measures only 
the selected molecule ions and characteristic fragments throughout the GC run 
(Hübschmann, 2009). Although LC-MS has been the most widely applied separation 
technique in lipidomics, some applications of GC-MS have been emerged. GC-MS has 
been mainly used to the analysis of fatty acids especially the cis/trans isomers (Kulig et 
al., 2006; Liu et al., 2010). The main limitations of GC for lipid analysis are the high 
temperatures used and the complexity of derivatization required before separation, 
being a time-consuming approach and removing most structural information about lipid 
molecular species. 
 
Liquid chromatography-mass spectrometry (LC-MS) 
When compared to GC, LC is not limited to the thermally stable volatile compounds 
and separation of polar and non-polar metabolites, salts, acids, bases and others is 
possible due the wide range of separation modes available. Reverse-phase LC (RPLC) 
is the most widely used LC method in untargeted metabolomics and lipidomics. 
However, hydrophilic interaction liquid chromatography (HILIC), particularly coupled to 
MS, has been emerged in these fields (Dunn et al., 2011a; Li et al., 2014). The RPLC 
method uses hydrophobic stationary phases (e.g., silica-based phases) and the mobile 
phases typically start with a high aqueous content (100% aqueous) to an increase of 
the organic phase fraction until the end (100% organic). This method provides efficient 
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retention and separation of relatively non-polar metabolites in a large Mw range (50 up 
to 1,500 Da) including high Mw lipid species (e.g., phospholipids and triglycerides) and 
non-polar amino acids among others (Dunn et al., 2011a). Compared to RPLC, HILIC 
enables the separation of more polar compounds typically non-retained in RPLC, thus 
combining both phases is possible to obtain a large coverage of the metabolites 
present in biofluids. HILIC stationary phases can be from three different types, namely 
neutral (no electrostatic interactions), charged (strong electrostatic interactions) and 
zwitterionic (weak electrostatic interactions), while the mobile phases usually are 
ammonium salts of acetic and formic acid at a suitable pH (Spagou et al., 2010). As an 
alternative to these techniques, ultra high performance chromatography (UPLC) has 
been applied. This technology combines high pressure with small particle size reverse 
phase packing material resulting in higher resolution, lower analysis time and increased 
sensitivity (Lindon et al., 2007). 
In metabolomics and lipidomics, the ionization source most widely used with LC-MS 
systems is ESI, in both positive and negative modes, in order to obtain the most 
comprehensive profile. Regarding mass analyzers, quadrupole-TOF (Q-TOF) has been 
largely applied in LC-MS analysis of biofluids. This hybrid mass spectrometer combines 
high efficiency, sensitivity, and accuracy being typically coupled to ESI sources (Want 
et al., 2006a). In untargeted metabolic profiling, full scan acquisition is used in order to 
enable the detection of compounds of every mass and LC-MS/MS studies to provide 
structural information (Griffiths et al., 2010). Targeted studies using LC-MS also require 
appropriate LC separation conditions to the specific compound class of interest by 
performing selected reaction monitoring (SRM) scans determining precisely and 
accurately relative concentrations of the metabolites. In SRM, the fragmentation of the 
known precursor ion is monitored to a known fragmentation ion and several SRM 
experiments are undertaken during a single LC-ESI-MS/MS analysis to monitor a wide 
range of metabolites. LC-MS based lipidomics enables the analysis of almost all lipid 
molecular species with several studies performed on untargeted lipid profiling (Cífková 
et al., 2012; Sarafian et al., 2014), phospholipid profiling (Want et al., 2006b; Xia and 
Jemal, 2009; Scherer et al., 2010) and sphingolipid profiling (Hammad et al., 2010; 
Scherer et al., 2011) of blood samples.  
 
Direct-infusion mass spectrometry (MS) 
Alternatively to GC- and LC-MS, direct-infusion MS has been applied, without 
previous separation, to analyse all the lipid classes together. Lipid extracts are directly 
infused into the mass spectrometer where different ion source polarities (to form 
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positive or negative ions) and infused ionization solution additives, are employed to 
provide a lipid class-specific favoured analysis (Harkewicz and Dennis, 2011). ESI and 
matrix-assisted laser desorption/ionization (MALDI) are the most widely used ion 
sources in direct-infusion MS. Both ionization methods enable the measurement of 
many components simultaneously in complex lipid samples with good signal-to-noise 
ratios and reproducibility, without prior derivatization or separation. Targeted lipidomic 
analysis using ESI-MS specific scan models is globally referred as shotgun-lipidomics 
and has become the most frequently used MS approach in lipid profiling from complex 
samples such as blood and tissues (Li et al., 2014). 
 
1.3.4. Statistical tools in metabolomics and lipidomics 
Data pre-processing  
The large and complex datasets generated by both NMR and MS-based techniques 
have to be first pre-processed for multivariate modelling. Usually, NMR data show 
variations in peak positions and intensity due to differences in sample matrix (i.e., pH or 
ionic strength, concentration). On the other hand, MS data commonly have 
background, noise and retention time fluctuations over a set of chromatograms. 
Therefore, pre-processing steps are very important to correct or minimize these 
variations. The pre-processing methods mainly used for both NMR and MS-based data 
are presented in Table 1.8. 
Regarding the NMR data, the spectra can be divided into multiple discrete regions 
(buckets) along the chemical shift axis which are integrated, a process known as 
binning or bucketing. It was firstly applied to correct peak shifts due to pH or ionic 
strength variation among samples and reduce matrix complexity, however it frequently 
leads to substantial information loss (Blekherman et al., 2011). Alternatively, alignment 
algorithms can be applied to full resolution spectra in order to minimise the problem of 
peak shifts without decreasing spectral resolution. In the scope of this thesis, the 
recursive segment-wise peak alignment (RSPA) was applied (Veselkov et al., 2009). 
This algorithm consists of realigning peak positions in a 1H NMR spectrum with respect 
to peak positions of a reference spectrum. It provides a fast and accurate spectral 
alignment using full spectral information and considering each individual signal as a 
whole and not as separate peaks. After either bucketing or alignment, a NMR two 
dimensional data table (or matrix) is constructed, consisting of n rows that correspond 
to observations/samples, and m columns that correspond to each variable (e.g., data 
point).   
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Table 1.8. Pre-processing methods mainly applied in both 
NMR and MS-based datasets. 
NMR data MS data 
 Binning/bucketing  Filtering 
 Alignment  Deconvolution 
 Normalization  Peak detection 
 Scaling  Alignment 
  Normalization 
  Scaling 
 
Subsequently, to reduce the variation on overall concentrations of samples, a 
normalization step is usually performed. This step is crucial to remove unwanted 
systematic variation between samples. For NMR data, two types of normalization 
methods are commonly applied such as total area (or total intensity) or probabilistic 
quotient normalization (PQN). Total area normalization refers to divide each variable by 
the total integrated intensity across the whole NMR profile (Veselkov et al., 2011). PQN 
is based on the calculation of a most probable dilution factor by looking at the 
distribution of quotients of the amplitudes of a test spectrum by those of a reference 
spectrum (e.g., controls) (Dieterle et al., 2006).  
The final pre-processing step is scaling which consists of compensating for the high 
dynamic range in metabolite concentration so that changes in abundant metabolites do 
not dominate statistical models. Scaling the data improves model interpretability, for 
example, unit variance (UV) consists in mean centering (i.e., subtracting the mean 
value of the sample) followed by the division of each variable by its standard deviation. 
Other scaling methods include pareto (division of each variable by the square root of 
the standard deviation of that variable) and logarithmic transformation (application of 
logarithm to each variable) (Veselkov et al., 2011). A more detailed description of pre-
processing steps commonly applied in NMR data can be found in several review 
articles (Issaq et al., 2009; Blekherman et al., 2011; Liland, 2011). 
 
For MS data, a higher number of pre-processing steps is required when compared 
to NMR. Spectral filtering is usually applied to remove random noise and baseline shift 
in the raw data (K   j m     d   eš č  2007). Then, spectrum deconvolution is used 
to separate two or more co-eluting or overlapping components in the MS spectral data. 
Peak detection enables the identification of all individual components caused by true 
ions and avoids detection of false positives providing accurate quantitative information. 
Chromatogram alignment consists of aligning the retention time to accurate m/z 
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ensuring that metabolites are identified as the same metabolite for all samples 
analysed, making the subsequent analysis more robust and accurate. The resulting 
dataset includes the retention time-m/z pairs, sample information, and peak areas. 
The normalization of MS-based data is commonly achieved using either single or 
multiple stable internal standards with known concentration spiked into the sample prior 
to or during the extraction step (Blekherman et al., 2011). Finally, the scaling methods 
typically applied to MS data are the same enumerated above for NMR data. For those 
interested in a more detailed description of each MS data pre-processing step and 
corresponding algorithms, a number of reviews have been published (Katajamaa and 
  eš č  2007  Iss q e   l   2009  Blekhe m   e   l   2011). 
 
Multivariate analysis (MVA) tools: general considerations 
Initially, unsupervised methods such as Principal Component Analysis (PCA) and 
hierarchical cluster analysis can be applied to NMR or MS-based datasets to reduce 
data complexity as well as visualize grouping trends and outliers (Lindon et al., 2001). 
PCA constructs a two-dimensional data table, called X matrix, containing n 
observations in a K-dimensional space (Figure 1.12a). The variation in the data table is 
reduced by a low dimensional model plane that approximates all rows (e.g. 
observations) in X, and is represented by points in Figure 1.12b. Hence, the variation in 
data matrix X is described by a scores matrix (T) which characterizes samples 
distribution, a loadings matrix (P) which gives the contribution of each variable to the 
samples distribution, and a residuals matrix (E) containing un-modeled variations, 
given by X=TPT+E. The 1st PCA component contains the largest matrix variance in the 
points. The 2nd PCA component is orthogonal to the first and contains the next largest 
variance and so on for a K-dimensional space. The scores (t1, t2, ..., tm) can be used to 
represent the relationship among the observations/samples in the model plane and 
provides an overview of all observations in the data table. Hence, groupings, trends, 
and outliers are made visible. The loading vectors (p1, p2, ..., pm) characterize the 
relationship among the measured variables and describe the contribution of those 
variables to the observed sample distribution. A central feature is that directions in the 
scores plot correspond to directions in the loadings plot, and vice-versa (Trygg et al., 
2007). 
Then, if needed, supervised methods such as partial least squares (PLS) and 
orthogonal PLS (OPLS) can be applied using the class information given for the 
training set of sample data to optimize the separation between two or more sample 
classes (Lindon et al., 2004). While PCA is a method that only considers the structure 
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of one matrix X, PLS constructs a set of orthogonal latent vectors from a matrix X 
(predictor variables) that maximizes the covariance between those vectors and a matrix 
Y (dependent variables), given by X=TPT+E and Y=TCT+F.  
 
   
  
Figure 1.12. a) Data organization as a matrix denoted as X, with N rows of observations and M 
columns of variables; b) Geometrically, the principal components are equivalent to a plane, 
which well fits the N points in the K-dimensional space. [Adapted from (Trygg et al., 2007)] 
 
PLS can be used for discrimination analysis, known as PLS-DA, where the Y matrix 
contains dummy values as class labels. In the case of two classes, usually the values 
of the dependent variable are given 1 for one class and 0 for the other class (Barker 
and Rayens, 2003). The metabolites contributing the most to the discrimination 
between the two classes are usually ascribed by plotting the loadings plots along with 
the variable importance to the projection (VIP). The metabolites with large VIP values 
in the model (higher than 1) are the most relevant and pointed as potential biomarkers 
(Mahadevan et al., 2008).  
On the other hand, OPLS method is often applied with the aim to improve 
interpretation of PLS models and reduce model complexity. OPLS removes variation 
from X that is not correlated to Y or, in other words, removes systematic variation in X 
that is orthogonal to Y (Trygg et al., 2007). Other supervised methods that are often 
used are linear discriminant analysis, soft independent modelling of class analogy and 
neural networks (Lindon et al., 2001).  
 
Variable selection 
The data sets obtained from NMR and MS based metabolomics contain a large 
amount of information with some irrelevant or redundant variables for classification 
purpose. Therefore, the number of variables can be reduced using variable selection 
methods in order to improve model performance and reduce model complexity with 
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minor loss of information (Smolinska et al., 2012a). Variable selection methods have 
been applied to obtain a small set of variables in both NMR and MS data of biological 
samples (e.g., plasma/serum, cerebrospinal fluid, urine, tissue) related with non-
alcoholic fatty liver disease (Quintás et al., 2009), multiple sclerosis (Smolinska et al., 
2012b), colorectal cancer (Nishiumi et al., 2012), and different prenatal disorders (Diaz 
et al., 2013b). The variable selection techniques commonly applied in metabolomics 
are based on the multivariate analysis parameters, namely VIP values, loadings and 
PLS regression coefficients (b-coefficient) (Andersen and Bro, 2010; Smolinska et al., 
2012a; Diaz et al., 2013b; Gromski et al., 2014).  
One of the most used selection method has been based on the VIP criteria. The 
VIP reflects the importance of variables in the model both with respect to Y (i.e., its 
correlation to the response), and with respect to X (the projection). The VIP value for 
the kth variable is given by Equation 1.5, where Wkj is the weight value for variable k 
component j, SSYj is the sum of squares of explained variance for the j
th component, K 
is the number of variables, SSYtotal is the total sum of squares explained of the 
dependent variable (Y), and J is the total number of components. A VIP value < 1 
indicates a variable not relevant for explaining Y, which could be removed from the 
model (Andersen and Bro, 2010). 
 
      
    
        
 
   
          
 Equation 1.5 
Other methods used in metabolomics studies are based on selectivity ratio, interval 
PLS (iPLS), genetic algorithms, Support Vector Machines-recursive feature elimination, 
random forests and recursive weighted PLS (rPLS). A detailed description of these 
methods can be found elsewhere (Rajalahti et al., 2009; Andersen and Bro, 2010; Lin 
et al., 2012; Gromski et al., 2014; Rinnan et al., 2014). 
 
Validation of MVA models 
When MVA is applied, the resulting models and respective discriminant metabolites 
have to be validated to ensure that the putative discovered biomarkers are not 
randomly correlated to the effect of interest. Usually, in order to determine whether 
overfitting occurred in MVA models, one of the most common methods used is n-fold 
cross-validation. Cross-validation consists of randomly spliting the dataset into n 
equally-sized blocks and then training the model n times each time holding out one of 
the folds as an internal validation set. The R2 and Q2 parameters are used to give 
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information about how well the data are modelled indicating the goodness of the fit and 
the predictive ability, respectively (Broadhurst and Kell, 2006). Thus, R2 around 1 
indicates perfect description of the data by the model, whereas Q2 around 1 indicates 
perfect predictability. However, it has been shown that in practice it is difficult to give a 
general limit for a good Q2 since this strongly depends on the properties of the dataset 
(e.g., number of observations included) (Triba et al., 2015). 
Other common method to validate the MVA models is permutation testing. The 
permutation tests evaluate whether the specific classification of the individuals in the 
two designed groups is significantly better than any other random classification in two 
arbitrary groups. In this method, the two class labels are subjected to multiple random 
rearrangements of the labels on the observed data points. The permutation test is 
repeated many times and the permuted and true models are then compared to this 
distribution of all possible models (Westerhuis et al., 2008). In this thesis, Monte Carlo 
Cross Validation (MCCV) was computed for randomly permuted and true (original 
memberships) classes. MCCV consists in splitting the data into training and prediction 
sets, the latter set being used for class membership prediction. Usually, MCCV method 
performs 500 to 1000 iterations and calculates for each iteration the Q2 value and 
confusion matrix, enabling at the end, the construction of a Q2 distribution and a 
receiver operating characteristics (ROC) graph that give the prediction ability and the 
performance of the classification model (Figure 1.13) (Xu and Liang, 2001; Xia et al., 
2013). 
Confusion matrix represents four possible outcomes, namely true positives (TP), 
false negatives (FN), true negatives (TN), and false positives (FP), as shown in Figure 
1.13a. It is the basis for several common metrics, such as classification rate (CR), 
sensitivity or true positive rate (TPR), and 1-specificity or false positive rate (FPR). The 
sensitivity (or TPR) is defined as the number of true positives as a percentage of all 
positives, given by Equation 1.6. 1-specificity (or FPR) is the number of false positives 
as a percentage of all negatives, defined by Equation 1.7. The classification rate (CR) 
is given by the ratio between the sum of true positives and negatives and the total 
number of classifications, as in Equation 1.8 (Fawcett, 2006). 
The Q2 distribution (Figure 1.13b) represents the Q2 values obtained for permuted 
(H0) and true models (HA) in all iterations performed in MCCV, being a good manner to 
evaluate the predictive power of the model. Minimal overlapping of Q2 values of true 
and permuted models usually indicates a model with good predictive power. 
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Figure 1.13. Examples of a) confusion matrix for two classes (disease and control), b) Q
2
 
distribution of true and permuted classes, and c) ROC graph of true and permuted models. 
ROC graphs are constructed from the confusion matrix by plotting the sensitivity 
(TPR) on the y axis as a function of the 1-specificity (FPR) on the x axis. The ROC 
graph shown in Figure 1.13c shows the perfect classification since the true classes 
have sensitivity and specificity equal to 1 (100%) and are clearly separated from the 
permuted classes, which have both sensitivity and specificity equal to 50% (random 
classification performance). Alternatively, the area under the ROC curve (AUC) can be 
used to measure the accuracy of the classification model and usually ranges from 0 to 
1. The AUC value goes to 1 for a perfect accuracy and separation between the 
classes. When two classes are not separated, the AUC value is close or lesser than 
0.5 (Fawcett, 2006).  
 
                  
  
     
 Equation 1.6 
 
                    
  
     
 Equation 1.7 
                          
     
           
 Equation 1.8 
 
Finally, the most reliable way to estimate the ability of the model to predict Y values 
of new individuals is to predict individuals from an independent sample set that were 
not used to build this model. If the same predictability appears in an independent study, 
the MVA models can be considered as reliable. However, in most metabolomics 
studies the number of samples is too low (dozens) to split the data into a training and a 
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test set, where the training set is used to build the model and the test set is used to 
estimate the predictability (Triba et al., 2015). 
 
Statistical total correlation spectroscopy (STOCSY) 
Statistical total correlation spectroscopy (STOCSY) has significantly enhanced 
information recovery from complex biological samples through the identification of 
multiple peaks from the same molecule, as well as the identification of different 
molecules involved in the same pathway (Cloarec et al., 2005). This method is based 
on the computation of correlation statistics between the intensities of all points in NMR 
spectra, thus generating links between signals from molecules that vary in 
concentration between samples (Cloarec et al., 2005; Coen et al., 2008). The 
application of STOCSY on metabolomic data was firstly reported by Cloarec et al. to 
decipher the structure of several metabolites in the 1H NMR spectra of urine samples 
(Cloarec et al., 2005). This method has been applied in the metabolomics context for 
rapid identification of drug metabolites in biofluid samples (Holmes et al., 2007), 
integration of data from the same samples acquired on heteronuclear NMR 
experiments (e.g., 1H and 31P) (Coen et al., 2007) or different analytical platforms (e.g., 
NMR and ultra-performance liquid chromatography-mass spectrometry (UPLC-MS)) 
(Graça et al., 2012b), integration of data from the same individuals across different 
biofluids or tissues (Maher et al., 2011), and integration of data of genome-phenotype 
data with metabolomic data (Dumas et al., 2007). 
The correlation matrix   is computed from a set of sample spectra according to 
Equation 1.9, where    and    are the autoscaled matrices composed by   spectra 
and   variables in the spectra of each matrix (Cloarec et al., 2005). The correlation 
coefficient gives information about the direction (positive or negative) and magnitude of 
the determined correlation ranging from 1 to -1. 
   
 
   
  
    Equation 1.9 
STOCSY can be applied in both 1D and 2D forms and to homo (e.g., 1H) or 
heteronuclear (e.g., 1H and 31P) data (Coen et al., 2008). The usefulness of STOCSY 
as a tool for molecular identification is clearly illustrated in Figure 1.14a, where all the 
1H NMR resonances from plasma glucose are highly correlated (red color). In addition, 
lower intermolecular correlations or anticorrelations represent molecules that may be 
involved in the same pathway, the concentrations of which are independent or under 
some common regulatory mechanism (Cloarec et al., 2005; Coen et al., 2008). 
Chapter 1 
 
42 
  
Figure 1.14. a) 1D STOCSY of the variable at δ 5.23 ppm correlated with the whole CPMG 
spectrum of blood plasma colored by the correlation coefficient (r); b) 2D STOCSY of CPMG 1H 
NMR spectra of blood plasma vs. cerebrospinal fluid (CSF). [Adapted from (Maher et al., 2011)] 
The application of STOCSY to identify dynamic interactions between metabolites in 
two different biofluids, namely blood plasma and cerebrospinal fluid (CSF) (Maher et 
al., 2011), is illustrated in Figure 1.14b. This 2D plot shows high statistical correlations 
for valine between the two biofluids, along with propylene glycol, a drug delivery 
vehicle. In addition, correlations corresponding to broad signals from lipoproteins are 
observed. 
Univariate statistical methods: general considerations 
Data analysis methods in metabolomics are mostly based in multivariate analysis, 
although univariate methods have been used to identify biomarkers statistically 
significant according to a critical threshold (Vinaixa et al., 2012). These methods are 
based on a null hypothesis (H0) which postulates a null difference between the mean 
(or median) of the areas or concentrations of the metabolites detected in the 
populations under study (e.g., controls and disease). The probability (p-value) for null 
hypothesis rejection is determined and if the p-value is below the pre-defined threshold 
of probability (, usually set at 5%), the null hypothesis is rejected (Vinaixa et al., 
2012). Univariate statistical methods can be parametric or non-parametric if the data 
follows a Gaussian or normal distribution or not, respectively (Vinaixa et al., 2012; 
Sheskin, 2014). Two types of parametric tests commonly used in metabolomics are 
  ude  ’s  -test and ANOVA (Analysis of Variance), while the Wilcoxon Rank Sum test 
is one of mostly used non-parametric tests.  
 
a) b) 
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1.4. Metabolomics and lipidomics in human prenatal and newborn health 
studies 
The ability of metabolomics methods to detect simultaneous changes in the 
metabolites present in biological samples has advanced enticing possibilities for 
improved prenatal health monitoring. Figure 1.15 illustrates the number of papers 
published in relation to metabolomics (based on NMR, MS and infrared (MIR and NIR)) 
and lipidomics of prenatal disorders comprising maternal, fetal and newborn conditions. 
Most metabolomic studies have taken place in the last four years (Figure 1.15a) with 
the number of papers starting to increase from 2011 (coinciding with the beginning of 
this thesis) until 2014. Lipidomic studies comprise only 8 papers focused on MS 
techniques (GC- and LC-MS) with only one based in NMR applied to measure 
lipoprotein concentrations.  
Regarding the biological matrices used in these studies, maternal blood (plasma 
and serum) has been the most explored biofluid, followed by amniotic fluid, maternal 
urine, umbilical cord blood, newborn blood and urine, placental extracts, breast milk, 
cervicovaginal fluid, bronchoalveolar lavage fluid, and hair, in decreasing order of 
number of publications (Figure 1.15b). For maternal blood plasma studies, three 
resulted from this thesis (Diaz and Pinto et al., 2011; Pinto et al., 2014b, 2014d). The 
most studied disorder was found to be preeclampsia, followed by PTD, FM, 
perturbations of fetal growth (including SGA, LBW, VLBW, IUGR and macrosomia), 
GDM, CD, healthy pregnancy, PROM, IEM and HIE, in decreasing order (Figure 
1.15c). The increasing awareness of the scientific community towards the usefulness of 
metabolomics in prenatal research has also been illustrated by a large number of 
reviews published from 2006 to 2014 (one of them resulted from the work developed 
during this thesis (Pinto et al., 2014a)) listed in Table 1.9 by research area. A brief 
review of the main results reported for prenatal and newborn health studies is 
presented below, firstly for healthy pregnancies and then for maternal and fetal 
disorders. More recent studies comprising higher number of samples will be presented 
in more detail, grouped first by biological matrices near the fetal environment (amniotic 
fluid and placenta), followed by maternal (blood and urine) and newborn biofluids 
(umbilical cord blood, dried blood spots and urine). 
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Figure 1.15. Number of metabolomics and lipidomics studies in human prenatal and 
newborn health research shown by a) year published (including reviews), b) biological 
matrix used and c) status (healthy or non healthy). BALF: bronchoalveolar lavage fluid, 
IEM: inborn errors of metabolism, HIE: hypoxic ischemic encephalopathy. Fetal growth 
anomalies include SGA, low birth weight (LBW), very low birth weight (VLBW), IUGR and 
m c  s m      he  s ud es   clude del ve y me h d   ewb   ’s  ge  b l   y    es     d 
hepatitis syndrome, pesticide exposure, breastfeeding, cytomegalovirus, respiratory 
distress syndrome, and bronchopulmonary dysplasia. 
 
Table 1.9. Metabolomics reviews of maternal, prenatal and newborn disorders. 
Research area Reference 
Maternal disorders (Romero et al., 2006), (Horgan et al., 2009), (Gracie et al., 2011), 
(Heazell et al., 2011), (Syggelou et al., 2012), (Fanos et al., 2013a), 
(Lowe and Karban, 2014), (Dessì et al., 2014a), (Huynh et al., 
2014), (Pinto et al., 2014a)  
Fetal disorders (Dessì et al., 2012), (Dessì et al., 2013), (Fanos et al., 2013a), 
(Dessì et al., 2014a), (Kamath-Rayne et al., 2014), (Pinto et al., 
2014a)  
Newborn disorders (Syggelou et al., 2012), (Fanos et al., 2013b), (Mussap et al., 
2013), (Moco et al., 2013), (Dessì et al., 2014b), (Pinto et al., 
2014a)  
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1.4.1. Healthy pregnancy and maternal disorders 
Table 1.10 lists the metabolomics studies carried out on different biological 
matrices in search for metabolite alterations in relation to healthy pregnancy and 
maternal disorders. Healthy pregnancies have been studied by metabolomics of 
amniotic fluid (Cohn et al., 2009, 2010; Ottolenghi et al., 2010), placental tissue 
extracts (Dunn et al., 2011b), maternal blood plasma (Luan et al., 2014; Pinto et al., 
2014b) and urine (Sachse et al., 2012; Diaz et al., 2013a; Trivedi and Iles, 2014a), one 
comprising results presented in this thesis (Pinto et al., 2014b). NMR and GC-MS 
metabolomics have revealed gestational age-related alterations in amniotic fluid levels 
of several amino acids (e.g., Ala, Val, Ile, Leu, Lys, Gln), betaine, creatinine, glucose, 
pyruvate and succinic acid (Cohn et al., 2009, 2010; Ottolenghi et al., 2010). For 
placental tissue extracts collected at early and late 1st trimester, significant changes in 
acyl carnitines, di- and triglycerides, nucleotides, fatty acids, phospholipids, 
sphingolipids and vitamin D metabolites were observed by UPLC-MS (Dunn et al., 
2011b).  
For maternal blood plasma, untargeted LC-MS and shotgun lipidomics of plasma 
extracts of 1st (n=30), 2nd (n=120) and 3rd (n=30) trimesters revealed increases in 
dihydrobiopterin, free carnitine, acetyl-alanine, leucyl-phenylalanine and in several 
phospholipid classes (phosphatidylcholines (PC), lyso-PC (LPC), lysophosphatidyletha-
nolamines (LPE) and lysophosphatidylserines (LPS)) (Luan et al., 2014). Regarding 
maternal urine alterations across pregnancy, a large (n=823 women) and multi ethnic 
study was performed by NMR metabolomics including samples collected during 
pregnancy (8-20 g.w. and 26-30 g.w.) and post partum (10-13 weeks after delivery) 
unveiling substantial differences between the time points, dominated by a steady 
increase of urinary lactose concentrations, and an increase during pregnancy and 
subsequent dramatic reduction of several unidentified NMR signals between 0.5 and 
1.1 ppm (Sachse et al., 2012). Other NMR metabolomics study of urine collected for 
non-pregnant (n=16) and pregnant at 1st (n=16), 2nd (n=20) and 3rd (n=19) trimesters 
revealed significant changes in 21 metabolites, 8 of which newly detected in relation to 
pregnancy: choline, creatinine, 4-deoxyerythronic acid, 4-deoxythreonic acid, 
furoylglycine, guanidoacetate, 3-hydroxybutyrate and lactate (Diaz et al., 2013a). 
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Table 1.10. Metabolomics studies of healthy pregnancy and maternal disorders by biological 
matrix. 
†
 lipidomics studies. NB: newborn; CVF: cervicovaginal fluid. 
Matrix Subject References 
Amniotic 
fluid 
Healthy  (Cohn et al., 2009), (Cohn et al., 2010), (Ottolenghi et al., 2010) 
Preeclampsia (Bock, 1994) 
PTD (Graça et al., 2010), (Romero et al., 2010), (Power et al., 2011), 
(Graça et al., 2012a), (Graça et al., 2012b), (Graça et al., 2013), 
(Menon et al., 2014) 
GDM (Bock, 1994), (Graça et al., 2010), (Graça et al., 2012a), (Graça 
et al., 2012b) 
PROM (Graça et al., 2010), (Graça et al., 2012a), (Graça et al., 2013) 
Placenta Healthy  (Dunn et al., 2011b) 
Preeclampsia (Heazell et al., 2008), (Dunn et al., 2009), (Dunn et al., 2011b), 
(Baig et al., 2013)
†
, (Korkes et al., 2014)
†
 
Maternal 
blood 
Healthy (Luan et al., 2014)
†
, (Pinto et al., 2014b) 
Preeclampsia (Kenny et al., 2005), (Turner et al., 2007), (Kenny et al., 2008), 
(Turner et al., 2008), (Kenny et al., 2010), (Odibo et al., 2011), 
(De Oliveira et al., 2012)
†
, (Bahado-Singh et al., 2012), (Bahado-
Singh et al., 2013a), (Austdal et al., 2014), (Kuc et al., 2014), 
(Pinto et al., 2014d)
†
, (Korkes et al., 2014)
†
 
PTD (Thorp et al., 2013)
†
, (Pinto et al., 2014d)
†
  
GDM (Chen et al., 2010)
†
, (Diaz and Pinto et al., 2011), (Graça et al., 
2012a), (Scholtens et al., 2014), (de Seymour et al., 2014) 
PROM (Diaz and Pinto et al., 2011), (Graça et al., 2012a) 
Maternal 
urine 
Healthy  (Sachse et al., 2012), (Diaz et al., 2013a), (Trivedi and Iles, 
2014a) 
Preeclampsia (Diaz et al., 2013b), (Austdal et al., 2014) 
PTD (Diaz and Pinto et al., 2011), (Graça et al., 2012a), (Diaz et al., 
2013b) 
GDM (Diaz and Pinto et al., 2011), (Graça et al., 2012a), (Graça et al., 
2012b), (Sachse et al., 2012), (Diaz et al., 2013b), (Dudzik et al., 
2014) 
PROM (Diaz and Pinto et al., 2011), (Graça et al., 2012a), (Diaz et al., 
2013b) 
Others (Bonvallot et al., 2013), (Sachse et al., 2014) 
Umbilical 
cord blood 
GDM (Dani et al., 2014) 
Delivery (Hashimoto et al., 2013) 
NB blood PTD (Wilson et al., 2014) 
NB urine PTD (Atzori et al., 2011), (Moltu et al., 2014) 
Breast milk PTD (Marincola et al., 2012), (Longini et al., 2014) 
CVF PTD (Auray-Blais et al., 2011) 
 
Preeclampsia 
Preeclampsia has been the subject of most of the metabolomics work carried out 
so far, with studies performed on amniotic fluid by NMR (Bock, 1994) and placenta by 
GC- and UPLC-MS (Heazell et al., 2008; Dunn et al., 2009, 2011b) comprising 
samples collected after diagnosis (at delivery) in small cohorts (n ≤ 11). Metabolic 
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profiling of amniotic fluid by NMR revealed higher acetate, succinate, choline and 
citrate in preeclampsia cases compared to controls (healthy pregnant women) (Bock, 
1994). Metabolomics studies (GC-MS and LC-MS) performed using placental extracts 
showed several alterations related with preeclampsia, suggesting oxidative stress and 
hypoxia (Heazell et al., 2008; Dunn et al., 2009, 2011b). In addition, lipidomics studies 
of placenta lipid extracts (preeclampsia cases n≤10, controls n≤10) unveiled alterations 
in total phosphatidylserines (PS), phosphatidylinositols (PI), phosphatidic acids (PA), 
and ganglioside mannoside 3 (Baig et al., 2013), as well as alterations in 
phosphatidylethanolamines (PE), phosphatidylglycerols (PG), diacylglycerols (DG), 
triacylglycerols (TG), acidic glycosphingolipids, and steroid conjugates (Korkes et al., 
2014). 
The first metabolomic studies of preeclampsia including maternal blood samples 
comprised small sample cohorts (n≤20) collected after diagnosis (> 20 g.w.) (Kenny et 
al., 2005, 2008; Turner et al., 2007, 2008). Thereafter the need for larger cohorts and 
sample collection before the onset of the disease (in 1st and early 2nd trimesters) was 
recognised in order to find potential predictive biomarkers. Kenny et al. found a 
discriminatory metabolite signature of pre-diagnostic preeclampsia (n=60 in test set 
and n=39 in validation set) composed by 14 metabolites (comprising amino acids, 
carbohydrates, carnitines, dicarboxylic acids, fatty acids, ketones, keto- and hydroxyl- 
fatty acids, lipids, phospholipids and steroids) in maternal plasma collected at 15±1 
g.w. with an AUC of 0.92 by UPLC-MS (Kenny et al., 2010). Moreover, several 
attempts have been made to predict specific subphenotypes of preeclampsia, namely 
late- and early-onset preeclampsia which require delivery before 34 g.w and ≥34 gw., 
respectively (Bahado-Singh et al., 2012, 2013a; Kuc et al., 2014). Bahado-Singh et al. 
reported a combination of maternal serum metabolites (citrate, glycerol, 
hydroxyisovalerate and Met measured by NMR), with uterine artery pulsatility index 
and fetal crown-rump length which showed better sensitivity (82.6%) and false positive 
rate (1.6%) for early-onset preeclampsia (n=30) than the set of metabolites alone 
(sensitivity 75.9%, FPR 4.9%) (Bahado-Singh et al., 2013a). Other authors reported 
lower detection rate and FPR (55% and 10%, respectively) for early-onset 
preeclampsia (n=68) combining metabolites (taurine and Asn measured by UPLC-MS) 
with mean arterial pressure (Kuc et al., 2014). To date, none (nor any combination) has 
emerged with the requisite specificity and sensitivity to be of clinical use. Regarding the 
application of lipidomics approach to find lipid changes related with the onset of 
preeclampsia, the first one resulted from the work developed in this thesis with focus 
on plasma phospholipid profiling by HILIC-LC/MS (Pinto et al., 2014d). Later on, 
Korkes et al. found increases in PC, PS, PA, sphingomyelins (SM), glycosphingolipids, 
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and steroid conjugates, and decreases in PE, PG and sterols, in plasma (32-39 g.w.) of 
women with diagnosed preeclampsia (n=10) compared to controls (n=10), by MALDI-
MS (Korkes et al., 2014). 
The search for predictive biomarkers of preeclampsia in maternal urine is less 
explored comprising only two publications by NMR (Diaz et al., 2013b; Austdal et al., 
2014). For pre-diagnostic preeclampsia apparently specific decreases in acetate, 
formate (Krebs cycle precursors) and fumarate (Krebs intermediate, along with 2-
ketoglutarate and succinate, also decreased), along with a decrease in Ile were 
detected by NMR in a small cohort of women who later developed preeclampsia (n=9, 
collected at 16-17 g.w.) (Diaz et al., 2013b). Urine samples collected after the 
diagnosis of preeclampsia (22-38 g.w.n n=10) revealed, by NMR, increased choline 
and decreased Gly, p-cresol sulfate and hippurate, which may be related to increased 
oxidative stress and kidney dysfunction (Austdal et al., 2014). 
 
Preterm delivery (PTD) 
The metabolomics studies of PTD have been focused in the search for potential 
predictive biomarkers of the disease, collecting samples with absence of clinical 
symptoms. These studies have been performed using amniotic fluid revealing 
alterations in allantoin, citrate, amino acids, organic acids, carbohydrates and proteins, 
which suggest oxidative stress, early perturbations in placental-amino acid transport, 
hyperglycaemia and changes in protein metabolism (Graça et al., 2010, 2012b, 2013; 
Romero et al., 2010; Power et al., 2011; Menon et al., 2014). 
The use of maternal plasma to study PTD is still very limited having been only 
explored by lipidomics for measurement of lipoprotein concentrations (Thorp et al., 
2013) as well as the study of phospholipid profile (Pinto et al., 2014d) before the onset 
of the disease, the latter comprising results presented in this thesis (Chapter 8, section 
8.3). Maternal plasma collected at 16-21 g.w. for 132 controls and 128 cases of 
recurrent PTD unveiled only alterations in VLDL particle size, with no changes in the 
remaining 16 lipoprotein classes measured by NMR spectroscopy (NMR Lipoprofile 
autoanalyzer) (Thorp et al., 2013). For maternal urine, the number of publications is 
also very limited, comprising one study by NMR which reported increased ketone 
bodies and decreased carnitine for pre-diagnostic PTD (n=26, collected at 15-25 g.w.), 
suggesting enhanced lipid oxidation and oxidative stress (Diaz et al., 2013b). Other 
studies aimed at analyse cervicovaginal fluid in women giving birth prematurely 
compared to term, by UPLC-MS with no further metabolite identification (Auray-Blais et 
al., 2011), and the metabolic profile of preterm breast milk by NMR and GC-MS 
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(Marincola et al., 2012). Urinary metabolic profiles of infants born preterm compared to 
term have revealed alterations in hippurate, Trp, Phe, malate, Tyr, hydroxybutyrate, N-
acetyl-glutamate and Pro (Atzori et al., 2011). 
 
Gestational Diabetes Mellitus (GDM) 
The first study on GDM by a metabolomics-based approach was published for 
amniotic fluid using NMR (Bock, 1994). The most complete study was performed by 
Graça et al. using NMR and comprising samples collected before the onset of GDM 
(14-25 g.w., n=27) (Graça et al., 2010). Compared with healthy women (n=82), pre-
diagnostic GDM women exhibited an average increase in glucose and small decreases 
in several amino acids along with acetate, formate, creatinine, and 
glycerolphosphocholine, suggesting hyperglycaemia, disturbances in amino acid and 
lipid metabolism, nucleotide biosynthesis and renal function. Later on, Graça et al. 
reported a new study to investigate the possible effects of pre-diagnostic GDM on the 
metabolic profiling of amniotic fluid viewed by UPLC-MS, revealing no significant 
alterations (Graça et al., 2012b).  
Metabolomics was also applied to study the metabolite profile of maternal blood 
and urine in cases of pre-diagnostic GDM (Diaz and Pinto et al., 2011, 2013b; Graça et 
al., 2012a; de Seymour et al., 2014), post-diagnostic GDM (Chen et al., 2010; Sachse 
et al., 2012; Dudzik et al., 2014), and pregnant women with hyperglycaemia (Chen et 
al., 2010; Scholtens et al., 2014). The search for metabolic alterations in maternal 
plasma preceding the onset of GDM was first performed in a small cohort of pre-
diagnostic GDM (n=19) women compared to controls (n=25) by NMR, in their 2nd 
trimester (16-22 g.w.) (Diaz and Pinto et al., 2011). Metabolite alterations comprise 
decreases in TMAO and betaine reflecting choline-related homocysteine-methionine 
conversion and possible alterations in renal function.  Seymour et al. investigated the 
serum metabolite profile of pre-diagnostic GDM cases (at 20 g.w. for n=22) by GC-MS 
whose results unveiled only a significant increase for itaconic acid (de Seymour et al., 
2014). Regarding post-diagnostic GDM, maternal plasma of pregnant women with 
GDM, collected at the day of OGTT (22-28 g.w., n=20), was compared with a control 
group (n=20) by a multiplatform system (LC-MS and GC-MS) (Dudzik et al., 2014). 
Results enabled the identification of some metabolites with a strong discriminative 
power for GDM (several lysophospholipids, taurine-bile acids and long-chain 
polyunsaturated fatty acid derivatives) indicative of low-grade inflammation and altered 
redox-balance. In addition, a targeted GC-MS study to serum fatty acids (FA) of 
controls (n=98), women with hyperglycaemia less severe than GDM (n=80), and 
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women with GDM (n=49), unveiled a graded increase in total FA and several 
individuals FA (e.g., linoleic, arachidonic, docohexaenoic) in the 3rd trimester (30 g.w.) 
(Chen et al., 2010).  
Maternal urine collected for pre-diagnostic GDM (n=42) cases and controls (n=84) 
at 16-22 g.w. revealed several metabolite alterations determined by NMR namely a 
marked increase in glucose (possible early sign of glycemia), and other changes in 
common with type 2 diabetes (increased acetate, N-methylnicotinamide and N-methyl-
2-pyridone-5-carboxamide, changes in creatine and creatinine and decreases in 
hippurate and phenylacetylglutamine) (Diaz et al., 2013b). The study of the urinary 
NMR profile of pregnant women diagnosed with GDM (three time points collection: 8-2 
and 26-30 g.w. and 10-16 weeks post partum, n=823 women with different ethnicity) 
unveiled no reliability to identity GDM cases suggesting only an increase in median 
citrate concentration with increasing hyperglycaemia (Sachse et al., 2012). 
An additional study performed the comparison of the NMR cord serum metabolite 
profile of infants of GDM mothers (IGDMs, n=30) to that of infants of healthy mothers 
(n=40), to evaluate if differences remain despite a strict control of GDM. Results 
showed lower glucose and higher levels of pyruvate, His, Ala, Val, Met, Arg, Lys, 
hypoxanthine, lipoproteins and lipids than controls (Dani et al., 2014). A recent review 
of metabolic profiling of GDM can be found elsewhere (Huynh et al., 2014). 
 
Premature rupture of membranes (PROM) 
The search for potentially predictive markers of PROM has also been attempted by 
analyzing amniotic fluid (Graça et al., 2010, 2012a, 2013), maternal blood plasma 
(comprising results presented in this thesis) (Diaz and Pinto et al., 2011) and maternal 
urine (Diaz and Pinto et al., 2011, 2013b) in the 2nd T (i.e. pre-diagnosis state). The 
NMR profile of amniotic fluid of 34 pre-PROM compared to 82 controls unveiled small 
metabolite changes (Met, Gln, Thr and two unassigned resonances at 3.11 and 3.29 
ppm) (Graça et al., 2010). In a later study, Graça et al. explored the potential of MIR 
metabolic profiling of amniotic fluid to unveil differences between 37 pre-PROM and 40 
controls, noting minor changes along with a low predictive power (Graça et al., 2013). 
The NMR metabolic profile of maternal urine was also explored to find differences 
related with pre-PROM (n=68) compared with controls (n=84) but without success 
since non predictive models were found (Diaz et al., 2013b). The low impact of PROM 
in amniotic fluid and maternal urine can be a) a direct reflection of the low gravity of 
PROM (after the 37th g.w.), as it is usually resolved by inducing labour without posing 
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significant risks for the mother and fetus, and/or b) the high interval from sample 
collection to diagnosis. 
1.4.2. Fetal and newborn disorders 
Table 1.11 lists the existing metabolomic reports on different biological matrices in 
relation to fetal and newborn disorders.  
Fetal Malformations (FM) 
Fetal disorders have an impact on fetal/maternal metabolism and the effects of fetal 
malformations (FM) on amniotic fluid metabolite profile have been investigated by 
NMR, UPLC-MS and MIR (Groenen et al., 2004; Graça et al., 2009, 2010, 2012a, 
2012b, 2013). Groenen et al. evaluated the effect of spina bifida (n=14 at 15 and 39 
g.w.) on amniotic fluid composition by NMR having found changes in succinic acid and 
Gln (increased levels) suggestive of derangement in amino acid metabolism (Groenen 
et al., 2004). Graça et al. performed several studies using different analytical 
techniques (NMR, UPLC-MS and MIR) to characterize a similar FM group comprising 
different types of malformations (central nervous system (CNS), abdominal, urogenital, 
cardiac and pulmonary), collected in 2nd T (15-25 g.w). These studies unveiled similar 
results reinforcing a metabolic picture of fetal hypoxia, enhanced gluconeogenesis, 
TCA activity and hindered kidney development affecting FM pregnancies, newly noted 
changes were obtained by UPLC-MS reflecting lipid oxidation, altered placental amino 
acid transfer and changes in polyol pathways (Graça et al., 2009, 2010, 2012a, 2012b, 
2013). 
Regarding maternal plasma, an initial study addressed the possible role of 
nutritional intervention in preventing neural tube defects (NTD), revealing changes in 
20 metabolites related to antioxidant capacity, proposed to relate to a reduction of NTD 
risk (Jiang et al., 2011). In a later study, GC-MS and UPLC-MS were used to 
characterize the sera metabolome of pregnant women (n=101) carrying NTD fetuses 
and controls (n=143), comprising all pregnancy trimesters (Zheng et al., 2011). Results 
unveiled 25 deregulated metabolites in NTD cases, suggesting a decreased activity of 
glycolysis, TCA cycle, mitochondrial electron transport, branched-chain amino acids 
and -aminobutyric acid metabolisms and methionine cycle. A parallel UPLC-MS study 
of 80 NTD affected women and 95 controls (mostly at < 28 g.w.) confirmed some of the 
above observations and suggested that, besides perturbation of the one-carbon unit 
metabolism, neurogenesis and oxidative stress are affected (Liang et al., 2012). The 
impact of fetal congenital heart defects (CHD) (n=27) on maternal serum metabolome 
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was also studied by MS and NMR, in 1st T (Bahado-Singh et al., 2014). The best 
markers for CHD prediction were hydroxypropionylcarnitine, glutaconylcarnitine and 
hydroxyl-tetradecadienylcarnitine (92.9% sensitivity and 93.2%, detected by direct 
infusion-MS), along with disturbances in lipid metabolism (PC and sphingolipids). In 
addition to the above studies, a general FM group (CNS, cardiac, urogenital, soft 
tissues and pulmonary malformations) was studied by 1H NMR of 2nd T maternal 
plasma comprising results presented in this thesis (Diaz and Pinto et al., 2011). 
 
Table 1.11. Metabolomics studies of fetal and newborn disorders by biological matrix. 
†
 
lipidomics studies. BALF: bronchoalveolar lavage fluid, NB: newborn, RDS: Respiratory 
distress syndrome. 
Matrix Subject References 
Amniotic 
fluid 
FM (Bock, 1994), (Groenen et al., 2004), (Graça et al., 2009), 
(Graça et al., 2010), (Graça et al., 2012a), (Graça et al., 
2012b), (Graça et al., 2013) 
CD (Graça et al., 2010), (Graça et al., 2012a), (Amorini et al., 
2012) 
Placenta FM (Chi et al., 2014) 
SGA (Horgan et al., 2010) 
Maternal 
blood 
FM (Jiang et al., 2011), (Diaz and Pinto et al., 2011), (Zheng et al., 
2011), (Graça et al., 2012a), (Liang et al., 2012), (Bahado-
Singh et al., 2014) 
CD (Diaz and Pinto et al., 2011), (Graça et al., 2012a), (Bahado-
Singh et al., 2013b), (Bahado-Singh et al., 2013c), (Pinto et al., 
2014d)
†
 
SGA (Horgan et al., 2010), (Heazell et al., 2012) 
LBW & VLBW (Ivorra et al., 2012), (Tea et al., 2012), (Alexandre-Gouabau et 
al., 2013) 
 Macrosomia (Ciborowski et al., 2014) 
Maternal 
urine 
FM (Diaz and Pinto et al., 2011), (Graça et al., 2012a), (Graça et 
al., 2012b), (Diaz et al., 2013b) 
CD (Diaz and Pinto et al., 2011), (Graça et al., 2012a), (Diaz et al., 
2013b), (Trivedi and Iles, 2014b) 
IUGR (Diaz et al., 2013b) 
Macrosomia (Walsh et al., 2014) 
Umbilical 
cord 
blood 
SGA (Horgan et al., 2011) 
LBW & VLBW (Ivorra et al., 2012), (Tea et al., 2012), (Alexandre-Gouabau et 
al., 2013) 
IUGR (Favretto et al., 2012), (Cosmi et al., 2013), (Sanz-Cortés et 
al., 2013)  
HIE (Walsh et al., 2012), (Reinke et al., 2013) 
NB blood IEM (Dénes et al., 2012), (Sahoo et al., 2012) 
Others (Koulman et al., 2014)
†
, (Zhao et al., 2014) 
NB urine IUGR (Dessì et al., 2011) 
Others (Fanos et al., 2013c), (Fanos et al., 2014) 
BALF RDS (Fabiano et al., 2011) 
Hair SGA (Sulek et al., 2014) 
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A significant impact on maternal urine composition has been reported in FM cases 
also comprising heterogeneous groups (CNS, abdominal, urogenital, cardiac, limbs 
and poli-malformations) in the 2nd T by NMR and UPLC-MS (Diaz and Pinto et al., 
2011, 2013b; Graça et al., 2012b). Results obtained by UPLC-MS for 22 FM and 26 
control cases unveiled higher excretion of conjugated products suggesting alterations 
in gut microflora, glucuronic acid and sulphate conjugation reactions (Graça et al., 
2012b). A more recent NMR study comprising higher number of samples of FM (n=35) 
and controls (n=84) revealed new changes being noted in enhanced gluconeogenesis, 
lipid oxidation and ketone body synthesis, respiratory chain and nucleotide 
metabolisms (Diaz et al., 2013b). 
 
 
Chromosomal disorders (CD) 
The impact of chromosomal disorders has been evaluated on amniotic fluid (Graça 
et al., 2010, 2012a; Amorini et al., 2012), maternal blood (Diaz and Pinto et al., 2011; 
Graça et al., 2012a; Bahado-Singh et al., 2013b, 2013c; Pinto et al., 2014d) and 
maternal urine (Diaz and Pinto et al., 2011, 2013b; Graça et al., 2012a). A small 
heterogeneous group of chromosomal disorders (n=10) was first studied by NMR, for 
which no relevant changes were found (Graça et al., 2010). In other study, the profile in 
amino group-c        g c mp u ds  f  m     c flu d f  m 24   w ’s sy d  me-
affected fetuses and 1257 normal pregnancies unveiled significant differences in Glu, 
Gln, Gly, Tau, Val, Ile, Leu, Orn, and Lys determined by HPLC (Amorini et al., 2012). 
In relation to maternal blood, the first study addressed a general group of 
chromosomal disorders collected in the 2nd T of pregnancy and comprises results 
presented in this thesis (Diaz and Pinto et al., 2011). The second study (Bahado-Singh 
et al., 2013b) considered the 1st T (11-14 g.w.) NMR metabolic profile of sera of 30 
women carrying T21 fetuses and 60 controls unveiling different levels of 11 
metabolites, of which 3-hydroxybutyrate, 3-hydroxyisovalerate and 2-hydroxybutyrate 
were mostly responsible for group discrimination (75% sensitivity and 86.2% 
specificity). These results were interpreted as reflecting oxidative stress, poor 
myelination and neurotoxicity of the brain in T21 fetuses. Afterwards, Bahado-Singh et 
al. applied the same methodology to detect biomarkers of T18 in sera of 30 pregnant 
women compared to 114 controls and 30 T21 cases in the 1st T (11-14 g.w) (Bahado-
Singh et al., 2013c). A combination of 2-hydroxybutyrate, glycerol, and maternal age 
gave 73.3% sensitivity and 96.6% specificity for T18 detection, while trimethylamine, 
Thr and creatine were sensitive for distinguishing T18 from T21. The possibility of an 
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increased antioxidant response in pregnancies with T18 was advanced by the authors. 
Finally, the most recent study of T21 cases using maternal blood samples was 
performed as part of this thesis with focus on plasma phospholipid profiling using a 
lipidomics MS approach (Pinto et al., 2014d). 
The metabolic profile of maternal urine to unveil biomarkers of chromosomal 
disorders have been less explored including two reports considering a general CD 
group and T21 (Diaz and Pinto et al., 2011; Diaz et al., 2013b), and one specific to T21 
(Trivedi and Iles, 2014b). The NMR-based urine profile of 33 women who had babies 
with general CD compared with 84 controls, at 2nd T (15-26 g.w.), resulted in a model 
with a sensitivity of 87% and a specificity of 84% which unveiled some effects similar to 
fetal malformations (other group studied in this paper) hinting at some sort of 
underlying general stress mechanism, while specific alterations included higher 
excretion of glucose and alterations in amino acid metabolism (Diaz et al., 2013b). In 
addition, the T21 group (n=13) was distinguished from other CD types (92% sensitivity 
and 95% specificity) by changes in energy metabolism (less excretion of glucose), as 
well as in nucleotide and amino acid metabolisms. In addition, the T21 group (n=13) 
was distinguished from other CD types by changes in energy metabolism (less 
excretion of glucose), as well as in nucleotide and amino acid metabolisms. Recently, a 
untargeted MS-based metabolomic study of urine of 23 women carrying a T21 fetus 
compared to 93 women with normal pregnancies between 9-23 g.w., revealed higher 
levels of dihydrouracil and lower levels of progesterone in the T21 group, along with 
changes in other metabolites not identified (m/z 109.1, 114.1 198.2 and 314.2) (Trivedi 
and Iles, 2014b). Changes in dihydrouracil were related with the liver abnormalities 
suffered by T21 fetuses during development, while progesterone may reflect 
impairment of placental function owing to oxidative stress.  
 
Fetal growth anomalies (SGA, LBW, VLBW, IUGR, macrosomia) 
Metabolomics studies of babies born small for gestational age (SGA) have been 
performed through the metabolic profiling of placental extracts (Horgan et al., 2010), 
and maternal and umbilical cord blood (Horgan et al., 2011; Heazell et al., 2012). 
These studies have bee  pe f  med    sm ll c h   s (  ≤ 9) us  g   ly M  
technologies (UPLC-MS). Placental extracts revealed alterations in 574 metabolite 
features related with SGA cases, suggesting that placental hypoxia and nutrient 
deficiency may play an important role in the pathophysiology of SGA (Horgan et al., 
2010). Studies of maternal blood have been integrated with umbilical cord blood 
profiles in an attempt to obtain further insight into mother/fetus metabolic interplay. 
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Using maternal and cord plasma collected at 14-16 g.w., a set of 19 metabolites altered 
in SGA was found comprising several amino acids, carnitines, fatty acids, 
glycerophospholipids, hydroxyl acids, phosphocholines, phospholipids, sphingolipids, 
and steroid conjugates (Horgan et al., 2011). Comparison with maternal plasma 
composition supported the occurrence of placental dysfunction in SGA cases. In a later 
study (Heazell et al., 2012), 28 sera of SGA cases collected at 28-42 g.w. were 
considered together with other poor perinatal outcomes and 40 controls. Results 
unveiled decreases in glycerolipids, fatty and organic acids, glycerophospholipids, 
sterol lipids and vitamin D metabolites, and increased sphingolipids, in the poor 
outcome group.  
Regarding LBW and VLBW studies, the biological matrices of choice to determine 
possible changes on maternal-fetal nutrient transfer and fetal metabolism have been 
the maternal and umbilical cord blood, analysed using both NMR and MS platforms. 
Ivorra et al. found a different NMR profile in umbilical cord blood of 20 LBW and 30 
normal birth weight newborns, namely higher levels of Phe and citrulline, lower levels 
of Pro, choline, Gln, Ala, glucose, but no differences in maternal blood. Disturbances in 
placental amino acids transport, anabolic state and epigenetic regulation in LBW cases 
were suggested (Ivorra et al., 2012). Other similar comparative studies (sample cohorts 
≤ 8)  eve led  l e      s    m  e   -fetal nutrient transfer and fetal oxidative stress 
(Tea et al., 2012), and in fetal energy, antioxidant defence, and polyamines and 
purines flux (Alexandre-Gouabau et al., 2013) as signatures of preterm VLBW. 
For IUGR cases, the first study performed to search for predictive biomarkers of 
IUGR in maternal urine was published by Diaz et al (Diaz et al., 2013b). Maternal urine 
was studied for 10 women who later gave birth to babies with IUGR (pre-IUGR) and 84 
controls, collected at 15-26 g.w, suggesting main disturbances in amino acid profile 
indicated by a decrease of several amino acids (Ala, Gln, Gly, Leu, Lys, Thr and Tyr) 
determined by NMR spectroscopy. Other studies aimed at define the metabolic 
patterns of IUGR in the newborns using umbilical cord blood (Favretto et al., 2012; 
Sanz-Cortés et al., 2013) and newborn urine (Dessì et al., 2011). Untargeted liquid 
chromatography high-resolution MS (LC-HRMS) metabolic profiling of umbilical cord 
sera of 22 IUGR and 21 appropriate for gestational age (AGA) newborns showed 
differences in 22 metabolites, within which Phe, Trp and glutamate were the best IUGR 
discriminants (sensitivity 91-100%, specificity 85-89%) (Favretto et al., 2012). In 
addition, the NMR metabolic profile of umbilical cord plasma of 23 early IUGR vs. 23 
matched AGA and 56 late IUGR vs. 56 matched AGA, with and without brain 
vasodilatation, showed an abnormal lipid metabolism in both cases mainly in 
unsaturated lipids of VLDL (Sanz-Cortés et al., 2013). Finally, the NMR metabolic 
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profiling of newborn urine of 26 neonates with IUGR and 30 neonates of proper 
gestational weight at birth, revealed differences in myo-inositol, sarcosine, creatine and 
creatinine (Dessì et al., 2011). 
Macrosomia has been studied with the aim to search for predictive biomarkers in 
maternal serum (Ciborowski et al., 2014) and urine (Walsh et al., 2014). Maternal 
serum of women delivering normal birth weight newborns (n=28) and high birth weight 
(n=20), collected at 12-14 g.w., were analysed by LC-MS unveiling lower levels of 
several lipid classes (phospholipids, lysophospholipids and monoacylglycerols) and 
vitamin D3 metabolites, as well as increased levels of bilirubin in macrosomia cases 
(Ciborowski et al., 2014).  
 
Other studies 
Other applications of metabolomics in prenatal research include the studies 
respiratory distress syndrome (Fabiano et al., 2011), inborn errors of metabolism (IEM) 
(Dénes et al., 2012; Sahoo et al., 2012), hypoxic ischemic encephalopathy (HIE) 
(Walsh et al., 2012; Reinke et al., 2013), pesticide exposure (Bonvallot et al., 2013), 
delivery method (Hashimoto et al., 2013), cytomegalovirus (Fanos et al., 2013c), 
 ewb   ’s  ge (Koulman et al., 2014), biliary atresia and hepatitis syndrome (Zhao et 
al., 2014), breastfeeding (Sachse et al., 2014), and bronchopulmonary dysplasia 
(Fanos et al., 2014).  
 
1.5. Aims of this thesis 
This work has entailed five main goals:  
1. To fill in existing gaps in the knowledge of human plasma degradability during 
handling and storage, and collection conditions such as fasting, paramount issues 
in NMR metabolomics. The contribution of this thesis to this issue was to address 
the effects of anti-coagulant collection tubes, room temperature stability, short- and 
long-term stability, freeze-thaw cycles and fasting vs. non-fasting state; 
2. To define the metabolic alterations occurring in NMR plasma metabolome 
throughout healthy pregnancies, to unveil the metabolic trajectories of healthy 
pregnancies against to which deviant behaviours related to diseases may be 
identified; 
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3. To evaluate the prospects of maternal plasma metabolomics and lipidomics to 
unveil potential biomarkers (either individual metabolites or metabolite profiles) for 
the recognition of CD, in general, and T21, specifically. This study aims at 
contributing to the improvement of screening and diagnostic methods presently 
available in both 1st and 2nd  trimesters; 
4. To identify and interpret the metabolic alterations occurring in maternal plasma 
caused by GDM and to search for potentially predictive signatures of this condition 
before the onset of the disease; 
5. To search for potential biomarkers of other prenatal disorders (FM, pre-PROM, pre-
PTD and pre-preeclampsia) on 2nd trimester maternal plasma metabolome.  
 
This thesis is organized as follows: chapter 1 describes the current status and 
challenges of prenatal health, the metabolomics strategy, and the state of the art of 
metabolomics in prenatal research; chapter 2 describes all experimental procedures 
performed; chapter 3 presents the plasma metabolome and lipidome of healthy 
subjects, as determined by NMR; chapter 4 evaluates the changes in the NMR plasma 
metabolic profile in connection to different handling and storage conditions, and with 
fasting/non-fasting conditions at collection; chapter 5 describes the metabolic trajectory 
found for maternal plasma throughout healthy pregnancies; chapter 6 and chapter 7 
presents the results obtained for prenatal disorders with major impact in plasma 
metabolome and lipidome, namely CD (including T21) and GDM; chapter 8 includes 
the metabolic variations found for other prenatal disorders (FM, pre-PROM, pre-PTD 
and pre-preeclampsia) on NMR plasma metabolome; finally chapter 9 presents the 
general conclusions and future perspectives. The results presented in chapters 4 to 7 
were fully published or submitted in peer-reviewed journals, while only part of the 
results of chapter 8 were published. All published and submitted articles are here 
adapted slightly onto the form of a thesis chapter, for the sake of clarity.  
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The present chapter describes the sample and metadata collection procedures, as 
well as the experimental and data analysis strategies used to conduct the experimental 
work presented throughout the thesis. This work was carried out with the collaboration 
of the Maternity Bissaya Barreto (MBB), Centro Hospitalar de Coimbra, where all 
samples were collected, from 2008 to 2013, and the Faculty of Medicine of the 
University of Coimbra (FMUC) where samples were stored immediately after collection. 
Between January 2008 and June 2011, this work was supported by the Portuguese 
Foundation of Science and Technology (FCT) funding through the 
PTDC/QUI/66523/2006 project. Samples were collected under ethical committee 
approval (Ref. 18/04 and 29/096) and informed consents were obtained, from all 
subjects participating in the study (see Annex for informed consents and individual 
questionnaires). The donors comprised Caucasian pregnant women from the central 
part of Portugal. 
2.1. Sampling 
2.1.1. Samples and clinical metadata 
For pregnant women, plasma samples were collected during medical appointments, 
in the morning period, under non-fasting conditions due to restrictions in 
c     ll  g/l m    g p eg     w me ’s d e   F      -pregnant women, samples were 
collected in fasting (overnight) conditions and non-fasting during the morning period (2h 
after breakfast). Whole blood was collected into sodium heparin tubes (Vacuette® 
Tube Sodium Heparin 9 mL) and centrifuged (1500 g, 10 min, 4°C) within 30 min of 
collection as illustrated in Figure 2.1. Supernatants were frozen at -20ºC for up to 2 
hours in MBB. Then, all samples were transferred from MBB to FMUC, where they 
were given a random code (to ensure patients confidentiality) and stored at -80ºC. 
Samples were then transported, in dry ice, to CICECO-Chemistry Department, at the 
University of Aveiro (UA) where they were stored and analysed. 
Clinical and obstetrical metadata including pre-pregnancy and prenatal health 
history were obtained through individual questionnaires filled at the time of collection 
and at the end of gestation for all pregnancies. Relevant parameters included pre-
existing diseases, medications, lifestyle and nutritional habits, blood type, maternal 
height and weight before pregnancy (used to calculate the body mass index, BMI), 
smoking habits, obstetrical background, blood pressure records, blood chemistry and 
urine analysis results, fetal karyotype and ultrasound monitoring results. Information 
about labour (or pregnancy termination for cases of FM or CD with poor prognostic) 
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and neonatal outcome was also obtained for each sample. The gathered metadata 
allowed the classification of the samples into controls and several disorder groups. 
Samples were classified into controls, if they were obtained from healthy pregnant 
women with a normal pregnancy course and delivered healthy term newborns, no pre-
existing maternal pathologies and not under medication. Criteria for the definitions of 
other groups are described throughout this section. 
Overall from 2008 to 2013, 942 blood plasma samples were collected, out of which 
297 were found eligible for this work. For the remaining samples, information obtained 
after labour revealed pre-existing diseases (e.g. chronic hypertension, diabetes 
mellitus, thyroid disorders), infections (e.g. cytomegalovirus), medication and 
incomplete metadata information (due to delivery in other hospitals).  
 
Figure 2.1. Schematic representation of the blood plasma collection protocol carried out in this 
thesis.  
2.1.2. Definition of sample groups 
This thesis is divided into five main studies described in Chapters 4 to 8. In Study 1 
(Chapter 4), key points of plasma stability during handling and storage were studied in 
order to fill some existing gaps in the knowledge about human plasma degradability. 
Study 2 (Chapter 5) aimed the identification of metabolic adaptations reflected in 
maternal blood plasma throughout healthy pregnancies and correlation to urine. In 
Study 3 (Chapter 6), the possibility of using 1st and 2nd T maternal blood plasma for the 
diagnosis of CD and T21 was explored. Study 4 (Chapter 7) aimed the identification 
and interpretation of blood plasma metabolic alterations related with pre and post-
diagnosis GDM cases in the 2nd T. Finally in Study 5 (Chapter 8), the effects of other 
prenatal disorders on maternal plasma metabolome of 2nd T were studied, namely FM 
and pre-diagnosis PROM, preterm delivery and preeclampsia. A schematic 
representation of Studies 1 to 5 with corresponding aims is shown in Figure 2.2. 
Blood collection (9 mL 
sodium heparin tube)
Gentle inversion 
of heparin tube
Max. 30 min
4ºC
Centrifugation
(1500 g, 10 min, 4ºC)
Supernatant collection 
and storage (-20ºC 2h, -80ºC)
A: Red blood cells
B: White blood 
cells and platelets
C: Plasma
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Figure 2.2. Schematic representation of Studies 1 to 5 with corresponding aims. 
 
 
 
Sample groups in study 1: Evaluation of plasma stability during handling and 
storage by NMR metabolomics 
Table 2.1 lists the groups of subjects employed in this work, which include, for 
some studies, healthy pregnant women in their 2nd T of pregnancy. Such samples do 
exhibit few compositional differences, compared to those from non-pregnant subjects 
(in particular, higher lipid levels), however, their stability properties are expected to be 
at least qualitatively equivalent.  
In order to study the effect of heparin and ethylene diamine tetraacetic acid (EDTA) 
tubes on plasma metabolome, whole blood of 5 non-fasting subjects was collected for 
both an EDTA tube (Vacuette® Tube EDTA K2 6mL) and a sodium heparin tube 
(Vacuette® Tube Sodium Heparin 9 mL). Supernatants were frozen at -20ºC for up to 2 
hours and then stored at -80ºC (3 days) until NMR analysis. For all other studies, blood 
plasma samples were collected into sodium heparin tubes. To evaluate the effects of 
storage at room temperature, 3 samples were thawed, prepared for NMR analysis and 
kept in the probe for 21 h. For the short-term stability study (at -20oC and -80oC), 
Study 1
(Chapter 4)
Plasma stability during handling and storage
Study 2
(Chapter 5)
Healthy pregnancy metabolism 
Study 3 
(Chapter 6)
Diagnosis of chromosomal disorders and trisomy 21
Study 4 
(Chapter 7)
Diagnosis and prediction of Gestational Diabetes Mellitus
Study 5 
(Chapter 8)
Diagnosis and prediction of  other prenatal disorders
• Anti-coagulant collection tubes
• Room temperature stability
• Short-term storage stability
• Freeze-thaw cycles
• Fasting and non-fasting
• Long-term storage stability
• Non-pregnant • 1st trimester • 2nd trimester • 3rd trimester • Delivery
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• CD
• T21
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• Pre-diagnosis GDM
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samples were split into aliquots prior to freezing, each sample being thawed after 3, 7 
and 31 days. For the freeze-thaw cycles study, each cycle involved sample thawing at 
room temperature for 30 min, followed by refreezing at -80oC. For the comparison of 
the NMR-metabolic profile of fasting and non-fasting subjects, plasma was collected 
from the same 16 subjects under fasting (range 8-14h) and non-fasting conditions (2 h 
later, after non-standardised breakfast). In order to determine the impact of long-term 
storage on plasma metabolome, plasma of different subjects were divided into three 
groups according the length of storage at -80ºC: 0.5 to 0.9 year (n=11), 1.2 to 1.6 years 
(n=17) and 1.7 to 2.5 years (n=21). 
 
 
Table 2.1. Blood plasma sample groups and corresponding identification of studies, number of 
subjects (n), age and BMI. In columns age and BMI, numbers in brackets indicate average 
values, for groups with larger number of subjects. The last column indicates that, for some 
studies, plasma samples were collected from healthy pregnant women in their 2
nd
 T of 
pregnancy (between 16 and 24 g.w.). 
Study n 
Age 
/years 
BMI 
/Kg.m
-2
 
Observations 
Anti-coagulant collection 
tubes 
5 23-49  19.8-34.8  Non-pregnant 
Room temperature 
stability  
3 29-37 21.8-32.5 Pregnant (16 g.w.) 
Short-term -20
o
C and      
-80
o
C storage stability  
3 25-35 19.8-34.8 Non-pregnant 
Freeze-thaw cycles 3 33-36 20.9-26.4 Pregnant (17 g.w.) 
Fasting and non-fasting  16 21-36 (27.4) 17.8-26.6 (22.0) Non-pregnant 
Long-term -80
o
C storage     
6-12 months 11 25-41 (34.1) 19.8-27.7 (23.6) Pregnant (16-22 g.w.) 
14-19 months 17 28-42 (35.7) 20.4-25.6 (23.3) Pregnant (16-20 g.w.) 
20-30 months 21 31-42 (36.3) 20.3-33.0 (24.0) Pregnant (16-24 g.w.) 
 
 
Sample groups in study 2: Following healthy pregnancy metabolism by NMR 
metabolomics of blood plasma 
In order to evaluate the metabolic adaptations reflected in plasma throughout 
healthy pregnancies, blood plasma samples were collected for healthy non-pregnant 
(NP) and pregnant women in their 1st, 2nd and 3rd trimesters of pregnancy, at their 
routine medical appointments, and at the time of delivery. All four groups were 
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independent (due to the logistics of sample collection in the clinic), therefore providing 
an average description of each pregnancy trimester. Consideration of representative 
populations may present advantages over individual follow-up since results are not 
dependent on individual phenotypes and identifies the more marked effects of 
pregnancy. Table 2.2 lists sample numbers and characteristics of each group of 
subjects considered, a lower number of subjects (n=7) being obtained for the delivery 
group.  
Table 2.2. List of whole blood plasma samples and lipid extracts collected for each 
independent group of subjects along with corresponding number of samples (n), 
ranges of maternal age (in years), gestational age at sampling (in gestational weeks) 
and pre-pregnancy body mass index (BMI, in kg.m
-2
). Values in brackets correspond 
to average values. T: trimester. 
Subjects 
group 
n 
Maternal age 
/years 
Gestational 
age /weeks 
Pre-pregnancy BMI 
/kg.m
-2
 
Whole blood plasma   
Non-pregnant  20 21-48 (28)  18-32 (23) [for n=20] 
1
st
 T  25 19-37 (30) 11-13 (12) 19-38 (26) [for n=18] 
2
nd
 T  30 25-42 (36) 16-22 (17) 20-33 (24) [for n=25] 
3
rd
 T 12 22-38 (31) 31-40 (37) 21-28 (23) [for n=9] 
Delivery 7 26-38 (32) 32-41 (38) 20-25 (23) [for n=3] 
 
 
Sample groups in study 3: First and second trimester maternal plasma for the 
diagnosis of chromosomal disorders and trisomy 21 
Maternal blood plasma was collected for women carrying fetuses diagnosed with 
CD and for healthy pregnant women (controls) in their 1st and 2nd T. These groups were 
independent since CD diagnosis was performed in one of the trimesters only. 1st T and 
2nd T CD cases were diagnosed by CVS (12-13 g.w.) and amniocentesis (14-23 g.w.), 
respectively. Sample numbers and group details are listed in Table 2.3, according to 
sub studies considering whole plasma profile, plasma lipid profile and plasma 
phospholipid profile. For plasma phospholipid profiling, plasma pools of different 
subjects were used thus enabling inter-individual variability to be averaged out and 
average T21 features to be identified. 
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Table 2.3. List of maternal samples collected for each group of subjects in Study 3, 
along with corresponding maternal age/years and gestational age/weeks at the time of 
collection, and pre-pregnancy BMI/kg.m
-2
. Values in brackets correspond to average 
values. n: number of samples; CD: chromosomal disorders; T21: trisomy 21; T: 
trimester. 
Subjects group n 
Maternal age 
/years 
Gestational 
age /weeks 
Pre-pregnancy BMI / 
kg.m
-2
 
Whole blood plasma    
Controls 1
st
 T 25 24-37 (31) 11-13 (13) 19-38 (25) [for n=23] 
CD 1
st
 T
 
15 21-44 (35) 12-13 (13) 19-39 (26) [for n=9] 
T21 1
st
 T 8 21-44 (35) 12-13 (13) 21-30 (24) [for n=5] 
Controls 2
nd
 T 49 25-42 (36) 16-24 (17) 20-33 (24) [for n=37] 
CD 2
nd
 T 30 25-43 (36) 14-23 (17) 19-34 (26) [for n=26] 
T21 2
nd
 T 14 26-43 (36) 15-23 (17) 20-33 (25) [for n=12] 
Plasma lipid extracts    
Controls 1
st
 T 15 24-37 (31) 12-13 (13) 22-35 (25) [for n=15] 
T21 1
st
 T 7 32-44 (37) 12-13 (13) 21-30 (25) [for n=4] 
Controls 2
nd
 T 15 28-42 (37) 16-22 (17) 20-26 (22) [for n=11] 
T21 2
nd
 T 12 26-43 (37) 14-23 (17) 22-33 (27) [for n=8] 
Plasma phospholipid extracts (pools)   
Control pool 1 2
nd
 T 5 30-38 (34) 16-18 (17) 26 [for n=1] 
Control pool 2 2
nd
 T 4 34-39 (36) 16-17 (17) 21-24 (22) [for n=4] 
Control pool 3 2
nd
 T 5 31-39 (36) 16-17 (17) 20-26 (23) [for n=4] 
T21 pool 2
nd
 T 5 39-43 (41) 15-18 (17) 22-33 (28) [for n=3] 
 
The CD group comprise cases from diverse types of CD in 1st and 2nd T, listed in 
Table 2.4.  
Table 2.4. List of specific types of CD along with corresponding number of 
samples (n). T: trimester. 
Chromosomal disorders (CD) 1
st 
T   Chromosomal disorders (CD) 2
nd
 T  
Type  n   Type n  
Trisomy 21  8  Trysomy 21  14 
Trisomy 13 2  Trisomy 18  2 
Trisomy 9 1  Kleinfelter syndrome 2 
Triploidy (69, XXX) 1  XYY syndrome  2 
Translocations (familial) 2  XXX syndrome  1 
Mosaicism (autosomal) 1  Triploidy (69, XXX) 1 
   Mosaicism (autosomal) 1 
   Marker chromosome  
(autosomal) 
1 
   Translocations (2 familial + 
1 de novo) 
3 
   Inversions (familial) 2 
   Deletion (autosomal) 1 
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Sample groups in study 4: Second trimester maternal plasma for the 
diagnosis and prediction of gestational diabetes mellitus (GDM) by NMR 
metabolomics 
For the study of metabolic alterations in 2nd T maternal plasma of pregnancies 
affected by GDM, samples were collected from independent groups of pregnant 
women during routine medical appointments and diabetes appointments. Blood 
samples were collected for healthy pregnant women, pregnant women who later 
developed GDM (pre-diagnosis GDM group, 2-21 g.w. prior to diagnosis) and women 
after GDM diagnosis (post-diagnosis GDM group, 1-2 weeks after the OGTT test, at 
18-38 g.w., and before any clinically advised treatment). GDM was diagnosed after a 
75g or 100g oral OGTT by measuring plasma glucose at fasting and after 1, 2 and 3 
(for the latter) hours according to the International Association of Diabetes and 
Pregnancy Study Groups criteria (Metzger et al., 2010). Sample numbers, maternal 
age range, gestational age range at collection, interval of time from sampling to 
diagnosis, gestational age range at delivery, baby weight and pre-pregnancy BMI 
range can be found in Table 2.5.  
Table 2.5. List of maternal plasma samples and lipid extracts obtained for each group of 
subjects, with corresponding number of samples (n); maternal age (years); gestational age 
(weeks) at collection and, for the pre-diagnosis GDM group, from collection to diagnosis; 
gestational age (weeks) at delivery; baby weight at birth (g) and pre-pregnancy body mass 
index (BMI, kg.m
-2
). Values in brackets correspond to average values. 
a
 Pre-diagnosis GDM 
includes cases of hypertension (n=1), twin pregnancy (n=2), preterm delivery (n=3), 
macrosomia (n=1) and intrauterine growth restriction (n=1). 
b
 Post-diagnosis GDM includes 
cases of hypertension (n=1), twin pregnancy (n=2) and preterm delivery (n=1). 
c
 This group 
includes one case of hypertension. 
Subjects group n 
Maternal 
age 
/years 
g.w. at 
collection 
/weeks 
g.w. to 
diagnosis 
/weeks 
g.w. at 
delivery 
/weeks 
Baby 
weight (g) 
Pre-
pregnancy 
BMI /kg.m
-2
 
Whole blood plasma       
Controls 49 25-42 
(36) 
16-24  
(17) 
- 37-41 
(39) 
2405-3960 
(3222) 
20-33 (24) 
[for n=37] 
Pre-diagn. GDM
a
 32 30-44 
(38) 
16-21  
(17) 
2-21  
(13) 
35-40 
(38) 
2125-3805 
(3115) 
18-35 (26) 
[for n=24] 
Post-diagn. GDM
b
 12 18-41 
(33) 
24-27  
(26) 
- 34-40 
(38) 
1745-3505 
(2736) 
18-36 (26) 
[for n=12] 
Plasma lipid extracts       
Controls 15 28-42 
(37) 
16-22  
(17) 
- 38-40 
(39) 
2560-3960 
(3288) 
20-26 (22) 
[for n=11] 
Pre-diagn. GDM
c
 14 36-42 
(39) 
16-19  
(17) 
2-19  
(12) 
36-40 
(38) 
2310-3805 
(3109) 
18-35 (24) 
[for n=14] 
Post-diagn. GDM
b
 12 18-41 
(33) 
24-27  
(26) 
- 34-40 
(38) 
1745-3505 
(2756) 
18-36 (26) 
[for n=12] 
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Sample groups in study 5: Study of the effects of other prenatal disorders on 
second trimester maternal plasma metabolome 
Maternal blood plasma was collected for women carrying fetuses diagnosed with 
fetal malformations (FM) and for other women with no apparent disorder at the time of 
collection developing later, premature rupture of the membranes (Pre-PROM), preterm 
delivery (pre-preterm delivery) and preeclampsia (pre-preeclampsia). For the pre-
preterm and pre-preeclampsia groups, a preliminary study of plasma phospholipids 
was performed considering plasma pools of different subjects. Sample numbers, 
maternal age, gestational ages at sampling, pre-pregnancy BMI and interval of time 
from sampling to diagnosis for pre-diagnostic disorders, are listed in Table 2.6. 
Table 2.6. List of maternal plasma samples and plasma phospholipid extracts collected for 
each group of subjects in Study 5, along with corresponding number of samples (n), 
maternal age/years and gestational age/weeks at the time of collection, pre-pregnancy 
BMI/kg.m
-2
, and for the pre-diagnosed group, g.w. between sampling and time of diagnosis. 
Values in brackets correspond to average values. 
Subjects group n 
Maternal 
age /years 
Gestational 
age /weeks 
Pre-pregnancy 
BMI /kg.m
-2
 
g.w. to 
diagnosis 
Whole blood plasma    
Controls 49 25-42 (36) 16-24 (17) 20-33 (24) 
[for n=37] 
- 
FM 36 19-45 (30) 14-27 (20) 18-36 (25) 
[for n=25] 
- 
Pre-PROM 36 27-44 (37) 16-20 (17) 20-33 (24) 
[for n=26] 
19-24 (22) 
Plasma phospholipid extracts (pools)   
Control 1 5 30-38 (34) 16-18 (17) 26 
[for n=1] 
- 
Control 2 4 34-39 (36) 16-17 (17) 21-24 (22) 
[for n=4] 
- 
Control 3 5 31-39 (36) 16-17 (17) 20-26 (23) 
[for n=4] 
- 
Pre-preterm 5 34-38 (37) 17-19 (17) 23-25 (24) 
[for n=4] 
14-18 (17) 
Pre-preeclampsia 4 35-41 (37) 16-17 (17) 19-33 
[for n=3] 
14-18 (16) 
 
FM cases were diagnosed by morphological ultrasound after 12 g.w., the group 
comprising cases of central nervous system (CNS), cardiac, limbs, urogenital, 
polimalformations and others, as listed in Table 2.7. Pre-PROM include women who 
had rupture premature of the membranes at 37-41 g.w., pre-preterm cases include 
women who had preterm deliveries at 29-36 g.w., and pre-preeclampsia comprise 
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women diagnosed at 31-34 g w   h  ugh bl  d p essu e ≥ 140/90 mmHg   d 
p   e  u    ≥ 0 3 g/L    24-h urine. No sufficient number of samples were gathered for 
other relevant disorders such as intrauterine growth restriction (n=4), fetal death (n=5), 
small for gestational age (n=4), and large for gestational age (n=6). 
 
Table 2.7. List of specific types of FM along with corresponding number of samples (n). 
Fetal malformations (FM) 2
nd
 T 
Type n Type n 
CNS 13 Polimalformation 6 
Corpus callosum agenesis 3 Club feet + left pielectasy + 
choroid plexus cysts 
1 
Arnold-Chiari 2 
Holoprosencephaly 2 Cystic hygroma + bladder 
agenesis 
1 
Ventriculomegaly 2 
Ventriculomegaly + polydactyly 1 Corpus callosum agenesis + 
pancreatic agenesis + bile ducts 
malformation 
1 
Spina bifida 1 
Craniosynostosis 1 
Myelomeningocele 1 Cystic hygroma + jugular sacs 1 
Cardiac 7 Diffuse renal dysplasia + 
adenomatoid malformation of the 
right lung 
1 
Cardiopathy 5 
Hypoplastic left heart syndrome 1 
Dextrocardia 1 Severe bilateral pleural effusion + 
severe cervical edema + club feet 
+ overlapping fingers in hands 
1 
Limbs 4 
Club feet 2 
Polydactyly 1 Others 4 
Lower limbs malformation 1 Enlarged stomach 1 
Urogenital 3 Cystic adenomatoid malformation 
in the right lung 
1 
Hydronephrosis 1 
Bladder agenesis 1 Congenital diaphragmatic hernia 1 
Hydronephrosis + pielectasy 1 Congenital disorder of 
glycosylation type Ia 
1 
   
 
2.2. Chemicals 
All solvents and solid chemicals used in the experimental work were of HPLC grade 
or equivalent and used as received, a) deuterated solvents: chloroform-d (CDCl3), 
CDCl3 with 0.03% tetramethylsilane (TMS) and deuterium oxide (D2O) (Eurisotop, 
France); b) non-deuterated solvents: acetonitrile (Fisher Scientific, Portugal), 
ammonium acetate (Merck Millipore, VWR, Portugal), ammonium hydroxide, formic 
acid and hexane (Fluka, Sigma Aldrich, Portugal), chloroform (CHCl3) (HiPerSolv 
Chromanorm, VWR, Portugal), Isopropanol (2-propanol) (Normapur, VWR, Portugal), 
Methyl-tert-butyl ether (MTBE) (Chromasolv, Sigma Aldrich, Portugal); and c) solid 
chemicals: 1,2-dimyristoyl-sn-glycero-3-phosphocholine (14:0/14:0 PC), 1-palmitoyl-2-
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hydroxy-sn-glycero-3-phosphocholine (16:0 LPC), 1-palmitoyl-2-linoleoyl-sn-glycero-3-
phosphocholine (16:0/18:2 PC),  1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanola-
mine (16:0/18:2 PE) and N-palmitoyl-D-erythro-sphingosylphos-phorylcholine 
(d18:1/16:0 SM) (Avanti Polar Lipids, Instruchemie, The Netherlands), cholesteryl 
octadecadienoate (18:2 CE), cholesteryl eicosatetraenoate (20:4 CE) and sodium 
azide (Sigma Aldrich, Portugal), sodium chloride (BioXtra, Sigma Aldrich Portugal). 
 
2.3. Profiling of maternal plasma by NMR spectroscopy 
2.3.1. Sample preparation 
Whole blood plasma 
Plasma samples were thawed at room temperature and 400 µL of saline solution 
(NaCl 0.9% in 10% D2O, with 3mM NaN3 for part of the room temperature study in 
Study 1 (Chapter 4)) were added to 200 µL of plasma. The mixture was then 
centrifuged (4500 g, 25ºC, 5 min) and 550 µL transferred into 5 mm NMR tubes.  
 
Plasma lipid extracts 
In order to study the NMR plasma lipidome, lipids from plasma samples were 
extracted in duplicate according to the methyl-tert-buthyl ether (MTBE) method 
(Matyash et al., 2008). This method was previously compared with other lipid extraction 
methods (Folch, Bligh and Dyer, acidified Bligh and Dyer, and hexane-isopropanol), in 
the context of a master thesis (Almeida, 2014), unveiling better reproducibility and 
easier protocol. A schematic representation of the MTBE-methanol extraction protocol 
is shown in Figure 2.3. Firstly, ice-cold (-20ºC) methanol (MeOH, 1.5 mL) was added to 
bl  d pl sm  (200 μL)   d  he m x u e v   exed (60 s), followed by the addition of ice-
cold MTBE (5.0 mL) and vortex mixing (60 s). Then, the mixture was incubated for 1 
hour on ice, with occasional vortex mixing. Phase separation was induced by adding 
ultrapure water (ultrapure H2O, 1.25 mL) and let it stand for 10 min on ice, with 
occasional mixing. After centrifugation (1000 g, 10 min), the organic phase (upper) was 
collected and the lower phase was reextracted with 2 mL of a mixture of ice-cold 
MTBE/MeOH/UP-H2O (10:3:2.5, v/v/v). Combined organic phases were dried in a 
vacuum centrifuge, followed by storage at -80ºC until NMR analysis. 
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Figure 2.3. General plasma lipid extraction steps performed using the methanol-MTBE method. 
 
Before NMR analysis, lipid extracts were thawed at room temperature, followed by 
addition of 600 L of chloroform-d with tetramethylsilane (TMS) (99.96% + 0.03%, v/v). 
The mixture (580 L) was then transferred into a 5 mm NMR tube. 
Details on urine collection and NMR analysis for Study 2 and Study 3 can be found 
elsewhere (Diaz et al., 2013a, 2013b). 
2.3.2. NMR analysis 
1D and 2D NMR acquisition of whole blood plasma  
The 1D and 2D NMR spectra were recorded, at 300 K, on a Bruker Avance DRX 
500 spectrometer operating at a 500.13 MHz frequency for proton and equipped with 
an actively shielded gradient unit with a maximum gradient strength output of 53.5 
G/cm. For each blood plasma sample, three 1D 1H NMR spectra were obtained: a 
standard spectrum (1D NOESY-presat), a Carr-Purcell-Meiboom-Gill (CPMG) 
spectrum and a diffusion-edited spectrum, using the noesypr1d (RD-90°-t-90°-tm-90°-
ACQ), cpmgpr (RD-90°-{-180°-}n-ACQ) (Meiboom and Gill, 1958) and ledbpgp2s1dpr 
(RD-90°-G1-180°-G1-90°-G2-T-90°-G1-180°-G1-90°-G2--90°-acquire FID) (Wu et al., 
Plasma 
(200 μL)
Ice-cold MeOH (1.5 mL)
and MTBE (5.0 mL)
Vortex (60 s)
Incubation
(1h on ice, occasional vortex mixing)
Washing step
(addition of ultrapure H2O, incubation 10 min)
Centrifugation
(1000 g, 10 min)
Aqueous phase
Organic phase
Protein pellet
Organic phase collected and dried
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1995) pulse sequences, respectively, from the Bruker library. Each free induction 
decay (FID) was zero-filled to 64 k points and multiplied by a 0.3 Hz exponential line-
broadening function prior to Fourier transformation. Spectra were manually phased and 
b sel  e c   ec ed   d chem c l sh f s  efe e ced    e   lly     he α-glucose H1 
resonance (at 5.23 ppm). A list of all acquisition and processing parameters is show in 
Table 2.8.  
Table 2.8. List of acquisition and processing parameters used for 1D and 2D NMR experiments 
of blood plasma. NS: number of scans, RD: relaxation delay, tm: mixing time, t: fixed delay, , 
echo time; n, number of (-180°-) loops; 2n, total spin-spin relaxation time;, gradient 
duration;  , diffusion time; g, strength gradient pulses as % of maximum gradient output (53.5 
G/cm); SW: spectral window, TD: size of FID, RG: receiver gain, SI: size of real spectrum, 
WDW: type of window function, qsine: sine-bell-squared function, F1: 1
st
 dimension, F2: 2
nd
 
dimension, LB: line broadening,  
Experiment Acquisition parameters Processing parameters 
Standard 1D 
(noesypr1d) 
NS: 128; RD: 4 s; tm: 100 ms   : 3 μs  
SW: 10330.58 Hz/ 20.66 ppm; TD: 
32 k; RG: 64 
SI: 64 k; WDW: exponential; 
LB: 0.30 Hz; Manual phase 
and baseline correction; 
Chemical shift calibration by -
glucose H1 resonance (at 5.23 
ppm) 
CPMG  
(cpmgpr) 
NS: 256; RD: 4 s; : 400 μs   : 80; 
2n: 64 ms; SW: 10330.58 Hz/ 20.66 
ppm; TD: 32 k; RG: 128 
Diffusion-edited 
(ledbpgp2s1dpr) 
N : 128  R : 4 s  δ: 2 ms   : 100 
ms; g: 90 % ; SW: 10330.58 Hz/ 
20.66 ppm; TD: 32 k; RG: 32 
TOCSY 
(clmlevprtp) 
NS: 32; RD: 2 s; tm: 96 ms; pl10: 15 
dB; TD [F1]: 128; TD [F2]: 2 k; SW 
[F1]: 8012.82 Hz; SW [F2]: 8012.82 
Hz 
SI [F1]: 1 k; SI [F2]: 4 k; WDW: 
qsine; Manual phase 
correction; Chemical shift 
calibration by -glucose H1 
resonance (at 5.23 ppm) HSQC 
(invietgpsi) 
NS: 48; RD: 2 s; TD [F1]: 300; TD 
[F2]: 4 k; SW [F1]: 25153.81 Hz; SW 
[F2]: 8012.82 Hz 
JRES 
(jresgpprqf) 
NS: 16; RD: 2 s; TD [F1]: 64; TD 
[F2]: 8 k; SW [F1]: 43.41 Hz; SW 
[F2]: 8012.82 Hz 
 
The TOCSY experiment was recorded in phase-sensitive mode using States-TPPI 
(time proportional phase incrementation) detection in t1 using a MLEV-17 pulse 
sequence (Bax and Davis, 1985), clmlevprtp. The HSQC spectra were recorded with 
inverse detection and 13C decoupling during acquisition using the invietgpsi pulse 
program. The JRES experiment was acquired using the jresgpprqf pulse sequence with 
presaturation during relaxation delay. The acquired FIDs were zero-filled according the 
data points defined in SI parameters shown in Table 2.8 and multiplied by a sine-bell-
squared function (qsine) prior to FT. All spectra were manually phased and baseline 
corrected, and chemical shifts calibrated internally using -glucose H1 resonance (at 
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5.23 ppm). All NMR data processing was carried out in TOPSPIN 2.0 and 3.2 versions 
(Bruker BioSpin, Reinstetten, Germany). 
Peak assignments were carried out using the 2D NMR experiments (TOCSY, 
HSQC and JRES), the Bruker Biorefcode spectral database, the Biological Magnetic 
Resonance Bank (BMRB) and the Human Metabolome Database (HMDB) (Seavey et 
al., 1991; Wishart et al., 2007). 
 
 
1D and 2D NMR acquisition of plasma total lipid extracts  
NMR spectra were recorded, at 298 K, on a Bruker Avance DRX 500 spectrometer 
operating at a 500.13 MHz frequency for proton and equipped with a triple resonance 
inverse (TXI) probe head. A list of all acquisition and processing parameters is show in 
Table 2.9. 1D NMR spectra were acquired using a standard Bruker proton pulse 
sequence (zg) with a 90º pulse, the acquisition time was 2.34 s with a relaxation delay 
of 5 s. Each FID was zero-filled to 64 K points, multiplied by a 0.3 Hz exponential line-
broadening function prior to Fourier transform. Spectra were manually phased and 
baseline corrected and chemical shifts referenced internally to TMS (at 0.0 ppm).  
 
Table 2.9. List of acquisition and processing parameters used for 1D and 2D NMR experiments 
of plasma total lipid extracts. NS: number of scans, RD: relaxation delay, tm: mixing time, SW: 
spectral window, TD: size of FID, RG: receiver gain, SI: size of real spectrum, WDW: type of 
window function, qsine: sine-bell-squared function, F1: 1
st
 dimension, F2: 2
nd
 dimension, LB: 
line broadening.  
Experiment Acquisition parameters Processing parameters 
Standard 
1
H 
(zg) 
NS: 128; RD: 5 s; SW: 7002.80 Hz/ 
14.00 ppm; TD: 32 k; RG: 32 
SI: 64 k; WDW: exponential; LB: 
0.30 Hz; Manual phase and 
baseline correction; Chemical 
shift calibration by TMS (0.0 ppm) 
TOCSY  
(dipsi2ph) 
NS: 16; RD: 2 s; tm: 70 ms; pl10: 15 
dB; TD [F1]: 256; TD [F2]: 4 k; SW 
[F1]: 7002.80 Hz; SW [F2]: 7002.80 
Hz 
SI [F1]: 1 k; SI [F2]: 4 k; WDW: 
qsine; Manual phase correction; 
Chemical shift calibration by TMS 
(0.0 ppm) 
HSQC 
(hsqcetgp) 
NS: 32; RD: 2 s; TD [F1]: 128; TD 
[F2]: 2 k; SW [F1]: 20831.98 Hz; SW 
[F2]: 7002.80  Hz 
J-resolved 
(jresgpprqf) 
NS: 16; RD: 2 s; TD [F1]: 40; TD [F2]: 
8 k; SW [F1]: 43.41 Hz; SW [F2]: 
7002.80 Hz 
 
 
2D NMR experiments were acquired for assignment namely TOCSY, HSQC and J-
res. TOCSY spectra were acquired in phase-sensitive mode using States-TPPI 
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detection with a DIPSI 2 sequence for mixing using the dipsi2ph pulse program. 1H-13C 
HSQC spectra were acquired using the hsqcetgp program with 1H/13C correlation via 
double inept transfer in phase-sensitive mode using Echo/Antiecho-TPPI gradient 
selection with decoupling during acquisition and using trim pulses in inept transfer. 
JRES spectra were acquired using the jresgpprqf pulse program with presaturation 
during relaxation delay and using gradients. The acquired FIDs were zero-filled 
according the data points defined in SI parameters shown in Table 2.9 and multiplied 
by a sine-bell-squared function (qsine) prior to FT. All spectra were manually phased, 
automatically baseline corrected and manually chemical shifts calibrated internally 
using TMS (at 0.0 ppm). All NMR data processing was carried out in TOPSPIN 3.2 
(Bruker BioSpin, Reinstetten, Germany). 
Peak assignments were carried out using the above described 2D NMR 
experiments (TOCSY, HSQC and JRES), as well as lipid standards and the multiple-
quantum NMR experiments described below. 
 
 
Multiple quantum (MQ) NMR acquisition for assignment of lipid extracts 
For further assignment and identification of overlapping signals in proton spectra of 
plasma lipid extracts, the potential of multiple quantum (MQ) NMR spectroscopy was 
evaluated using a simplified lipid mixture composed by a set of four phospholipids and 
two cholesteryl esters. Phospholipid standards included 1-palmitoyl-2-hydroxy-sn-
glycero-3-phosphocholine (16:0 LPC), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phospho-
choline (16:0/18:2 PC), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine 
(16:0/18:2 PE) and N-palmitoyl-D-erythro-sphingosylphosphorylcholine (d18:1/16:0). 
Cholesteryl ester standards included cholesteryl octadecadienoate (18:2 CE) and 
cholesteryl eicosatetraenoate (20:4 CE). All lipid standards were analysed in pure state 
(1.25 mM in CDCl3) and in a mixture (1 mM of each one in CDCl3).   
NMR experiments were performed by courtesy of Institut des Sciences 
Moléculaires de Marseille (UMR 7313 iSm2), Aix Marseille Université. NMR acquisition 
was performed at 298 K using a Bruker Avance-600 NMR spectrometer equipped with 
a TXI probe capable of generating gradients fields up to 60 G/cm. First, a set of 1D and 
2D NMR experiments were performed, namely a standard 1H spectrum (zg) and 1H-1H 
correlation spectroscopy (COSY). The COSY experiment was performed using a 2D 
homonuclear shift correlation with gradient pulses for selection and purge pulses 
before relaxation delay, with the cosygpppqf pulse sequence from Bruker library. A list 
of all acquisition and processing parameters is show in Table 2.10.  
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Table 2.10. List of acquisition and processing parameters used for 1D and 2D NMR 
experiments and multiple quantum NMR experiments of lipid standards and lipid mixture. NS: 
number of scans, RD: relaxation delay, Q: quantum, delay for MQ creation, t1: fixed delay, t2: 
delay for gradient recovery, G1: first pulsed field gradient as % of maximum gradient output (60 
G/cm),G2: second pulsed field gradient as % of maximum gradient output (60 G/cm), SW: 
spectral window, F1: 1
st
 dimension, F2: 2
nd
 dimension, O1: transmitter frequency offset, TD: size 
of FID, SI: size of real spectrum, WDW: type of window function, SR: spectrum reference 
frequency. 
Experiment Acquisition parameters Processing parameters 
Standard 
1
H 
(zg) 
NS: 128; RD: 2 s; TD: 32 k; SW: 
9014.42Hz/ 15.02 ppm; RG: 228 
SI: 140 k; WDW: exponential; LB: 
0.30 Hz; Manual phase and 
baseline correction; Chemical shift 
calibration by CDCl3 (7.26 ppm) 
COSY 
(cosygpppqf) 
NS: 16; RD: 2 s; TD[F1]: 256; TD[F2]: 8 
k; SW[F1]: 7201.59 Hz; SW[F2]: 
7201.59 Hz 
SI [F1]: 1 k; SI [F2]: 1 k; WDW: 
qsine; Manual phase correction; 
Chemical shift calibration by CDCl3 
(7.26 ppm) 
2Q-1Q 
correlation 
NS: 16; RD: 2 s; 15 ms; t1: 3 μs   2: 
200 μs   1: 15%; G2: -30%; TD[F1]: 
128; TD[F2]: 8 k; SW[F1]: 10802.37 Hz; 
SW[F2]: 5405.41 Hz; O1: 2700.58 Hz 
SI [F1]: 1 k; SI [F2]: 512; WDW: 
sine; F1 in magnitude mode; 
Chemical shift calibration using the 
SR value of 1D 
3Q-1Q 
correlation 
NS: 16; RD: 2 s; 30 ms; t1: 3 μs   2: 
200 μs   1: 15%; G2: -45%; TD[F1]: 
256; TD[F2]: 8 k; SW[F1]: 16203.58 Hz; 
SW[F2]: 5405.41 Hz; O1: 2700.58 Hz 
SI [F1]: 1 k; SI [F2]: 8 k; WDW: 
sine; F1 in magnitude mode; 
Chemical shift calibration using the 
SR value of 1D 
4Q-1Q 
correlation 
NS: 16; RD: 2 s; 45 ms; t1: 3 μs   2: 
200 μs   1: 15%; G2: -60%; TD[F1]: 
256; TD[F2]: 8 k; SW[F1]: 16203.58 Hz; 
SW[F2]: 5405.41 Hz; O1: 2700.58 Hz 
SI [F1]: 1 k; SI [F2]: 512; WDW: 
sine; F1 in magnitude mode; 
Chemical shift calibration using the 
SR value of 1D 
5Q-1Q 
correlation 
NS: 16; RD: 2 s; 110 ms; t1: 3 μs   2: 
200 μs   1: 10%; G2: -50%; TD[F1]: 
256; TD[F2]: 8 k; SW[F1]: 27005.96 Hz; 
SW[F2]: 5405.41 Hz; O1: 2700.58 Hz 
SI [F1]: 1 k; SI [F2]: 512; WDW: 
sine; F1 in magnitude mode; 
Chemical shift calibration using the 
SR value of 1D 
 
1H multiple quantum coherences were excited and detected with the basic pulse 
sequence RD-90x--180x--90Φ-t1-90x-t2-ACQ (Reddy and Caldarelli, 2010). The value 
of  was optimized by eye to obtain the highest and most uniform signal intensity along 
the series of molecules. The phase Φ was chosen to select odd or even MQ orders (x 
or y for even or odd order excitation, respectively). Unwanted coherences were 
effectively dephased using a couple of sine-shaped pulse field gradients, G1 and G2, 
placed before and after the last 90 pulse, respectively. The ratio of the gradient pulse 
was selected to fulfill G2 = p × G1 (Keeler et al., 1994), where p is the MQ coherence of 
choice (i.e. 2 for double coherence, 3 for triple and so on). In this work, the double 
quantum-single quantum (2Q-1Q), triple quantum-single quantum (3Q-1Q), quadruple 
quantum-single quantum (4Q-1Q) and quintuple quantum-single quantum (5Q-1Q) 
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correlations were acquired and processed with the parameters shown in Table 2.10. All 
NMR data processing was carried out in TOPSPIN 3.2 version (Bruker BioSpin, 
Reinstetten, Germany). 
 
2.3.3. Data pre-processing and analysis 
Alignment and normalization 
NMR spectra were converted to a matrix of n rows (corresponding to n samples), 
and m columns (corresponding to variables). For whole blood plasma, the full 
resolution spectra (standard -1 to 10.5 ppm, CPMG 0.5 to 8.5 ppm and diffusion-edited 
-1 to 10.5 ppm) were used to construct data matrices for multivariate analysis using 
Amix 3.9.5 (Bruker BioSpin, Rheinstetten, Germany). The water region (4.5-5.0 ppm) 
was excluded as was that of ethanol (1.15-1.20 and 3.62-3.68 ppm), which was found 
randomly in blood samples, possibly due to skin disinfection prior to collection. 
Standard and CPMG spectra were aligned using recursive segment-wise peak 
alignment (RSPA) (Veselkov et al., 2009) to minimize chemical shift variations in some 
low molecular weight metabolites (e.g. valine, alanine, citrate), and data were 
normalized using probabilistic quotient normalization (PQN) (Dieterle et al., 2006) to 
account for differences in sample concentration. For plasma total lipid extracts, the full 
resolution standard 1H spectra (0.5 to 9 ppm) were used excluding the water (1.60-1.97 
ppm) and CDCl3 (7.04-7.05, 7.21-7.315 and 7.46-7.472 ppm) regions. Spectra were 
then aligned using RSPA to minimize chemical shift variations in the phospholipids 
resonances and normalized using PQN, as described above for whole plasma. 
Alignment and normalization were performed in Matlab 7.9.0 (The MathWorks, Inc.).  
 
Variable selection 
For Studies 3 to 5 (in chapters 6 to 8), variables (spectral data points) were 
selected through the intersection of three parameters: a) VIP>1, b) VIP/VIPcvSE>1 and 
c) b/bcvSE>1 (Diaz et al., 2013b). Parameters b) and c) define variables with lower 
standard errors in relation to VIP (VIPcvSE) and to b-coefficients (bcvSE). The standard 
error obtained by cross validation (cvSE) provides a measurement of the uncertainty of 
a parameter based on the concept of signal to noise ratio using a jack-knife approach 
which estimates the statistical error by re-computing models using a random subset of 
samples (Andersen and Bro, 2010). This concept was applied to the VIP and b-
coefficient parameters. The VIP values reflect the importance of each variable to the 
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projection in the low dimensional space i.e. the magnitude of the contribution of each 
variable to the separation, whilst b-coefficients reflects the discriminant and predictive 
capability of each variable i.e. their contribution for samples classification. 
 
Multivariate analysis (MVA) 
MVA was performed in NMR data of whole plasma and plasma lipid extracts after 
pre-processing and, in some cases, after variable selection using SIMCA-P 11.5 
software (Umetrics, Umeå, Sweden). In study 3 (chapter 6), row-concatenated matrix 
of 2nd T plasma and urine spectra obtained from common donors (22 controls, 26 CDs, 
12 T21) was considered for PLS-DA.  
PCA (Jolliffe, 2002) and PLS-DA (Barker and Rayens, 2003) were performed on 
data scaled by different methods, for comparison purposes: unit variance (UV), Pareto 
and centered scaling, with UV providing the best results. Model robustness was initially 
evaluated in terms of Q2 (goodness of prediction or prediction power), a parameter 
obtained by 7-fold cross validation in SIMCA-P 11.5 software. The corresponding 
loading plots of PCA and PLS-DA were back-transformed by multiplying the loading 
weight [w] by the variable standard deviation. PLS-DA loading plots were further 
colored according to each VIP, using Matlab 7.9.0. (The MathWorks, Inc.).  
Additionally, Partial Least Squares (PLS) regression analysis was performed in 
study 4 to enable the identification of metabolites varying significantly (at 95% 
confidence level) between post-diagnosis GDM and controls (X matrix) in relation to 
gestational age (y vector).  
 
 
Model validation 
For PLS-DA models, Monte Carlo cross-validation (MCCV, using in-house 
developed software) (7 blocks, 500 runs) was carried out with recovery of Q2 values 
and confusion matrices. Classification rates, specificity (spec.) and sensitivity (sens.) 
were computed and the predictive power of each model was further assessed using a 
receiver operating characteristic (ROC) map, a function of the true positive rate (TPR 
or sensitivity), and false positive rate (FPR or 1-specificity). PLS-DA models were 
considered robust when minimal overlapping of the distribution of true and permuted Q2 
was obtained (Wiklund et al., 2007; Westerhuis et al., 2008).  
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Univariate analysis 
Relevant peaks identified in loading profiles were integrated in Amix 3.9.5 (Bruker 
BioSpin, Rheinstetten, Germany) and PQN normalized. For plasma lipid extracts, the 
N(CH3)3 choline resonance of SM (3.31 ppm) and PC (3.34 ppm) were subjected to 
deconvolution in order to better integrate the two close peaks. A Lorentzian curve fitting 
was used with a default line width of 3 Hz, in Amix 3.9.5 (Bruker BioSpin, Rheinstetten, 
Germany).  
The individual statistical significance of each peak integral was computed by 
Shapiro-W lk  es  (   de e m  e  f d    w s    m lly d s   bu ed)    ude  ’s  -test (used 
for normally distributed data) or Wilcoxon rank sum test (used for non-normally 
distributed data), with R-statistical software (R. D. C. Team, 2010). For each set of 
significant metabolites, considering a significance level of 95% (p<0.05), the 
percentage of variation and the effect size value were calculated. The percentage of 
variation and the uncertainty were calculated according to Equation 2.1 and Equation 
2.2, respectively, where    denotes the average value,   the standard deviation and   
the sample numbers for both groups   and  . The effect size (E.S.) and the respective 
standard error were calculated according to Equation 2.3 and Equation 2.4, 
respectively, where    denotes the average value,   the standard deviation and   the 
sample numbers for both groups   and   (Berben et al., 2012). The distributions of 
peak integrals were also accessed with aid of box-and-whisker plots (boxplots) for 
group comparison.  
 
 
Equation 2.1 
 
 
Equation 2.2 
 
 
Equation 2.3 
 
 
Equation 2.4 
 
For study 1, the coefficient of variation (CV) was computed for each variable (PQN 
normalized data point) as the ratio between the standard deviation and the average 
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value; in this calculation, the noise was estimated and removed from the data 
according to the exclusion criteria if    
      
             , where   
    and   
     
are respectively the maximum and minimum intensities for each data point and        , 
is the 10th percentile of the standard deviation for all data points, based on references 
(Golotvin and Williams, 2000; Parsons et al., 2009).  
For study 1 and 2, the metabolite variations were also expressed in a heatmap 
representation with integral values normalized to unity and shown in a qualitative color 
scale, in R-s    s  c l s f w  e  I  s udy 3  4   d 5  e ch    eg  ls’ effec  s  e   d 
statistical significance (p-value) were further represented by means of a Volcano plot 
which is a graphical summary of the effect size vs. -log(p-value) (Cui and Churchill, 
2003). Additionally, in study 4, Bonferroni correction was used to adjust p-values for 
multiple comparisons by setting the significance cut- ff    α/  w  h α=0 05   d 
n=number of metabolites/resonances simultaneously tested. 
 
 
Correlation studies 
Statistical total correlation spectroscopy (STOCSY) was performed for each 
unassigned NMR resonance and for the CH3 resonances (at 0.84, 0.86 and 0.87 ppm) 
of lipoprotein particles in order to identify peaks arising from the same molecule and/or 
metabolically related compounds. The correlation coefficient and the covariance were 
calculated between each resonance and the complete spectrum matrix. The 
covariance was then plotted and colored according to the correlation coefficient (r), in 
Matlab 7.9.0 (The MathWorks, Inc.) (Cloarec et al., 2005). In order to facilitate the 
identification of the correlated peaks, the 1D STOCSY was plotted without any 
threshold.  
For study 2 (chapter 5), in order to define a more complete picture of pregnancy 
biofluid metabolome, plasma changes were correlated, using Pearson Product-Moment 
correlation analysis, to those observed in urine (Diaz et al., 2013a) collected for a 
partially overlapped cohort (in a total of 69 subjects, 30 provided both plasma and 
urine: 15 in the NP group and the remaining distributed by the different pregnancy 
trimesters) recruited with the same criteria as for plasma. Intra-biofluid correlations 
(plasma/plasma and urine/urine) were also calculated. A correlation coefficient (r) and 
s g  f c  ce  h esh ld  f | | ≥ 0 6   d p< 0 05 we e  ppl ed (   selec   he   p 3%  f 
correlation values) and correlations were confirmed by scatter plotting each pair of 
correlated integrals in Matlab 7.9.0 (The MathWorks, Inc.). These pairs were then used 
to compute a correlation network, using the Gephi 0.8.2 software (Bastian et al., 2009). 
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In study 3 (chapter 6), the plasma and urine metabolites found to change in CD cases 
compared to controls (26 CD and 22 controls from common donors) were used for 
intra- and inter-biofluid Pearson Product-Moment correlation analysis (R-statistical 
software). Correlation coefficients (r) ranged from -0.609 to 0.988 and correlations were 
confirmed by scatter plot inspection.  
 
2.4. Profiling of maternal plasma by Hydrophilic Interaction Liquid 
Chromatography-Mass Spectrometry (HILIC-LC/MS) phospholipid analysis 
2.4.1. Sample preparation 
Blood plasma pools were thawed at room temperature and prior to phospholipids 
extraction, 5 µg (7.4 pM) of an internal standard (1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC)) was added to 100 µL of each pooled sample. Phospholipids 
extraction was performed in a HybridSPE-Phospholipid (HybridSPE-PL) column 
(Sigma Aldrich, Portugal), as illustrated in Figure 2.4.  
 
 
 
Figure 2.4. Schematic representation of extraction of phospholipids from pooled plasma 
samples using the hybridSPE-PL column. 
 
Briefly, 900 µL of acetonitrile (ACN) with 1% formic acid were added to 100 µL of 
pooled sample, vortexed (30 s) and centrifuged (5000 g, 3 min). The supernatant was 
transferred to the HybridSPE-PL column, followed by addition of ACN with 1% formic 
acid (1 mL) and ACN (1 mL). The retained phospholipids were eluted with two 
consecutive aliquots of ACN with 5% ammonium hydroxide (NH4OH) (1 mL). The flow-
through was collected, dried, and stored at -20ºC until analysis. The interaction 
between the zirconia coated silica in the HybridSPE-PL column and plasma 
phospholipids is based on Lewis acid-base chemistry and the recovery of 
phospholipids is over 95% as has been thoroughly discussed in reference (Lu and Ye, 
DMPC (7.4 pM) + 
plasma pool (100 μL)
ACN/1% FA 
(900 μL)
Supernatant transferred to hybridSPE-PL column 
Vortex 30 s
Centrifugation
Protein 
pellet
Eluents (1 mL each one):
1st: ACN/1% formic acid
2nd: ACN
3rd: ACN/5% NH4OH
4th: ACN/5% NH4OH
Zirconia 
coated silica
ACN
Collection of PLs eluted 
with ACN/5% NH4OH
Protein precipitation
(5000xg, 3 min)
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2010). Before HILIC-LC/MS analysis, phospholipid extracts were thawed and 
resuspended in 200 μL  f CHCl3  f  m wh ch 2 μL we e   ke    d d  ed u de       ge   
Af e  d y  g   he  l qu    f ph sph l p d ex   c  w s d lu ed w  h 90 μL  f m b le ph se 
B (60% acetonitrile, 40% methanol with 1 mM ammonium acetate). 
 
2.4.2. HILIC-LC/MS analysis 
Phospholipid classes were separated by HILIC-LC/MS, performed on an HPLC 
system (Waters Alliance 2690) coupled to an electrospray (ESI) linear ion trap mass 
spectrometer LXQ (ThermoFinnigan, San Jose, CA, USA). The mobile phase A 
consisted of 10% water, 55% acetonitrile and 35% (v/v) methanol with 1 mM 
ammonium acetate. The mobile phase B consisted of 60% acetonitrile, 40% methanol 
with 1 mM ammonium acetate. Phospholipid extracts diluted in the mobile phase B (15 
μL) we e      duced         Asce   s    H LC    e c lum  (15 cm × 1 0 mm  3 μm  
Sigma-Aldrich). A pre-column split (Acurate, LC Packings, USA) was used in order to 
obtains a flow rate of 50 μL min−1. The solvent gradient was programmed as follows: 
100% of B was held isocratically for 15 min, followed by a linear increase to 100% A 
during 5 min, and held isocratically for 25 min, returning to the initial conditions in 5 
min.  
Phospholipid detection and identification was carried out under positive ionization 
mode on an ESI linear ion trap mass spectrometer (ThermoFinnigan, San Jose, CA, 
USA). ESI conditions on linear ion trap mass spectrometer were as follows: 
electrospray voltage was 5 kV; capillary temperature was 275ºC and the sheath gas 
flow was 8 units. To obtain the product-ion spectra of the major components during LC 
experiments, cycles consisting of one full scan mass spectrum and four data-
dependent MS/MS scans were repeated continuously throughout the experiments with 
the following dynamic exclusion settings: repeat count 1; repeat duration 30 s; 
exclusion duration 45 s. MS data were collected in centroid mode in the m/z range 80-
2000. Data acquisition was carried out with an Xcalibur data system (V2.0). 
Phospholipid classes were identified using the MS/MS data and the LIPID MAPS MS 
predict tool (Fahy et al., 2007). 
 
 
2.4.3. Data pre-processing and analysis 
Data filtering, peak detection, chromatogram deconvolution and chromatogram 
alignment (i.e. matching of equivalent peaks across multiple samples) were performed 
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using MZmine (version 2.10, MZmine Development Team) (Pluskal et al., 2010). The 
parameters were set as follow: RT range 7.0-50.0 min, m/z range 450.0 – 950.0, MS 
data noise level 1.5E2; m/z tolerance 0.5 m/z or 300 ppm; minimum time span of 
chromatographic peaks 1.0 min; and a minimum intensity of a peak in chromatogram of 
1.5E2. The area of each peak, after being recognized and aligned, was normalized to 
the area of the internal standard DMPC added to each plasma pool before 
phospholipid extraction. Isotopic peaks were excluded for processing. 
The resulting data, m/z-RT pair, sample name and normalized ion area were 
subjected to multivariate analysis. PCA and PLS-DA were performed on data scaled by 
unit variance (UV), using SIMCA-P 11.5 software (Umetrics, Umeå, Sweden). For PLS-
DA models, MCCV (7 blocks, 500 runs, using in-house-developed software) was 
carried out with recovery of Q2 values and computation of classification rates, 
sensitivity and specificity, as described above for NMR data. Relevant m/z-RT pairs 
identified in loadings profiles with VIP higher than 1, were analysed using univariate 
analysis tests: Shapiro-W lk    m l  y  es     ude  ’s  -test or Wilcoxon test, with R-
statistical software. Effect size (E.S.) was computed for m/z pairs with statistically 
significant differences between control and diseases (p<0.05), corrected for small 
sample numbers (Equation 2.5 and Equation 2.6).  
 
 
 
Equation 2.5 
 
 
Equation 2.6 
 
The correction is performed through the multiplication of E.S. and E.S.standard error  
(Equation 2.3 and Equation 2.4, defined above for NMR data) by a factor   defining two 
new equations, where   is the sample numbers for both groups   and   (Berben et al., 
2012). 
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This chapter begins by presenting the NMR plasma metabolome obtained by 1D 
and 2D experiments of whole blood plasma and the resulting complete list of 
metabolites identified. Secondly, the NMR plasma lipidome characterization through 1D 
and 2D NMR experiments is presented, comprising results of the application of MQ 
spectroscopy for lipid assignment in complex samples.  
 
3.1. NMR spectra of blood plasma and spectral assignment 
Blood plasma is the most important transport medium in the body containing 
metabolites that are intermediates and end products of metabolism in cells, tissues, 
organs and other biofluids. In order to characterize blood plasma composition, plasma 
samples were analysed at 500 MHz and prepared as described in Chapter 2 (section 
2.3). The presence of low and high Mw compounds in plasma enforces the use of 
standard 1D, CPMG (or T2-edited) and diffusion-edited spectra to characterize the 
NMR plasma metabolome. Figure 3.1 shows an example of the typical 1H NMR spectra 
obtained for a healthy non-pregnant woman. The standard 1D spectrum (Figure 3.1a) 
is dominated by the broad resonances of large molecules, mostly lipoproteins and 
proteins, as well as by many signals from low Mw metabolites. A high number of signals 
arise from the different types of protons in the fatty acids (FA), free cholesterol (FC), 
esterified cholesterol (EC), triglycerides (TG) and phospholipids (PL) present in 
lipoprotein particles. In addition, broad signals from the N-acetyl groups of 
glycoproteins, lysyl groups of albumin (most abundant plasma protein) and NH from 
total proteins, are detected. Furthermore, several resonances from small metabolites 
can be identified in the standard 1D spectrum, such as glucose, some amino acids 
(valine, alanine, arginine, creatine, glutamine, threonine), organic acids (lactate, 
acetate, pyruvate, citrate), ketone bodies (acetone, acetoacetate), creatinine, betaine 
and trimethylamine N-oxide (TMAO). These metabolites are more clearly detected in 
the CPMG spectrum (Figure 3.1b), due to the substantial attenuation of signals from 
proteins and lipoproteins, with the addition of others present in lower concentrations 
(leucine, isoleucine, glycine, lysine, histidine, tyrosine, formate, dimethyl sulfone). The 
diffusion-edited spectrum (Figure 3.1c) is especially useful to study the lipidic 
components of plasma without the interference of narrow peaks from low Mw 
metabolites (e.g., glucose, lactate). This spectrum is dominated by the CH3, (CH2)n and 
unsaturated protons from fatty acids, N(CH3)3 choline resonances of choline-containing 
PL, and glyceryl protons in PL and TG. The N-acetyl glycoprotein and albumin-lysyl 
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signals are also observed, as well as the large signal of NH from total proteins at  5.5-
11.0. 
 
Figure 3.1. 1D 
1
H NMR 500 MHz spectra of plasma of a healthy non-pregnant woman: a) 
standard, b) CPMG (T2-edited), and c) diffusion-edited spectra. Assignment: 1- C18H3 
cholesterol, 2- CH3 lipids, 3- valine, 4- (CH2)n lipids, 5- lactate, 6- alanine, 7- CH2CH2CO lipids, 
8- CH2CH2CH=, 9- acetate, 10- CH2CH= lipids, 11- N-acetyl glycoproteins, 12- CH2CO lipids, 
13- acetoacetate, 14- pyruvate, 15- glutamine, 16- citrate, 17- =CHCH2CH= lipids, 18- albumin-
lysyl, 19- creatine, 20- creatinine, 21- N(CH3)3 choline of PL, 22- α- and β- glucose, 23- 
CH2N(CH3)3 choline of PL, 24- glyceryl-C1,3H, 25- glyceryl-C1 3H’, 26- HC=CH lipids, 27- urea, 
28- tyrosine, 29- histidine, 30- formate, 31- NH proteins. *: cut off spectral region corresponding 
to water signal. 
 
In order to improve the assignment of the 1H NMR spectra of plasma, 2D 1H-1H 
TOCSY, 1H-13C HSQC and J-resolved experiments were acquired. The 1H-1H TOCSY 
spectrum of blood plasma for the same healthy non-pregnant woman is shown in 
Figure 3.2a. This spectrum is dominated by broad signals arising from the high Mw 
metabolites described above, but still enabling the confirmation of spin systems from 
a) 
b) 
c) 
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metabolites (e.g., leucine, lysine, β-hydoxybutyrate) present in low concentrations and 
obscured in the 1D spectra. The 1H-13C HSQC, in Figure 3.2b, contains only the signals 
from lipidic resonances, N-acetyl glycoproteins, albumin-lysyl and glucose. Finally, the 
J-res experiment (not shown) was also acquired, enabling the further confirmation of 
peak assignments from low Mw compounds through their multiplicity and J-coupling 
constants. Furthermore, peak assignment was confirmed by comparison with several 
databases, such as the BMRB (Seavey et al., 1991), HMDB (Wishart et al., 2007) and 
Bruker Biorefcode spectral database (courtesy of Bruker Biospin, Rheinsteten, 
Germany), and previous reports (Nicholson et al., 1995; Liu et al., 2002; Engelke et al., 
2005). 
 
 
Figure 3.2. 2D 500 MHz spectra of plasma from a healthy non-pregnant woman: a) TOCSY, 
and b) 
1
H-
13
C HSQC. Peak assignments correspond to that shown in Figure 3.1, with the 
addition of 32- leucine, 33- β-hydroxybutyrate, 34- lysine. 
a) 
b) 
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Overall, 31 low Mw metabolites, lipids and proteins (albumin and N-acetyl 
glycoproteins) were identified in plasma, all having been previously identified in human 
blood plasma/serum by NMR (Nicholson et al., 1995; Liu et al., 2002; Engelke et al., 
2005), except 1,5-anhydroglucitol (present at 73.0-243.0 M in blood (Wishart et al., 
2007)) reported only in a GC-MS study (Scholtens et al., 2014). A comprehensive list of 
1H and 13C (measured in HSQC) NMR assignment of plasma metabolites is presented 
in Table 3.1, along with the corresponding chemical shifts and multiplicity. 
Table 3.1. 500 MHz 
1
H and 
13
C NMR assignment of metabolites present in human plasma 
samples (average pH 7.86). s: singlet, d: duplet, dd: doublet of doublets, dt: doublet of triplets, t: 
triplet, q: quartet, m: multiplet, br: broad. 
a
 identified here for the first time to our knowledge, by 
NMR spectroscopy. 
Compound δ 
1
H in ppm (multiplicity, assignment) / δ 
13
C in ppm 
Acetate 1.91 (s,CH3) 
Acetoacetate 2.27 (s,CH3) 
Acetone 2.22 (s, CH3) 
Alanine 1.46 (d,CH3); 3.75 (q, -CH) 
Albumin lysyl 2 90 (   єCH2)/42.14; 2.96 (t, CH2)/42.14; 3.01 (t, CH2)/42.14 
1,5-anhydroglucitol 
a
 3.26 (t, C1H); 3.34 (m, C4,5H); 3.43 (m, C3H); 3.58 (m, C2H); 3.68 (dd, 
C6H)  3 87 (d  C6H’)  3.97 (dd, C1H’) 
Betaine  3.29 (s, NCH3) 
Cholesterol  0.65 (m, C18H) 
Citrate 2.51 (d, ,CH); 2.66 (d, ’ ’CH) 
Citrulline 1.57 (m, CH2); 1.86 (m, CH2); 3.15 (t, ’CH2); 3.70 (m, CH) 
Creatine 3.03 (s, NCH3); 3.92 (s, NCH2) 
Creatinine 3.04 (s, NCH3); 4.05 (s, NCH2) 
Dimethylsulfone  3.14 (s, CH3) 
Formate 8.45 (s, CH) 
-glucose 3.41 (t, C5H)/72.40; 3.53 (dd, C2H)/74.30; 3.71 (t, C3H)/75.57; 3.76 
(dd, C6H)/63.48; 3.83 (m  C4H)/74 18  3 83 (m  C6H’)/63 40; 5.23 (d, 
C1H)/94.96 
-glucose 3.23 (dd, C2H)/77.10; 3.40 (t, C5H)/72.40; 3.47 (dd, C4H)/78.70; 3.49 
(   C3H)/78 49  3 71 (dd C6H’)/63 70; 3.89 (m, C6H)/63.70; 4.64 (d, 
C1H)/98.74 
Glutamine 2.12 (m, CH2); 2.44 (m, CH2); 3.75 (t, CH) 
Glycerol 3 55 (dd  C1 3H)  3 65 (dd  C1 3H’)  3 78 (m  C2H) 
Glycine  3.55 (s, CH) 
-hydroxybutyrate 1.19 (d, CH3), 2.30 (m, CH2), 2.40 (m, CH2), 4.15 (m, CH) 
Histidine  3.10 (dd, CH2); 3.19 (dd, ’CH2); 3.91 (dd, CH); 7.04 (s, C4H, ring); 
7.74 (s, C2H, ring) 
Isoleucine  0.93 (t, CH3); 1.00 (d, CH3) 
Lactate  1.32 (d, CH3); 4.10 (q, CH)/22.61 
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Table 3.1. (cont.) 
Compound δ 
1
H in ppm (multiplicity, assignment) / δ 
13
C in ppm 
Leucine 0.95 (d, ,’CH)/25 65  1 70 (m  ,CH); 3.72 (t, CH)/57.42 
Lipids 0.85 (br, CH3)/16.58, 25.20; 1.25 (br, (CH2)n)/25.19, 32.25, 34.55; 1.53 
(br, CH2CH2CO); 1.70 (br, CH2CH2C=C); 1.99 (br, CH2C=C)/29.79; 2.22 
(br, CH2CO)/36.43; 2.74 (br, C=CCH2C=C)/28.13; 3.21 (br, N(CH3)3 
choline)/56.58; 3.66 (br, CH2-N(CH3)3 choline)/68.70; 4.11 (br, glyceryl-
C1,3H) /71.27, 4.24 (br, glyceryl-C1,3H’)/62.14, 5.19 (br, glyceryl-C2H), 
5.29 (m, HC=CH)/131.20 
Lysine  1.71 (m, CH2); 1.89 (m, CH2); 2.99 (t, CH2);  
Methanol 3.36 (s, CH3) 
N-acetyl 
glycoproteins 
2.03 (s,CH3)/24.93 
Phenylalanine 3.12 (dd, CH2); 3.26 (dd, ’CH2); 3.97 (dd, CH); 7.31 (m, C2H/C6H); 
7.36 (m, C4H); 7.41 (m, C3H/C5H) 
Proline 2.01 (m, CH2); 2.07 (m, CH2); 2.34 (m, ’CH2); 3.34 (dt, CH2); 3.45 
(m, ’CH2); 4.12 (dd, CH) 
Pyruvate  2.36 (s, CH3) 
Threonine  1.32 (d, CH); 3.57 (d, CH); 4.24 (m, CH) 
Trimethylamine N-
oxide (TMAO) 
3.27 (s, NCH3) 
Tyrosine 3.06 (dd, CH2); 3.16 (dd, ’CH2); 3.94 (dd, CH); 6.89 (d, C3H/C5H); 
7.18 (d, C2H/C6H) 
Valine  0.98 (d, CH3); 1.03 (d, ’CH3); 2.26 (m, CH); 3.60 (d, CH) 
Urea 5.77 (br, NH2) 
 
 
Regarding the identification of different lipoprotein particles by NMR, some reports 
have identified some degree of peak resolution in the CH3 and (CH2)n resonances, 
without physical isolation, due the slightly chemical shift differences in HDL, LDL and 
VLDL (Otvos et al., 1991; Ala-korpela et al., 1994; Liu et al., 2002). In this work, 
statistical total correlation spectroscopy (STOCSY) analysis was found to be a useful 
tool to identify the 1H resonances arising from HDL and LDL+VLDL as will be shown in 
Chapter 4 (section 4.2) and 5 (section 5.1). 
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3.2. NMR spectra of plasma lipid extracts and spectral assignment 
3.2.1. 1D and 2D NMR  
In order to better characterize the lipidic components of blood plasma, an extraction 
procedure was applied followed by 500 MHz 1D and 2D NMR acquisition, as described 
in Chapter 2 (section 2.3). The lipid extraction procedure enables the solubilisation of 
all lipid classes present in lipoprotein particles. Different extraction procedures for 
plasma lipid extraction were previously analysed and compared by NMR in a master 
thesis (Almeida, 2014), unveiling that the most suitable method is the MTBE-methanol 
(easier extraction and more reproducible). A recent LC-MS study (Sarafian et al., 2014) 
also reported broad lipid coverage with recoveries of about 60%, and 99% protein 
removal using this method for plasma lipid extraction. Figure 3.3 shows the comparison 
of the diffusion-edited spectrum of plasma and the corresponding 1H spectrum of lipid 
extract, for a healthy pregnant woman in 1st T. Compared with whole plasma, the lipid 
extract shows better resolution of lipid classes but still with high overlap, namely in the 
fatty acyl and cholesterol (free and esterified) resonances. The region  0.65-1.40 is 
dominated by the 1H resonances of free cholesterol (FC) and esterified cholesterol 
(EC), partially superimposed in the CH3 resonance of FA, as well as the (CH2)n signal 
of FA. Distinct resonances from FC and EC can be found at  1.01 and  3.53, and  
1.02 and  4.61, respectively. The two most abundant PL classes in plasma, PC (1974 
M) and SM (303 M) (Quehenberger et al., 2010), are clearly detected in the region  
3.20-3.40, while in the region  3.4-4.7, it is possible the identification of glyceryl 
resonances of total PL and TG. Furthermore, the assignment of several unsaturated 
FA resonances was possible through 2D spectra (TOCSY and HSQC, Figure 3.4a and 
b) and 1D STOCSY (Figure 3.4c), namely oleic acid (18:1), linoleic acid (18:2), 
arachidonic acid (20:4) and docosahexaenoic acid (22:6). These unsaturated FA are 
the most abundant in plasma, with reported percentages of contribution to the total 
plasma FA composition of 24.7% for 18:1, 21.2% for 18:2, 5.1% for 20:4 and 1.3% for 
22:6 (Glaser et al., 2010). In Figure 3.4c, the resonance of 20:4 FA at  2.82 was 
correlated with the whole spectrum and peaks arising from the same molecule are 
clearly observed with high covariance and correlation (red and orange). STOCSY 
added information mainly in the identification of CH3 resonances of polyunsaturated 
FA, which were highly overlapped even in the 2D spectra. In some cases, lipid 
assignments were confirmed by 1H NMR experiments of pure standards (18:2 CE, 20:4 
CE, 16:0/18:2 PC, d18:1/16:0 SM) and computer simulations (1H and 13C NMR 
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prediction tool of ChemBioDraw Ultra 14.0, CambridgeSoft Corporation, PerkinElmer, 
Inc.).  
 
Figure 3.3. a) 500 MHz diffusion-edited spectrum of blood plasma and b) 500 MHz 
1
H spectrum 
of plasma lipid extract of a healthy pregnant woman in the 1
st
 trimester. Assignment: 1- C18H3 
cholesterol, 2- CH3 lipids, 3- (CH2)n lipids, 4- CH2CH2CO lipids, 5- CH2CH2CH= lipids, 6- 
CH2CH= lipids, 7- CH2CO lipids, 8- =CHCH2CH= lipids, 9- N(CH3)3 choline of PL, 10- 
CH2N(CH3)3 choline of PL, 11- glyceryl protons of lipids, 12- HC=CH lipids, 13- C18H3 FC and 
EC, 14- C26H3 and C27H3 FC and EC, 15- CH3 FA, 16- C21H3 FC and EC, 17- C19H3 FC, 18- 
C19H3 EC, 19- (CH2)n FA, 20- =CHCH2(CH2)n FA, 21- multiple protons from FC and EC, 22- 
CH2CH2CH= 18:1 FA, 23- CH2CH= FA, 24- C4H’ FC, 25- CH2CO FA, 26- =CHCH2CH= 18:2 
FA, 27- =CHCH2CH= 20:4 FA, 28- N(CH3)3 choline SM, 29- N(CH3)3 choline PC, 30- C3H FC, 
31- CH2N(CH3)3 choline PL, 32- glyceryl-C3H2 PL, 33- glyceryl-C1,3H TG, 34- glyceryl-C1,3H’ 
TG, 35- POCH2 PL, 36- glyceryl-C1H2 PL, 37- C3H EC, 38- glyceryl-C2H PL, 39- glyceryl-C2H 
TG, 40- HC=CH FA. *: cut off spectral region corresponding to water signal in a), and water and 
CDCl3 in b). 
 
Overall, four distinct unsaturated FA, total saturated FA, FC, EC, total PL, PC, SM 
and TG were identified in plasma lipid extracts. All these lipidic components were 
detected before in plasma and serum lipid extracts by NMR (Willker and Leibfritz, 1998; 
Oostendorp et al., 2006; Tukiainen et al., 2008; Srivastava et al., 2010). Table 3.2 lists 
the 1H and 13C (from HSQC) resonances identified for each lipid class and individual 
unsaturated FA, along with the corresponding multiplicity and assignment. 
a) 
b) 
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Figure 3.4. 500 MHz a) TOCSY, b) 
1
H-
13
C HSQC and c) STOCSY spectra of lipid extract of a 
healthy pregnant woman in the 1
st
 T. Peak assignments correspond to that shown in Figure 3.3, 
with the addition of 41- C1H FC, 42- C2H EC, 43- C2H FC, 44- C2H EC, 45- C25H, C15H’   d 
C16H’ FC   d EC, 46- C7H EC, 47- CH2CH= 20:4 FA, 48- C4H’ EC, 49- CH2CO 22:6 FA, 50- 
C9H FC and EC, 51- C14H FC and EC, 52- C17H FC and EC, 53- C23H FC and EC, 54- 
=CHCH2(CH2)n 18:1, 55- =CHCH2(CH2)n 20:4 and 18:2, 56- C2H FC, 57- C2H EC, 58- C4H FC, 
59- C4H EC, 60- C7H FC and EC, 61- HC=CH 18:1 and 18:2 FA, 62- HC=CH 20:4, 63- HC=CH 
22:6, 64- CH3 20:4 FA.  
a) 
b) 
c) 
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 Table 3.2. 500 MHz 
1
H and 
13
C NMR assignment of lipids present in human plasma lipid 
extracts. s: singlet, d: duplet, dd: doublet of doublets, t: triplet, q: quartet, m: multiplet, br: broad. 
Compound δ 
1
H in ppm (multiplicity, assignment) / δ 
13
C in ppm 
Arachidonic acid 
(20:4) 
0.98 (t, CH3); 1.34 (m, =CHCH2(CH2)n)/35.95; 2.07 (q, CH2CH=)/27.19; 
2.81 (m, =CHCH2CH=)/25.63; 5.37 (m, HC=CH)/128.28 
Docosahexaenoic 
acid (22:6) 
2.38 (t, CH2CO)/33.20; 2.82 (m, =CHCH2CH=); 5.36 (m, HC=CH)/122.66 
Esterified 
cholesterol 
0.68 (s, C18H3)/11.84; 0.86 (d, C26H3)/22.66; 0.87 (d, C27H3)/22.66; 0.91 
(d, C21H3)/18.70; 0.95 (m, C9H)/49.96; 0.99 (m, C14H)/56.91; 1.02 (s, 
C19H3)/19.38; 1.10 (m, C17H)/56.05; 1.12 (m, C23H)/23.90; 1.12 (m, 
C24H)/39.70; 1.13 (m, C22H)/37.17; 1.15 (m, C1H)/39.65; 1.35 (m, 
C20H)/35.94; 1.58 (m, C2H)/24.89; 1.60 (m, C15H, C16H)/24.83; 1.84 (t, 
C4H)/28.03; 1.87 (t, C15H’  C16H’); 1.95 (t, C7H)/32.05; 1.99 (t, 
C7H’)/31 86  2.31 (t, C4H’)/34.41; 4.61 (m, C3H)/73.86 
Free cholesterol 0.68 (s, C18H3)/11.84; 0.86 (d, C26H3)/22.66; 0.87 (d, C27H3)/22.66; 0.91 
(d, C21H3)/18.70; 0.95 (m, C9H)/49.96; 0.99 (m, C14H)/56.91; 1.01 (s, 
C19H3)/19.38; 1.07 (m, C1H)/39.65; 1.10 (m, C17H)/56.05; 1.12 (m, 
C23H)/23.90; 1.12 (m, C24H)/39.70; 1.13 (m, C22H)/37.17; 1.35 (m, 
C20H)/35.94; 1.49 (m, C11H)/21.04; 1.51 (m, C2H)/21.06; 1.60 (t, 
C16H)/24.83; 1.84 (m, C4H)/28.08; 1.87 (t, C16H);1.95 (t, C7H)/32.05; 
1 99 (   C7H’)/31 86  2.26 (t, C4H’)/34.41; 3.53 (m, C3H)  
Linoleic acid 
(18:2) 
0.98 (t, CH3); 1.33 (m, =CHCH2(CH2)n)/35.95; 2.04 (q, CH2CH=)/27.19; 
2.77 (t, =CHCH2CH=)/25.71; 5.34 (m, HC=CH)/130.00 
Oleic acid (18:1) 0.95 (t, CH3); 1.30 (m, (CH2)n)/22.60; 2.00 (m, CH2CH2CH=)/39.70; 5.34 
(m, HC=CH)/130.00 
Phospholipids 3.29 (s, N(CH3)3 SM)/54.43; 3.31 (s, N(CH3)3 PC)/54.54; 3.75 (br, 
CH2N(CH3)3)/66.47; 3.94 (br, glyceryl-C3H2)/59.43; 4.32 (br, PO-
CH2)/59.44; 4.38 (br, glyceryl-C1H2)/62.90; 5.20 (br, glyceryl-C2H)/70.46 
Saturated fatty 
acids 
0.89 (br, CH3)/14.12; 1.25 (br, (CH2)n)/29.6; 1.26(br, (CH2)n)/31.80; 1.60 
(m, CH2CH2CO)/24.88; 2.30 (m, CH2CO)/34.14, 38.22;  
Triglycerides 4.14 (dd, glyceryl-C1,3H)/62.28; 4.29 (dd, glyceryl-C1,3H’)/62.14; 5.26 (m, 
glyceryl-C2H)/62.04 
 
 
3.2.2 Multiple quantum (MQ) spectroscopy 
In an attempt to overcome the complex overlap of 1H signals in complex mixtures, 
such as plasma lipid extracts, the potential of multiple quantum (MQ) spectroscopy to 
generate a specific fingerprint of a given molecular structure was evaluated. This work 
was performed as courtesy of Institut des Sciences Moléculaires de Marseille (UMR 
7313 iSm2), Aix Marseille Université, and the detailed experimental procedure can be 
found in Chapter 2 (section 2.3). A set of pure lipid standards were chosen based on 
the lipidic composition of plasma (more abundant ones), comprising a total of 6 lipid 
standards, 4 PL with the same fatty acyl chains (16:0 LPC, 16:0/18:2 PC, 16:0/18:2 PE, 
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d18:1/16:0 SM), and 2 EC (18:2 EC and 20:4 EC). Due the high similarity in the 
molecular structures, it was expected that the proton resonances in 1D and 2D spectra 
would be largely overlapped as shown above for plasma lipid extracts. An example of a 
1H-1H COSY spectrum of 18:2 EC is shown in Figure 3.5a. This experiment was used 
for assignment of each pure molecule giving only the information about the coupled 
spins, thus simpler than TOCSY (all spins in a spin system). As expected, the COSY 
spectrum is also dominated by a largely overlap of protons from the cholesterol part 
with the methyl (CH3), methylene (CH2) and allylic (=CHCH2) groups of fatty acyl part. 
MQ spectroscopy appears here as a challenge to search for a specific MQ signature 
for each molecule based on the separation of molecular fragments through a 
correlation of their higher quantum coherence order (double quantum (2Q), triple 
quantum (3Q) and so on) on one dimension along with the regular 1H spectrum (1Q) on 
the other dimension (Reddy and Caldarelli, 2010, 2011, 2012). Figure 3.5b-e shows the 
progressive simplification of the correlation peaks for 18:2 EC structure along the 
spectral MQ series (from 2Q to 5Q), due to the filtering out of spin systems incapable of 
generating a given MQ coherence. The 2Q spectrum (Figure 3.5b) gives very similar 
information to that obtained from COSY spectrum (Figure 3.5a), since coupled spins 
are detected without the diagonal peaks. The C19H3 (s,  1.02) resonance is not 
detected here since there are no coupled spins (see 18:2 EC molecular structure in 
Figure 3.5a). In Figure 3.5c, the 3Q spectrum shows lesser peaks when compared with 
2Q, namely the C18H3 (s,  0.68), C26H3 (d,  0.86), C27H3 (d,  0.87) and C21H3 (d, 
0.91) resonances. Three of these methyl groups are present in the side chain (C21, 
C26 and C27) and one (C18) linked to the last ring in cholesterol part. The 4Q 
spectrum (Figure 3.5d), compared to 3Q, shows a similar pattern of peaks with loss of 
C9H (m,  0.95), C14H (m,  0.99) and C4H’ (    2.26) resonances. In addition, some 
simplification is observed in the region  1.21-1.29 corresponding to the methylene 
protons of the fatty acyl chain. Finally, the 5Q spectrum (Figure 3.5e) shows the 
simplest spectrum obtained, with loss of resonances in regions  1.09-1.20 (C17H, 
C23H2, C24H2, C22H2, C1H’),  1.40-1.50 (C11H, C12H) and  1.93-2 02 (C7H  C7H’), 
when compared with the 4Q spectrum (Figure 3.5d). Hence, the 5Q spectrum of 18:2 
EC gives information about the CH3 (t,  0.89), (CH2)n (m,  1.30), =CHCH2 (q,  2.04), 
CH2CO (m,  2.30), =CHCH2CH= (t,  2.77) and HC=CH (m,  5.35) of 18:2 fatty acyl 
chain, as well as the C1H (m,  1.06) and C2H (t,  1.58) of cholesterol part. Overall, 
the MQ spectra showed reduced peak intensities possible due to loss of magnetization 
during the two  delays for MQ creation (Keeler, 2002a), especially evident in 5Q 
spectrum (longer  delays).  
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Figure 3.5. 600 MHz a) 
1
H-
1
H COSY, b-e) series of MQ-1Q correlation spectra of the 18:2 EC 
pure standard (1.25 mM), with the coherence order ranging from 2 to 5. The cholesteryl part of 
18:2 EC in a) is numbered as originally described by Fieser and Fieser in 1959 (Christie, 2014).  
 
 
a) 
b) c) 
d) e) 
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The series MQ-1Q correlation spectra obtained for the lipid mixture showed a 
fingerprint equal to the sum of the pure compound spectra for the corresponding 
coherence order. As mentioned above, the 2Q spectrum showed similar information to 
COSY, where the resonances mentioned above for 18:2 EC (Figure 3.5b) were found 
with the addition of characteristic resonances from 20:4 FA (CH2CH2CO, CH2CH=, 
CH2CO, =CHCH2CH=) and PL (PE CH2NH3; LPC, PC and SM N(CH3)3 and 
CH2N(CH3)3;  LPC, PC and PE glyceryl; CH2CONH SM). These resonances showed 
large overlap making very hard the identification of LPC proton resonances. The 3Q 
spectrum of lipid mixture is shown in Figure 3.6a, where it is possible to identify specific 
resonances from 20:4 FA (A boxes), EC (B boxes), SM (C box), 18:2 FA (D box), and 
PC+PE (E boxes).  
 
 
Figure 3.6. a) 600 MHz 3Q-1Q spectrum of lipid mixture (16:0 LPC, 16:0/18:2 PC and PE, 
d18:1/16:0 SM, 18:2 EC and 20:4 EC). b) 500 MHz 3Q-1Q spectrum of plasma lipid extract of a 
healthy pregnant woman in 1
st
 T. A: CH2CH2CO ( 1.70), CH2CH= ( 2.11) and =CHCH2CH= ( 
2.82) of 20:4 FA, B: C4H, C15H’   d C16H’ ( 1.77-1.90) and C3H ( 4.61) of cholesterol part of 
EC, C: CH2CHNH ( 2.20) of SM, D: =CHCH2CH= ( 2.77) of 18:2 FA, E: glyceryl protons ( 
4.14,  4.84,  5.22) of PC+PE, F: glyceryl protons ( 4.14,  4.80,  5.26) of TG. 
a) 
b) 
NMR plasma metabolome and lipidome 
 
97 
This spectrum gives some simplification compared to 2Q-1Q, mainly in the region  
2.16-2.24 where now it is possible to identify the CH2CONH resonance of SM (C box in 
Figure 3.6a). Compared to 3Q-1Q, the 4Q-1Q spectrum showed the disappearance of 
the resonances in the  3.30-5.27 and  5.42-5.80 regions, corresponding to the 
glyceryl protons of PC and PE, and unsaturated protons of SM, respectively. Hence, in 
the 4Q-1Q spectrum, the information about the presence of PL in the mixture is lost. 
Finally, the 5Q-1Q spectrum showed the simplest profile being very similar to that 
shown in Figure 3.5e for 18:2 EC, only with the addition of  1.70 (CH2CH2CO) and  
2.30 (CH2CO) resonances of 20:4 FA. Hence, this spectrum only gives information 
about the fatty acyl chains and few resonances of cholesterol part of EC. 
Finally, the series of MQ experiments performed before for pure lipid standards and 
lipid mixture were used in the acquisition of a plasma lipid extract of a healthy pregnant 
woman in 1st T. Interestingly, the 1D spectrum of plasma lipid extract is very similar to 
the lipid mixture of pure compounds only with the addition of FC (C19H3 at  1.0, C3H 
at  3.52) and TG (4.14 (glyceryl-C1,3H at  4.14, glyceryl-C1,3H’ at  4.29, glyceryl-
C2H at  5.26) specific resonances. Hence, the 2Q-1Q spectrum of plasma lipid extract 
is similar to the 2Q-1Q spectrum of lipid mixture with large overlap and containing more 
signals, namely the glyceryl of TG (overlapped with that from PL) and FC resonances 
(overlapped with that from EC). The 3Q-1Q spectrum of plasma lipid extract is shown 
in Figure 3.6b, where a similar profile is observed when compared with the lipid mixture 
(Figure 3.6a) with main differences only in the presence of glyceryl protons of TG and 
the absence of glyceryl protons of PL. The 4Q-1Q spectrum of the plasma lipid extract 
showed a slightly profile difference when compared with the lipid mixture, namely in the 
absence of resonances from 20:4 FA, possible due to a lower concentration in plasma 
lipid extract. Finally, the 5Q-1Q spectrum showed only three resonances with very 
reduced intensities from cholesterol protons ( 1.13), (CH2)n FA ( 1.30) and HC=CH 
FA ( 5.35). 
Overall, MQ spectroscopy showed simpler spectral profiles when compared with 1D 
and 1H-1H COSY spectra, with specificity based on the J-coupling networks. Despite 
the identification of specific signals from different molecules in a mixture, the 
assignment of a complete structure was not possible, i.e. the attribution of the side fatty 
acyl chain linked to the PL or EC characteristic groups. However, the unambiguous 
identification of poly- and monocyclic aromatic hydrocarbons (Reddy and Caldarelli, 
2010) and phenolic molecules in an extract of extra virgin oil (Reddy and Caldarelli, 
2011) was previously achieved by MQ spectroscopy showing the potential of these 
technique for these specific type of molecules.      
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clarity: 
Pinto, J.; Domingues, M. R. M.; Galhano, E.; Pita, C.; Almeida, M. do C.; Carreira, I. 
M.; Gil, A. M. Human Plasma Stability during Handling and Storage: Impact on NMR 
Metabolomics. The Analyst 2014, 139, 1168–1177.  
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Abstract 
This work contributes to fill in some existing gaps in the knowledge of human plasma 
degradability during handling and storage, a paramount issue in NMR metabolomics. 
Regarding the comparison between heparin and EDTA anti-coagulant collection tubes, 
the former showed no interference of the polysaccharide, while conserving full spectral 
information. In relation to time/temperature conditions, room temperature was seen to 
have a large impact on lipoproteins and choline compounds from 2.5 hours. In addition, 
short-term storage at -20oC was found suitable up to 7 days but, for periods up to 1 
month, -80oC was recommended. Furthermore, in the case of reusing plasma samples, 
no more than 3 consecutive freeze-thaw cycles were found advisable. Finally, the 
impact of long-term -80oC storage (up to 2.5 years) was found almost negligible, as 
evaluated on a partially matched non-fasting cohort (n=49), after having investigated 
the possible confounding nature of the particular non-fasting conditions employed.  
 
Brief state of the art 
Over the years, much concern has been expressed in relation to the high 
perishability of biological samples such as blood plasma/serum (Teahan et al., 2006; 
Barri and Dragsted, 2013) and urine (Dunn et al., 2008; Bernini et al., 2011), and its 
impact on the detectable metabolome, viewed both by NMR and MS. It has been 
recognised that the implementation of adequate intra- and inter-laboratory standard 
operating procedures (SOPs) for blood samples is imperative and several possible bias 
sources have been investigated 1) blood plasma collection tubes containing different 
anti-coagulants, namely EDTA, citrate or heparin  (Barton et al., 2010; Barri and 
Dragsted, 2013; Gonzalez-Covarrubias et al., 2013; Yin et al., 2013), 2) different 
temperature/time conditions during sample handling, analysis and storage (Deprez et 
al., 2002; Teahan et al., 2006; Barton et al., 2008; Dunn et al., 2008; Trabi et al., 2013), 
3) multiple freeze-thaw cycles (Teahan et al., 2006; Fliniaux et al., 2011), when it is 
necessary to reuse the sample for confirmation or analysis by complementary methods 
(e.g. MS, metabolite extraction, genetic, proteomic assays). Besides the collection and 
handling considerations, potential confounders are expected to have important impacts 
on the blood metabolome e.g. gender (Lawton et al., 2008), age (Lawton et al., 2008; 
Yu et al., 2012), BMI (Lawton et al., 2008), diet and fasting/non-fasting (Gu et al., 2007; 
Park et al., 2009; Peré-Trepat et al., 2010), ethnicity (Lawton et al., 2008), co-
morbidities or medication. In spite of the high work volume carried out in this context, a 
few questions remain unanswered thus justifying the work presented in this chapter.  
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Therefore, this work reports a human plasma NMR metabolomics study which 
evaluates the changes in the metabolic profile in connection to a) the use of heparin 
collection tubes, in comparison to EDTA tubes; b) hourly stability at room temperature 
up to 21 h, with and without sodium azide as preservative; sample stability c) at -20oC 
and -80oC up to one month and d) during 5 consecutive freeze-thaw cycles. 
Additionally, the possible confounding effects of non-fasting conditions (2 hours after 
uncontrolled meal) and of long-term storage at -80oC (up to 2.5 years) will be 
presented. This work contributes towards a more complete picture of SOPs for NMR 
metabolomics of human plasma, while providing information about two potentially 
important confounders (non-fasting conditions at collection and long-term -80oC 
storage) in a large partially-matched population. 
 
4.1. Effects of heparin and EDTA tubes on plasma spectral profile 
Although EDTA and citrate plasma collection tubes have previously been compared 
in terms of their impact on the 1H NMR spectra of plasma (Barton et al., 2010), to our 
knowledge, heparin tubes have not been investigated in this context, a general 
assumption being that heparin (a linear polysaccharide composed of sulphated 
glucosamine (GlcN), N-acetyl-D-glucosamine (GlcNAc), D-glucuronic acid (GlcA) and 
L-iduronic acid (IdoA) (Liu et al., 2009; Tovar et al., 2012) does not add significant 
broad components to the spectra. Indeed, visual comparison of the standard 1H NMR 
spectra of plasma collected in EDTA and heparin tubes (overlaid in Figure 4.1a) shows 
almost total superposition of all regions of the spectra, except for the region where the 
predominant EDTA forms resonate (free and complexed with Ca2+/Mg2+). Multivariate 
analysis of the spectra obtained for five different controls was performed, after 
removing the spectral regions where EDTA peaks resonate. PCA of spectra of sample 
pairs (Figure 4.1b) confirmed the agreement between EDTA- and heparin-collected 
spectra, the slight deviations noted being smaller than inter-individual variability (which 
seemed largely determined by lipid content and BMI value, both higher for subject 2). 
This was confirmed by similar analysis of the CPMG and diffusion-edited spectra and 
subtraction of heparin- and EDTA-collected sample spectra (not shown). Spectral 
subtraction unveiled higher levels of pyruvate (26.6 ± 4.7%, singlet at 2.36 ppm, 
p=0.0023) and two unassigned compounds (111.9 ± 5.7%, singlet at 2.64 ppm, 
p=0.0079 and 121.1 ± 12.1%, singlet at 3.31 ppm, p=0.0043) in EDTA-collected 
samples. Pyruvate was indeed detected in a concentrated blank solution left in an 
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EDTA tube (for 20-30 min), together with acetate (1.91 ppm, s), formate (8.45 ppm, s), 
lactate (1.33 ppm, d) and several other unidentified small peaks (Figure 4.2a).  
 
 
 
 
Figure 4.1. a) Superimposed standard 
1
H NMR spectra of plasma from the same subject, 
collected with an EDTA tube (black) and a sodium heparin tube (grey). Peak legend: 1- 
NCH2CO of CaEDTA
2-
, 2- NCH2CO of MgEDTA
2-
, 3- NCH2CH2N of CaEDTA
2-
, 4- NCH2CO of 
free EDTA, 5- NCH2CH2N of MgEDTA
2-
 overlapped with N(CH3)3 of choline-containing 
metabolites, 6- NCH2CH2N of free EDTA (assignment of EDTA resonances based on reference 
(Barton et al., 2010)); b) PCA scores plot of the standard 
1
H NMR spectra of plasma collected 
into EDTA tubes ()   d      s d um hep      ubes (□)   f e  exclus     f  he  eg   s 
accommodating EDTA peaks (2.50-2.60 ppm, 2.66-2.72 ppm, 3.04-3.28 ppm and 3.53-3.65 
ppm), filled in grey in Figure 4.1a. 
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Regarding heparin tubes, the corresponding concentrated blank solution spectrum 
(Figure 4.2b) showed a clear broad polysaccharide profile, together with a lesser 
number of interfering resonances (residual formate, lactate and two unidentified 
signals). For both tube types, however, the expected contaminants concentration 
should be negligible compared to the plasma spectrum (note that the blank solutions 
are 10x and 15x more concentrated than a typical plasma sample, Figure 4.2). Due to 
the overlap with EDTA peaks, we could not confirm the higher choline levels (up to 
10%) noted in a previous targeted LC-MS/MS study (Yue et al., 2008) for heparin-
collected samples, compared to EDTA ones. Given the above results, both EDTA and 
heparin tubes seem equally suitable for plasma collection for NMR analysis, as long as 
the loss of sample resonances overlapping with EDTA peaks is affordable. Overlapped 
metabolites identified here comprised choline, citrate, dimethylamine, glucose, glycerol, 
myo-inositol, His, Met, Thr, Tyr and Val. Of these, citrate, free choline and 
dimethylamine do not give rise to other resonances and choline-containing compounds 
such as PC, LPC and SM are not easily studied in other spectral regions such as the 
aliphatic or glyceryl regions. A comprehensive list of possible plasma metabolites 
overlapping with EDTA resonances may be found elsewhere (Barton et al., 2010). 
 
 
Figure 4.2. Standard 
1
H NMR spectra of blank solutions added to (a) an EDTA collection tube 
(D2O, 0.005% TSP) and (b) a sodium heparin collection tube (D2O, no TSP). In order to obtain 
spectra with good signal-to-noise ratio, the blank solutions were concentrated by a factor of 10 
and 15 times, respectively (EDTA and heparin assignments based on references (Liu et al., 
2009; Barton et al., 2010). 
a) 
b) 
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4.2. Short-term plasma stability at room temperature 
Considering either the standard or edited (CPMG and diffusion-edited) 1H NMR 
spectra, the effects of time at room temperature on plasma composition became clear 
roughly from 2.5 h onwards, as shown below. PCA of the CPMG 1H NMR spectra of 
three independent plasma samples recorded at room temperature, approximately every 
hour up to 21 hours, showed that samples follow similar variation trends (Figure 4.3a). 
It is noted that the plasma of subject 7, incidentally richer in lipids, seems to exhibit a 
higher magnitude of variation. Computation of the coefficient of variation (Figure 4.3b) 
indicated that the most significant changes (marked red/orange) affect lipid and choline 
resonances. Based on this, several resonances were integrated and plotted in a 
heatmap (Figure 4.3c). This showed that some aliphatic lipid resonances were 
decreased from ca. 2.5 h, including LDL/VLDL (CH2)n and CH3 groups at 1.270 and 
0.875 ppm (Liu et al., 2002), respectively. On the other hand, HDL methyls, at 0.850-
0.820 ppm (Liu et al., 2002), were significantly increased, reflecting a ca. 6% increase 
in the intensity ratio [CH3 HDL]/[CH3 LDL+VLDL]. In addition, several choline 
resonances were noted to increase, namely the overlapped contributions of PC, LPC, 
SM (Soininen et al., 2007) at 3.210 ppm and the peak at 3.194 ppm. We suggest that 
the increase in choline phospholipids may be related to the HDL/(LDL+VLDL) increase, 
considering the possible discarding of phospholipids from LDL+VLDL (which, taken 
together, comprise higher phospholipid content) to form HDL. The peak at 3.194 ppm, 
assigned here mainly to free choline (since it is intensified in CPMG spectra and almost 
absent in diffusion-edited spectra), showed an increase of up to 20% with time at room 
temperature. This is in broad agreement with a previous LC-MS/MS report of increase 
of choline in human plasma during the first hour at room temperature (ca. 10%), 
reaching up to 30% at > 250 min (Yue et al., 2008), due to enzymatic cleavage of 
choline esters. This process seems to occur concomitantly with the lipoprotein 
changes, as shown by a 1D STOCSY experiment on the free choline resonance 
(Figure 4.4a). This confirmed that choline seems to be biochemically correlated to HDL 
and phospholipids (positive correlation) and to LDL/VLDL (negative correlation). The 
STOCSY results also helped to identify cleaner and more resolved spin systems for 
each lipoprotein type: HDL (CH3: 0.820, 0.840, 0.850; (CH2)n: 1.220, 1.245; other CH2: 
1.52, 1.98, 2.73; CH=CH: 5.28 ppm) and LDL/VLDL (CH3: 0.875; (CH2)n: 1.270; other 
CH2: 1.57, 2.01, 2.22; CH=CH: 5.30, 5.33 ppm). In this way, two main HC=CH 
environments were identified as referring to HDL (5.28 ppm) and LDL/VLDL (5.30 ppm) 
and, thus, varying in opposite directions with the time at room temperature (Figure 
4.4b). 
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Figure 4.3. a) PCA scores plot obtained for the plasma CPMG 
1
H NMR spectra of subjects 6, 7 
and 8, up to 21h at room temperature; b) average (of three subjects) CPMG 
1
H NMR spectrum, 
colored for coefficient of variation (CV) as determined for the overall 21h period; c) heatmap 
representing the average CPMG integrals of the varying metabolites from minimum (dark blue) 
to maximum (dark red) values; metabolites are ordered from those exhibiting decreases (above) 
to those showing increases (below); in the case of largely overlapped regions, the chemical shift 
indicated corresponds to the maximum intensity observed. 
 
The inverse prominence of these resonances in the CPMG and diffusion-edited spectra 
(Figure 4.4b) suggested higher mobility of LDL+VLDL unsaturated lipids, compared to 
those in HDL. Since the average unsaturation degree given by the area ratio [all 
HC=CH]/[all CH3] remains unchanged, a conservative change of fatty acid chains from 
LDL/VLDL to HDL environments seems to be taking place, without lipid oxidation 
occurring. As to the origin of the above changes, the room temperature study carried 
out with sodium azide produced identical changes (not shown) as in its absence, 
indicating the occurrence of enzymatic lipolytic action without microbial growth (also 
a) b) 
c) 
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confirmed by the absence of other indicators of microbial growth e.g. lactate). Previous 
studies have indeed reported changes in lipids after 3 hours (Teahan et al., 2006) and 
6 hours (Bernini et al., 2011) at room temperature, however in not as much detail as in 
this study. Other changes reported in relation to amino acids, glycerol and citrate 
(Deprez et al., 2002; Teahan et al., 2006; Bernini et al., 2011) were not noted here. 
 
 
 
Figure 4.4. a) 1D STOCSY obtained using the -N(CH3)3 choline peak at 3.194 ppm as root 
peak (see arrow in inset), with color scale expressing the correlation (r) value; b) expansions of 
the HC=CH region of the average CPMG (left) and diffusion-edited (right) 
1
H NMR spectra 
recorded as a function of time, at room temperature (only selected times are shown). RT: room 
temperature. 
 
b) 
a) 
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4.4. Short-term plasma stability at -20ºC and -80ºC and effect of freeze-
thaw cycles 
Regarding the compositional stability of plasma stored up to 1 month at -20oC and 
at -80oC, both standard and diffusion-edited spectra showed remarkable spectral 
agreement over the whole period (not shown), only the CPMG spectra reflecting the 
occurrence of small variations, as shown by PCA (Figure 4.5a). Visual spectral 
inspection and integration confirmed small changes observable only at 31 days (Figure 
4.5b): 1) proline (ca. +31%, p=0.033, at -20oC), 2) glucose (ca. +9%, p=0.019, at -
20oC) and 3) unassigned broad peak at 6.8-7.1 ppm (ca. -50%, p=0.00036 and 0.0022, 
at -20oC and -80oC respectively), the latter variation probably due to protein 
precipitation (also supported by visual observation). In previous studies, no significant 
changes had been seen in the NMR spectra of rat plasma stored for 1 month at -20oC 
or -80oC (Deprez et al., 2002).  
 
 
 
 
Figure 4.5. a) PCA scores plot obtained for the CPMG 
1
H NMR spectra of three plasma 
samples (subject 1, 2 and 3) stored at -20ºC (filled symbols) or at -80ºC (open symbols) for up 
to 31 days; b) histogram of metabolite integrals illustrating the variations occurring during 
plasma storage at -20ºC and -80ºC up to 1 month (*, p-values < 0.05); c) PCA scores plot 
obtained for the standard 
1
H NMR spectra of three plasma samples (subjects 9, 10 and 11) 
subjected to consecutive freeze-thaw cycles (numbers indicate number of cycles). 
a) b) 
b) 
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Regarding the effects of up to 5 freeze-thaw cycles on plasma composition, the 
PCA of standard spectra shown in Figure 4.5c expresses an interesting result, since 
the degree of sample dispersion resulting from freeze-thaw cycles 1 to 5 is clearly 
sample dependent. The original plasma composition of subject 10 comprised higher 
contents of lipids (CH3, (CH2)n), choline-containing compounds, Val , Ala and lactate, 
compared to the remaining two samples, such composition (particularly in regard to 
lipids) possibly leading to higher degradability of the sample. For this subject, changes 
upon 5 consecutive freeze-thaw cycles were found to arise from: 1) lipids decrease (ca. 
-5%), 2) choline phospholipids increase (ca. 7%), 3) Ala, glucose and pyruvate 
increases (ca. 2-7%) and acetone decrease (ca. -16%). These results are in broad 
agreement with previous studies of 1 freeze-thaw cycle (Teahan et al., 2006), which 
reported unspecified alterations in lipids, Ala, glucose and lactate. A more recent study 
(Fliniaux et al., 2011) on serum noted statistically relevant (p value < 0.05) changes 
upon 5 and 10 freeze-thaw cycles (decreases in choline resonance at 3.20 ppm, 
glycerol, methanol, ethanol, proline, unassigned peak at 1.91 ppm), none of which 
having been noted in the conditions of this study. Furthermore, the present study has 
shown that most variations take place at the fourth freeze-thaw cycles and thereafter, 
so that no more than 3 freeze-thaw cycles are recommendable.  
4.5. Possible confounding factors: subject non-fasting and long-term 
plasma storage at -80ºC 
A cohort of healthy pregnant women in their 2nd trimester of pregnancy, partially 
matched for age, BMI and gestational age, was considered in order to study the effects 
of -80oC storage for up to 2.5 years. As such samples were collected in non-fasting 
conditions, a possible confounder superimposed on the eventual effects of long-term 
storage, the effects of non-fasting were firstly studied on a group of non-pregnant 
women. The PCA plot shown in Figure 4.6a indicated that, as expected, each subject 
responded differently to meal intake (see arrows shown as examples); however, no 
group separation took place, the overall sample groups remaining largely overlapped. 
Hence, the particular non-fasting conditions characterising sample collection for the 
pregnant women in this study (2 hours after ingestion of uncontrolled breakfast) are not 
expected to have a strong effect on the overall characteristics of the sample group. 
Regarding long-term storage at -80oC, multivariate analysis of the spectra for 6-12 
months and 14-19 months groups (not shown) detected no significant changes, minor 
changes being noted when comparing the 14-19 months to 20-30 months groups. This 
was expressed by a weak non-predictive PLS-DA model (Q2 0.28) (Figure 4.6b), which 
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upon inspection of the spectra translated into a small (ca. 2%) increase in cholesterol 
(p = 0.023) and slight variations in N-acetyl glycoproteins and creatine (found to be 
largely determined by two outliers with larger BMI and gestational age, respectively), in 
the 20-30 months storage period.  
  
Figure 4.6. a) PCA scores plot obtained for the standard 
1
H NMR spectra of plasma samples 
obtained for the same set of subjects (n=16), under fasting () and non-f s   g (□) c  d     s  
arrows represent changes from fasting to non-fasting for selected subjects. b) PLS-DA scores 
plot obtained for standard 
1
H NMR spectra of plasma samples stored at -80
o
C for 14-19 months 
(, n=17) and 20-30 months (, n=21). 
The above results expressed the low degree of change induced on plasma 
composition, as viewed by NMR, by the non-fasting conditions used in this work and by 
storage up to 30 months at -80oC, after which samples may safely be studied (although 
interpreting with care eventual changes in cholesterol, after 20 months). Previous NMR 
results have shown changes in amino acids resonances and the disappearance of 
citrate resonances in rat plasma stored at -80ºC for 9 months (Deprez et al., 2002), 
whereas -20oC storage of bovine plasma for between 2-15 years revealed changes in 
lipids and several low MW metabolites (glycerol, -hydroxybutyrate, amino acids) (Trabi 
et al., 2013). To our knowledge, no long-term storage study of human plasma had been 
carried out before by NMR, a very recent report existing on the subject, using UPLC-
MS (Hebels et al., 2013), and reporting no significant changes. 
4.6. Conclusions 
In this work, we have shown that EDTA and heparin tubes seem equally suitable for 
plasma collection for NMR analysis, as long as 1) the level of interfering peaks (in 
higher number in EDTA tubes) is kept low compared to sample peaks of interest and 2) 
the loss of sample resonances overlapping with EDTA peaks (and removed from the 
b) a) 
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dataset) is affordable. The latter is particularly important for compounds not giving rise 
to other resonances (citrate, free choline and dimethylamine) and choline-containing 
compounds PC, LPC and SM, which are not easily studied in other spectral regions 
such as the aliphatic or glyceryl regions.  
Room temperature stability studies revealed significant changes in the lipidic 
components of plasma, after ca. 2.5 hours. Such changes indicated choline formation 
(increased up to 20%) through enzymatic cleavage of phospholipids, along with 
LDL/VLDL conversion into HDL (increase of ca. 6 % in HDL/(LDL+VLDL) ratio), 
possibly also in connection with the increase noted in PC, LPC and SM levels. In 
addition to these compounds, no other significant changes in plasma composition were 
observed at room temperature (up to 21 hours). In relation to short-term (up to 1 
month) storage stability, results revealed that plasma samples may be kept at least up 
to 7 days at -20oC without significant changes occurring. Upon 1 month of storage, 
increases in proline and glucose and a decrease of a broad resonance at 6.8-7.1 ppm 
(possibly reflecting protein precipitation) were observed for samples kept at -20oC. For 
samples stored at -80oC for the same length of time, only the latter variation was 
observed. In relation to freeze-thaw cycles (-80oC), the effects of up to 5 cycles were 
found to be strongly sample dependent, a larger impact noted for a sample richer in 
lipids. Most variations were seen to take place upon cycle 4 and thereafter, so that no 
more than 3 freeze-thaw cycles are recommendable. Changes comprised small 
decreases in lipids and acetone and increases in choline compounds, Ala, glucose and 
pyruvate. The longer-term stability of human plasma, at -80oC (up to 2.5 years), was 
studied on a large cohort (n=49) of pregnant women, for whom plasma collection was 
performed under non-fasting conditions. In order to investigate the possible 
confounding effect of non-fasting, this factor was singled out first and studied on a 
smaller group of subjects (n=16), proving not to affect the overall characteristics of the 
group of samples, as viewed by multivariate analysis. Subsequently, the effects of 
long-term -80oC storage were found almost negligible up to 30 months, a small 
increase in cholesterol having been noted after 20 months storage. 
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The results presented in this chapter were fully published in the article below 
and are here adapted slightly onto the form of a thesis chapter, for the sake of 
clarity: 
Pinto, J.; Barros, A. S.; Domingues, M. R. M.; Goodfellow, B. J.; Galhano, E.; Pita, C.; 
Almeida, M. C.; Carreira, I. M.; Gil, A. M. Following Healthy Pregnancy by NMR 
Metabolomics of Plasma and Correlation to Urine. Journal of Proteome Research 
2014, 14, 1263-1274. 
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Abstract 
This work presents the first NMR metabolomics study of maternal plasma during 
pregnancy, including correlation between plasma and urine metabolites. The expected 
decrease in circulating amino acids early in pregnancy was confirmed with six amino 
acids being identified as required by the fetus in larger extents. Newly observed 
changes in citrate, lactate and dimethyl sulfone suggested early adjustments in energy 
and gut microflora metabolisms. Alterations in creatine levels were also noted, in 
addition to creatinine variations reflecting alterations in glomerular filtration rate. 
Regarding plasma macromolecules, HDL and LDL+VLDL levels were confirmed to 
increase throughout pregnancy, although at different rates and accompanied by 
increases in fatty acid chain length and degree of unsaturation. Correlation studies 
suggested a) an inverse relationship between lipoproteins (HDL and LDL+VLDL) and 
albumin, with a possible direct correlation to excreted (unassigned) pregnancy markers 
resonating at  0.55 and  0.63; b) a direct link between LDL+VLDL and N-acetyl-
glycoproteins, together with excreted marker at  0.55 and c) correlation of plasma 
albumin with particular circulating and excreted metabolites. These results have 
unveiled specific lipoprotein/protein metabolic aspects of pregnancy with impact on the 
excreted metabolome and, therefore, provide an interesting lead for the further 
understanding of pregnancy metabolism. 
 
Brief state of the art 
In order to define robust prenatal disease biomarkers, the complex metabolic 
evolutions related to gestational age in healthy pregnancies must be taken into 
account. Healthy pregnancies have been studied by metabolomics of amniotic fluid 
(Cohn et al., 2009) and maternal urine (Diaz et al., 2013a; Trivedi and Iles, 2014a) by 
1H NMR spectroscopy and by liquid chromatography (LC)-MS, and of maternal blood 
plasma by LC-MS (Luan et al., 2014). NMR metabolomics has revealed gestational 
age-related alterations in amniotic fluid levels of alanine, valine, creatinine and glucose 
(Cohn et al., 2009) and significant changes in 21 maternal urine metabolites (8 of which 
newly detected in relation to pregnancy: choline, creatinine, 4-deoxyerythronic acid, 4-
deoxythreonic acid, furoylglycine, guanidoacetate, -hydroxybutyrate and lactate) (Diaz 
et al., 2013a). In addition, a recent untargeted LC-MS and shotgun lipidomics of 
maternal plasma extracts revealed increases in dihydrobiopterin, free carnitine, acetyl-
alanine, leucyl-phenylalanine, LPC (18:1) and LPC (20:4), along with changes in total 
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concentrations of LPC, PC, lysophosphatidylethanolamines (LPE) and 
lysophosphatidylserines (LPS) (Luan et al., 2014). 
The present paper describes for the first time, to our knowledge, an untargeted 1H 
NMR study of maternal blood plasma collected for healthy non-pregnant and pregnant 
women in their 1st, 2nd and 3rd trimesters of pregnancy, as well as at delivery, with the 
aim of evaluating the metabolic adaptations reflected in plasma throughout healthy 
pregnancies. This complements the recent MS-based studies (Luan et al., 2014) by 
giving an overview of the changes in the set of more abundant (mM and M) plasma 
metabolites. Furthermore, dynamic changes measured in plasma are correlated here to 
those observed in maternal urine, a novel approach enabling a more complete two-
biofluid metabolic picture of pregnancy to be obtained. The results provide confirmation 
of known metabolic alterations occurring during pregnancy and reveal additional 
metabolite changes and relationships, particularly in relation to lipoproteins composition 
and their links to other circulating and excreted compounds. The detailed metabolic 
signature of healthy pregnancies obtained here constitutes an important step towards 
the identification of disease-related deviations allowing improved disease prediction, 
diagnosis and monitoring.  
 
5.1. Analysis of whole plasma  
The average CPMG spectra of maternal plasma across pregnancy (Figure 5.1) 
show some changes, namely in lipids, choline metabolites, lactate, valine, alanine, 
glutamine, citrate, creatine, creatinine, histidine and tyrosine. Such changes were more 
clearly illustrated in the CPMG spectra, compared to the standard and diffusion-edited 
spectra of blood plasma, where large overlap of broad resonances (arising from high 
Mw compounds) hinders spectral inspection. PCA of the CPMG 
1H NMR spectra of 
maternal plasma (Figure 5.2A, left) revealed three partially overlapped groups of 
samples: NP (), 1st and 2nd T samples ( and ), and 3rd T together with delivery 
samples (▲ and ). The 3rd T outlier corresponds to higher gestational age and BMI, its 
spectrum reflecting higher lipid and N-acetyl glycoprotein (2.0 ppm, s) contents. PLS-
DA (Figure 5.1A, right) unveiled a clearer metabolic trajectory for healthy pregnancies, 
with overlap of plasma collected in the 3rd T and at delivery. Pairwise PCA (not shown) 
and PLS-DA (Figure 5.2B) confirmed separation for NP/1st T (R2X 0.20, R2Y 0.93, Q2 
0.76, 98% sens., 89% spec.), 1st/2nd T (R2X 0.18, R2Y 0.83, Q2 0.55, 83% sens., 87% 
spec.) and 2nd/3rd T (R2X 0.18, R2Y 0.91, Q2 0.45, 71% sens., 100% spec.), again with 
the exception of 3rdT/delivery samples, which overlap in all models. Model robustness 
was assessed by MCCV and confirmed for all three models (Figure 5.3).  
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Figure 5.1. Average 500 MHz CPMG 
1
H NMR spectra of blood plasma of a) non-pregnant (NP) 
and pregnant women at b) 1
st
 (11-13 g.w.), c) 2
nd
 (16-22 g.w.), d) 3
rd
 (31-40 g.w.) and e) delivery 
(32-41 g.w.). Assignment (with 3-letter codes for amino acids): 1- CH3 lipids, 2- Val, 3- (CH2)n 
lipids, 4- lactate, 5- Ala, 6- CH2CH2CO lipids, 7- N-acetyl glycoproteins, 8- pyruvate, 9- Gln, 10- 
citrate, 11- creatine, 12- creatinine, 13- N(CH3)3 choline metabolites, 14- glucose, 15- HC=CH 
lipids, 16- Tyr, 17- His. The arrows guide the eye for some visible spectral alterations (increase 
and decrease). 
 
 
Based on the analysis of loading plots (Figure 5.2B, right) and peak integration, 11 
low MW metabolites (6 amino acids, citrate, creatine, creatinine, dimethyl sulfone and 
lactate) were found to vary significantly at some stage in pregnancy, together with 
lipoproteins (HDL, LDL+VLDL) and other proteins (N-acetyl glycoproteins 2.0, 
albumin-lysyl 2.9-3.0 and the set of broad NH resonances reflecting total protein  
5.5-9.0) (Table 5.1).  
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A 
  
B  
 
 
 
 
 
 
Figure 5.2. A) PCA a) and PLS-DA b) scores scatter plot for CPMG 
1
H NMR plasma spectra of 
NP (), and pregnant women at 1
st
 T (), 2nd T (), 3rd T (▲) and delivery (). The arrow in a) 
indicates a 3
rd
 T outlier with higher BMI than the remaining samples. The curved arrow in b) 
indicates the trajectory followed across pregnancy. B) PLS-DA score (left) and loading plots 
(right) for CPMG 
1
H NMR plasma spectra of a) NP () vs 1
st
 T (), b) 1st T () vs 2nd T () and 
c) 2
nd
 T () vs 3
rd
 T (▲) groups. Loadings are colored according to VIP. Three-letter codes are 
used for amino acids. 
a) 
b) a) 
b) 
c) 
Sens.= 98% 
Spec.= 89% 
Sens.= 83% 
Spec.= 87% 
Sens.= 71% 
Spec.= 100% 
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Changes in citrate, creatine, dimethyl sulfone and lactate were registered here for 
the first time, to our knowledge, related to pregnancy (* in Table 5.1). The information 
shown in Table 5.1 and time course changes (selected examples in Figure 5.4) indicate 
that relevant changes in low MW metabolites occur mainly from the NP state to the 1
st 
T, with decreased levels of valine, alanine, glutamine, tyrosine, histidine and citrulline, 
citrate, creatine, creatinine and dimethyl sulfone, and a suggestion of increased lactate 
levels.   
 
 
  
  
  
Figure 5.3. True and permuted model Q
2
 distributions (left) and ROC plots (right) given by  
MCCV of the PLS-DA models obtained for CPMG 
1
H NMR plasma spectra of a) NP vs 1
st
 T, b) 
1
st
 T vs 2
nd
 T and c) 2
nd
 T vs 3
rd
 T groups. TPR: true positive rate, FPR: false positive rate. 
 
 
a) 
b) 
c) 
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Table 5.1. List of blood plasma compounds changing in content from the NP state to 1
st
 T, from 
1
st
 to 2
nd
 T, and from 2
nd
 to 3
rd
 T. s: singlet, d: doublet, q: quartet, m: multiplet, br: broad signal. 
a
 
%Variation determined as (  –  )/  ×100, where   denotes the average value for each group 
a and b. 
b 
E.S.: effect size determined as described in (Berben et al., 2012); values in brackets 
correspond to high uncertainties. 
c
 Significance level 95% (p-value < 0.05). 
d,e,f
 Metabolite 
integrals measured in the CPMG, diffusion-edited and standard spectra, respectively. 
*
 
Metabolites observed to vary in maternal blood plasma for the first time throughout pregnancy. 
Compound 
Chemical 
shift/ppm 
NP vs. 1
st
 T 1
st
 vs. 2
nd
 T 2
nd
 vs. 3
rd
 T 
%Variat.
a
 E.S.
 b
 p-value
c
 %Variat.
a
 E.S.
 b
 p-value
c
 %Variat.
a
 E.S.
 b
 p-value
c
 
Low molecular weight 
         
Alanine
d
 1.45 (d) -17.7±5.1 -1.3±0.6 6.7×10
-4
 7.4±3.0 0.6±0.5 2.2×10
-2
    
Glutamine
d
 2.45 (m) -20.1±4.6 -1.6±0.7 4.2×10
-5
    -10.7±3.4 -1.1±0.8 4.2×10
-3
 
Histidine
d
 7.04 (s) -11.4±4.8 -0.8±0.6 1.8×10
-2
       
Tyrosine
d
 6.89 (d) -30.9±11.8 -1.0±0.6 1.1×10
-4
 22.4±5.7 0.9±0.6 1.2×10
-3
    
Valine
d
 1.03 (d) -8.8±3.8 -0.7±0.6 2.1×10
-2
       
Citrate
d,*
 2.51 (m) -12.7±4.8 -0.9±0.6 2.9×10
-3
 5.6±3.3 (0.4±0.5) 4.0×10
-2
    
Citrulline
d
 1.88 (m) -14.4±2.8 -1.8±0.7 6.4×10
-6
       
Creatine
d,*
 3.03 (s) -18.7±4.5 -1.5±0.7 5.3×10
-5
       
Creatinine
d
 4.05 (s) -14.1±3.1 -1.6±0.7 3.0×10
-5
    14.6±5.2 1.1±0.8 2.0×10
-2
 
Dimethyl 
sulfone
d, *
 
3.14 (s) -19.4±4.8 -1.5±0.7 1.1×10
-4
       
Lactate
d, *
 4.1 (q) 35.5 ± 8.8 0.9 ± 0.6 4.7×10
-4
 -21.4±9.0 -0.8±0.6 1.4×10
-3
    
High molecular weight 
         
Lipid resonances: 
         
C18H cholest.
e
 0.6-0.7 (br)       5.2±1.5 1.5±0.8 5.5×10
-3
 
CH3
 e
 0.8-0.9 (br) 5.1±2.4 (0.6±0.6) 4.3×10
-2
 7.9±1.8 1.1±0.6 1.5×10
-4
 21.7±4.3 2.6±0.9 7.2×10
-4
 
(CH2)n
e
 1.1-1.4 (br) 7.4±3.3 0.7 ±0.6 3.8×10
-2
 15.0±2.5 1.5±0.6 6.7×10
-7
 34.7±6.9 2.5±0.9 1.0×10
-3
 
CH2CH2CO
 e
 1.4-1.6 (br)    4.9±0.9 1.4±0.6 1.8×10
-6
 12.1±2.6 2.4±0.9 1.0×10
-3
 
CH2CH=
 e
 1.9-2.0 (br)    6.6±1.2 1.4±0.6 3.2×10
-6
 15.2±3.0 2.6±0.9 5.9×10
-4
 
CH2CO
 e
 2.2-2.3 (br)    7.2±1.3 1.4±0.6 1.3×10
-6
 18.6±4.4 2.2±0.9 2.3×10
-3
 
=CHCH2CH=
 e
 2.6-2.8 (br) 7.1±2.1 1.0±0.6 3.7×10
-4
 5.5±1.4 1.1±0.6 2.4×10
-4
 6.6±2.2 1.2±0.8 1.2×10
-2
 
N(CH3)3 cho.
 e
 3.2-3.3 (br) 12.8±3.0 1.2±0.6 3.5×10
-4
 5.6±2.3 0.6±0.5 2.2×10
-2
 8.6±2.9 1.1±0.8 1.1×10
-2
 
CH2N(CH3)3 
cho.
e
 
3.6-3.7 (br) 8.0±1.3 1.8±0.7 1.3×10
-6
    5.1±1.9 1.1±0.8 1.8×10
-2
 
Glyc.-C1,3H
 e
 4.0-4.1 (br)       8.0±2.3 1.8±0.8 6.6×10
-3
 
Glyc.-C1 3H’
 e
 4.2-4.3 (br) 3.7±0.9 1.2±0.6 4.5×10
-4
    7.8±2.3 1.7±0.8 7.1×10
-3
 
Glyc.-C2H
e
 5.1-5.2 (br)    16.4±2.0 2.1±0.7 7.4×10
-10
 33.9±4.6 3.6±1.1 4.6×10
-5
 
HC=CH
e
 5.2-5.4 (br) 13.8±5.0 0.8±0.6 1.4×10
-2
 19.2±3.2 1.5±0.6 2.2×10
-6
 25.5±6.1 1.9±0.8 2.5×10
-3
 
(CH2)n/CH3 
e
     6.6±1.0 1.6±0.6 2.9×10
-7
 10.2±2.7 1.8±0.8 5.8×10
-4
 
HC=CH/CH3
 e
  8.7±2.9 0.9±0.6 1.9×10
-3
 10.7±1.9 1.4±0.6 5.2×10
-6
    
Protein resonances:          
N-acetyl 
glycoproteins
d
 
2.0 (s)    8.9±2.1 1.1±0.6 1.5×10
-4
 10.7±3.3 1.2±0.8 8.7×10
-3
 
Albumin-lysyl
d
 2.9-3.0 (br) -6.5±2.1 -1.0±0.6 4.0×10
-3
 -4.9±1.3 -1.1±0.6 2.9×10
-4
 -7.2±2.5 -1.3±0.8 1.5×10
-2
 
Proteins NH
f
 5.5-9.0 (br)       -7.0±0.8 -4.1±1.1 2.1×10
-6
 
 
 
In the 2nd T, a few changes seem to be partially reverted (namely for alanine, 
tyrosine, citrate and lactate) and, in the 3rd T, only glutamine (decrease) and creatinine 
(increase) are seen to change. Conversely, changes in macromolecules become 
gradually more relevant as pregnancy proceeds (Table 5.1, Figure 5.4), with increases 
in lipids (viewed by CH3, (CH2)n, =CHCH2CH=, glyceryl-C1 3H’   d HC=CH 
resonances) and choline metabolites (viewed by -N(CH3)3 and -CH2N(CH3)3 
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resonances), while consistent variations are seen for albumin-lysyl  (decrease) and N-
acetyl glycoproteins (increase) resonances.  
 
    
    
    
    
Figure 5.4. Boxplots illustrating the variations (PQN normalized) observed for some metabolites 
varying from the non-pregnant state and across pregnancy (graphs follow the peak order listed 
in Table 5.1 i.e. amino acids, other low MW metabolites, lipids and proteins). The variations 
represented were measured in the CPMG spectra for all compounds with the exception of lipids 
and NH proteins, for which the diffusion-edited and standard spectra, respectively, were 
considered. Graphs corresponding to lipids, choline and cholesterol correspond to the 
integration of all environments detected for each family i.e. total lipids, total choline-compounds 
and total cholesterol. 
 
Closer inspection of the diffusion-edited spectra (not shown) provided additional 
information on the changes affecting lipoproteins and, based on reported assignments 
(Pinto et al., 2014c) and STOCSY results driven by different methyl resonances (Figure 
5.5), distinct lipoprotein spin systems were identified and subsequently monitored 
separately (Table 5.2).  
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Figure 5.5. a) Average  0.75-1.0 ppm region of diffusion-edited 
1
H NMR spectra of blood 
plasma of pregnant women. b) 1D STOCSY of diffusion-edited 
1
H NMR spectra of blood plasma 
obtained using the CH3 lipids resonances at 0.84, 0.86 and 0.87 ppm as the root peaks, 
respectively, with color scale expressing the correlation (r) value. 
 
In this way, distinct C18H cholesterol and -N(CH3)3 choline resonances were 
identified as arising either from HDL or from LDL+VLDL (Table 5.2) thus contributing to 
the respective spin systems: a) for HDL: C18H cholesterol  0.65 (broad), CH3  0.85, 
(CH2)n 1.23other CH2 groups  1.50, 1.98, 2.20, 2.75, -N(CH3)3 choline  3.20 (here 
named choline A) and  3.22 (named choline B), and HC=CH 5.27 and b) for 
LDL+VLDL: C18H cholesterol   0.69 (broad), CH3  0.86 and  0.87, (CH2)n  1.27, 
a) 
b) 
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other CH2 groups 1.57, 2.01, 2.22, 2.75, -N(CH3)3  3.20 (choline A) and  3.24 
(named choline C), and HC=CH 5.30.  Choline assignments are partially in 
agreement with previous reports based on purified lipoprotein subfractions (Lan et al., 
2007), which identified choline resonances at 3.21 and 3.22 respectively as SM and 
PC in HDL, and choline resonances at 3.24 and 3.25 for SM and PC in LDL. In this 
study, it is apparent that, in blood plasma, both HDL and LDL contribute to the  3.20 
choline resonance (choline A). Free choline (typically resonating at 3.19 ppm (Sitter et 
al., 2002; Pinto et al., 2014c)) is not identified, as expected, based on its low 
concentration in the plasma of pregnant women (14-17 M, i.e. below the detection 
limit of NMR), compared to that found for phospholipid-bound choline (3300-3500 M) 
(Ilcol et al., 2002).  
 
Table 5.2. List of specific variations of HDL and LDL+VLDL, measured in the diffusion-edited 
1
H 
NMR spectra of blood plasma of NP state to 1
st
 T, from 1
st
 to 2
nd
 T, and from 2
nd
 to 3
rd
 T. 
a
 
%Variation determined as (  –  )/  ×100, where   denotes the average for each group a and 
b. 
b 
E.S.: effect size determined as in (Berben et al., 2012); values in brackets correspond to 
high uncertainties. 
c
 Significance level 95% (p-value < 0.05). 
Integrated lipoprotein 
resonances/ppm 
NP vs. 1
st
 T 1
st
 vs. 2
nd
 T 2
nd
 vs. 3
rd
 T 
%Variat.
a
 E.S.
 b
 p-value
c
 %Variat.
a
 E.S.
 b
 p-value
c
 %Variat.
a
 E.S.
 b
 p-value
c
 
HDL          
C18H cholest./ 0.65       3.6±1.4 1.0±0.7 2.8×10
-2
 
CH3/ 0.85 7.7±2.5 0.9±0.6 5.0×10
-3
 6.3±1.8 0.9±0.6 1.5×10
-3
 9.4±2.7 1.4±0.8 5.6×10
-3
 
(CH2)n/ 1.23 7.7±2.5 0.9±0.6 6.3×10
-4
 11.8±2.3 1.3±0.6 1.5×10
-5
 13.1±4.4 1.4±0.8 1.4×10
-2
 
N(CH3)3 cho. A/ 3.20 3.6±1.5 0.7±0.6 1.8×10
-2
    8.2±1.8 1.6±0.8 4.8×10
-4
 
N(CH3)3 cho. B/ 3.22 23.8±5.2 1.3±0.6 2.6×10
-4
 10.1±3.5 0.7±0.5 8.4×10
-3
    
HC=CH/ 5.27 16.0±4.9 0.9±0.6 5.4×10
-3
 16.8 ± 3.0 1.4±0.6 4.4×10
-6
 18.8±5.2 1.6±0.8 5.2×10
-3
 
(CH2)n/CH3 ratio 6.4±1.5 1.3±0.7 2.5×10
-4
 5.2±1.0 1.4±0.6 4.3×10
-6
    
HC=CH/CH3 ratio 8.2±2.8 0.9±0.6 8.5×10
-3
 10.1±1.7 1.5±0.6 9.8×10
-7
 8.3±2.9 1.2±0.8 1.5×10
-2
 
LDL+VLDL          
C18H cholest./  0.69       8.0±1.9 2.1±0.8 1.7×10
-3
 
CH3/ 0.86; 0.87    10.0±2.2 1.2±0.6 1.0×10
-4
 33.2±6.2 2.8±0.9 6.1×10
-4
 
(CH2)n/ 1.27    19.4±3.1 1.5±0.6 8.0×10
-7
 50.2±9.3 2.7±0.9 8.0×10
-4
 
N(CH3)3 cho. A/ 3.20 3.6±1.5 0.7±0.6 1.8×10
-2
    8.2±1.8 1.6±0.8 4.8×10
-4
 
N(CH3)3 cho. C/ 3.24 7.1±2.6 0.8±0.6 1.3×10
-2
    21.1±4.4 2.2±0.9 9.0×10
-4
 
HC=CH/ 5.30 12.0±5.4 (0.6±0.6) 4.4×10
-2
 21.4±3.7 1.4±0.6 3.5×10
-6
 31.2±7.4 1.9±0.8 2.5×10
-3
 
(CH2)n/CH3 ratio    8.5±1.3 1.7±0.6 4.8×10
-8
 12.1±3.0 1.9±0.8 2.4×10
-3
 
HC=CH/CH3 ratio 8.7±3.1 0.8±0.6 1.2×10
-2
 10.6±2.1 1.3±0.6 2.2×10
-5
    
HDL/LDL+VLDL         
   CH3/CH3 ratio        -16.9±3.5 -2.1±0.9 2.4×10
-4
 
 
Based on the variations noted for HDL and LDL+VLDL spin systems (Table 5.2 and 
heatmap in Figure 5.6A), it becomes clear that both lipoprotein levels increase towards 
the 3rd T, HDL increasing from earlier on in pregnancy but to a lesser extent, compared 
to LDL+VLDL. The 17% decrease in the methyl resonance ratio CH3(HDL)/ 
CH3(LDL+VLDL) (Figure 5.6B), in the 3
rd T, reflects the more marked increase of 
LDL+VLDL in late pregnancy (Table 5.2). 
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Figure 5.6. Heatmaps of A) normalized integrals of the different lipoprotein resonances (HDL 
and LDL+VLDL) and corresponding choline and cholesterol environments and B) ratio of methyl 
resonances in HDL and LDL+VLDL: CH3(HDL)/CH3(LDL+VLDL), across pregnancy. Rows 
represent subjects and columns lipoprotein resonances (or ratios). Integrals are shown using a 
color scale from minimum (dark blue) to maximum (dark red). 
 
Furthermore, both lipoprotein types change across pregnancy in terms of FA 
characteristics: increased average chain length and unsaturation degree, respectively 
given by (CH2)n/CH3 and HC=CH/CH3 ratios. Such changes seem to follow different 
dynamics since 1) average FA chain length increases up to the 2nd T for HDL, and only 
later in pregnancy for LDL+VLDL and 2) FA unsaturation increases throughout 
pregnancy for HDL and only in early pregnancy for LDL+VLDL. 
 
5.2. Correlation of plasma changes with urine 
Finding metabolite correlations should give additional information on pregnancy 
metabolism, although the origin of correlations and inter-metabolite distance in 
metabolic space may not be defined without further biochemical studies. The 
correlation map in Figure 5.7, panel A shows that, besides correlating positively with 
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each other, HDL and LDL+VLDL lipoproteins correlate negatively with albumin-lysyl (r -
0.80 and -0.72) and total protein (viewed by protein NH resonances, r -0.73 and -0.83), 
suggesting an inverse metabolic relationship between the two plasma macromolecule 
classes.  
 
 
Figure 5.7. Correlation analysis of metabolite integrals that vary significantly in maternal blood 
plasma and urine throughout pregnancy. Panels A, B and C show metabolite correlations in 
plasma/plasma, in urine/urine and in plasma/urine respectively. Only metabolite correlations 
with |r| ≥ 0 6   d p < 0 05 we e c  s de ed  These c   el     s we e c  f  med by  ev ew  g  he 
scatter plots of each pair of correlated integrals. 
 
Inter-metabolite correlations in plasma are comprehensively illustrated in Figure 5.8 
(left), where line thickness and colour reflect correlation strength and sign respectively. 
The negative correlations between lipoproteins and albumin/total protein form an 
evident correlation pattern, along with strong (positive) correlations of HDL with 
LDL+VLDL (r 0.83) and of albumin with NH resonances (r 0.75), the latter observation 
being consistent with albumin being the most abundant protein in plasma. Interestingly, 
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LDL+VLDL seems specifically (and positively, r 0.71) correlated to N-acetyl-
glycoproteins (and these, in turn, to creatinine with r 0.60). Albumin levels are 
apparently also related to changes in creatine (r 0.66) (in turn correlated to valine (r 
0.66) and glutamine (r 0.60)), glutamine (r 0.71) (in turn correlated to alanine (r 0.60) 
and citrulline (r 0.64)) and dimethyl sulfone (r 0.70). 
 
 
 
Figure 5.8. Correlation network of maternal plasma and urine metabolites observed to change 
 h  ugh u  p eg   cy  b sed     e  s  ’s c   el      c eff c e  s (| | ≥ 0 6   d p < 0 05)  N de 
size denotes the highest effect size across pregnancy for each metabolite. Node colours 
indicate direction of variation throughout pregnancy with red for decrease, green for increase 
and gray for metabolites that showed both decrease and increase. Dark red lines correspond to 
positive correlations, whereas blue lines correspond to negative correlations. Line thickness 
reflec s  he m g   ude  f  he c   el      c eff c e  s (| |≥ 0 6   h    0 7 ≤ | | <0 8  med um  | | ≥ 
0.8, broad). 
 
Metabolite correlations between maternal plasma and urine and within urine were 
also calculated (Figure 5.7 and Figure 5.8). The strongest correlations within maternal 
urine during pregnancy (Figure 5.7, panel B and Figure 5.8) confirmed previous reports 
(Diaz et al., 2013a) and the importance of the pregnancy urinary markers 4-
deoxyerythronic acid (4-DEA), 4-deoxythreonic acid (4-DTA) and unassigned spin 
systems Un 1 ( 0.55, s) and Un 2 ( 0.63, s). These unassigned systems have been 
suggested to arise from excreted bile acids (Diaz et al., 2013a) but confirmation is still 
lacking. Metabolic relationships between excreted and circulatory metabolomes, during 
pregnancy, are illustrated here for the first time to our knowledge through plasma/urine 
correlations (Figure 5.7, panel C and Figure 5.8). The fact that plasma and urine 
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samples correspond to partially overlapped cohorts means that measured correlations 
reflect average cohort behaviour, rather than individual behaviour. Lipid metabolism 
seems to be related to the excretion of Un 1 (correlated to LDL+VLDL alone with r 
0.68) and Un 2 (correlated to both HDL and LDL+VLDL, with r 0.60 and 0.66). 
Furthermore, LDL+VLDL metabolism seems to also specifically relate to glycoproteins 
(r 0.71). Both Un 1 (r -0.68) and Un 2 (r -0.65) are themselves negatively correlated to 
changes in total plasma proteins (viewed by the NH spectral region), but not to albumin 
(for which only weak correlations are seen, with r 0.50 and r 0.59), probably reflecting a 
relationship between the unassigned compounds and other proteins or peptide 
hormones known to change across pregnancy (e.g. human Chorionic Gonadotropin 
(hCG), known to decrease in the 3rd T (Edelstam et al., 2007)). In turn, albumin shows 
apparent positive and negative correlations to excreted creatinine (r 0.60) and alanine 
(r -0.60), respectively (Figure 5.7 and Figure 5.8).  
 
 
5.3. Proposed metabolic interpretation of plasma changes 
Low Mw compounds  
The decreased levels of circulating amino acids during pregnancy is well 
documented and explained in terms of the increased placental transfer of amino acids 
to the fetus, favouring nitrogen conservation for fetal growth (King, 2000; Herrera and 
Ortega, 2008). The lower levels noted here for valine, alanine, glutamine, tyrosine, 
histidine and citrulline in the 1st T identify these amino acids as particularly important in 
serving the fetus, early on in pregnancy. Previous reports have also associated 
decreases in alanine and citrulline to the slowing down of urea synthesis late in 
pregnancy (King, 2000). Indeed, an association between alanine and citrulline is 
apparent in this work, possibly involving glutamine too (Figure 5.8). In the 2nd T, lower 
amounts of alanine and tyrosine seem to be needed, since maternal circulatory levels 
are partially recovered. Other amino acids are generally maintained at a low level until 
the end of pregnancy, an enhanced use of glutamine being noted in the 3rd T. Our 
correlation results suggest a strong positive correlation linking glutamine to albumin 
metabolism, the exact nature of which remains unknown at this stage. The amino acid 
variations noted here are in broad agreement with the literature, although the exact 
amino acid fluctuations accompanying healthy pregnancies seems to vary significantly 
between studies (Di Giulio et al., 2004; Dasarathy et al., 2010), a fact that may be 
explained by either different analytical aspects (e.g. experimental/analytical design, 
sample numbers) and/or different population phenotypes. Other small metabolites that 
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vary include citrate, dimethyl sulfone, lactate, creatine and creatinine. To our 
knowledge, no changes in circulating citrate and lactate have been reported in 
connection to pregnancy, these metabolites probably indicating a shift in maternal 
energy metabolism in the 1st T, partially compensated in the 2nd T. The early decrease 
in dimethyl sulfone, also newly observed here, may be indicative of an early change in 
intestinal bacterial metabolism and/or endogenous methanethiol (a known source of 
dimethyl sulfone in blood) metabolism (Dasarathy et al., 2010), although a dietary 
source cannot be entirely ruled out. Regarding creatine and creatinine, only alterations 
in the latter have been reported to our knowledge in a pregnancy context, namely lower 
circulating levels and increased excretion, together with ammonia and uric acid (King, 
2000; Creasy et al., 2009; Cheung and Lafayette, 2013). A rise in glomerular filtration 
rate (GFR), without substantial alterations in the production of creatinine and urea, has 
been advanced to explain these variations. In this work, both plasma creatine and 
creatinine decrease in the 1st T and this seems to be compensated for creatinine later 
in pregnancy, possibly due to a GFR decrease known to occur near term (Creasy et al., 
2009). The absence of a visible correlation of creatine with creatinine (either in plasma 
or between plasma and urine) suggests that a dynamically complex network involves 
these two metabolites, an issue to be investigated in future targeted studies.  
 
High Mw compounds  
Our results confirm the expected increases in lipoproteins and lipoprotein-
cholesterol, described in several reports (Butte, 2000; Lippi et al., 2007; Herrera and 
Ortega, 2008; Hadden and McLaughlin, 2009; Mankuta et al., 2010). Maternal fat 
deposition in early and mid-pregnancy is used as an energy source for the mother so 
that glucose is spared for the fetus (Hadden and McLaughlin, 2009). In the 3rd T, 
lipolysis is promoted and lipogenesis suppressed, leading to increased levels of 
triacyglycerols (in both HDL and LDL) and VLDL particles in maternal blood plasma 
(Herrera and Ortega, 2008; Hadden and McLaughlin, 2009). Evidence of this metabolic 
switch is clearly illustrated by the high 3rd T levels of HDL and LDL+VLDL seen here, 
although the corresponding dynamic evolution is quite distinct, leading to a 17% 
decrease in HDL/LDL+VLDL in the 3rd T. Our results suggest that the onset of lipolysis 
late in pregnancy seems to preferentially produce longer and more unsaturated FAs, 
which become components of 3rd T HDL and LDL+VLDL.  
Furthermore, our correlation studies have shown that the increases in HDL and 
LDL+VLDL display a strong correlation with the observed albumin decrease across 
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pregnancy (the latter variation having been reported previously (Whittaker and Lind, 
1993; Bacq et al., 1996; King, 2000)) and, interestingly, to the excretion of the still 
unassigned pregnancy marker Un 2 ( 0.63 ppm, s). On the other hand, LDL+VLDL 
metabolism seems to have its own specific signature (distinct from HDL), involving a 
link to glycoprotein metabolism and excretion of another unassigned pregnancy marker 
Un 1 ( 0.55 ppm, s). These observations reveal specific links between different 
lipoproteins and other protein classes in plasma, and between circulating and excreted 
metabolomes. The increase in N-acetyl-glycoproteins may reflect a number of proteins 
(1-acid glycoprotein, 1-antitrypsin and haptoglobulin (Torri et al., 1999)), previously 
reported as changing during pregnancy (Honda et al., 1990; Larsson et al., 2008). The 
decrease in albumin seen here has been reported in several studies (Whittaker and 
Lind, 1993; Bacq et al., 1996; King, 2000), although different reasons have been 
advanced for this observation. The most common explanation relates to an increase in 
plasma volume during pregnancy (Bacq et al., 1996), however, in this work, data 
normalization should account for such a general concentration effect. Indeed, other 
possible origins for plasma albumin depletion in pregnancy may relate to reported 
changes in albumin metabolism (Whittaker and Lind, 1993), increased excretion (Higby 
et al., 1994) or increased transfer to the fetus (Sutcliffe, 1975). The origin of the 
apparent correlation of albumin with plasma creatine, glutamine and dimethyl sulfone 
and with excreted alanine and creatinine is unclear at this stage, although a possible 
relation to the selective action of this protein as a transport agent in blood circulation 
may be advanced.  
 
5.4. Conclusions 
This work describes the first NMR metabolomic study of pregnancy using maternal 
plasma and correlation between plasma and urine metabolites. The expected decrease 
in circulating amino acids early in pregnancy was confirmed with six amino acids 
identified as being required to larger extents by the fetus. Novel observations include 
early changes in citrate, lactate and dimethyl sulfone levels, possibly due to an 
metabolic energy shift and gut microflora adjustments taking place in the 1st T. 
Alteration in creatine levels was also noted, along with creatinine changes with the 
latter known to reflect changes in GFR during pregnancy.  
Plasma HDL and LDL+VLDL levels were confirmed to increase throughout 
pregnancy, but at different rates and accompanied by increases in fatty acid chain 
length and unsaturation degree. Distinct correlation patterns suggested a) an inverse 
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link between HDL and LDL+VLDL and plasma albumin, along with a direct link with 
excreted pregnancy markers Un 1 (singlet at  0.55) and Un 2 (singlet at  0.63); b) a 
direct specific relationship between LDL+VLDL and N-acetyl-glycoproteins, together 
with excreted Un 1 and c) a number of correlations of plasma albumin with specific 
circulating (possibly due to selective transportation) and excreted small metabolites. 
These results unveil specific lipoprotein/protein metabolic aspects of pregnancy, with 
an impact on the excreted metabolome, and as such provide an interesting lead for the 
further understanding of pregnancy metabolism. 
 
 
  
 
Chapter 6. First and second trimester maternal 
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The results presented in this chapter were fully submitted/published in the 
articles below and are here adapted slightly onto the form of a thesis chapter, for 
the sake of clarity:  
Pinto, J.; Almeida, L. M.; Martins, A. S.; Duarte, D.; Domingues, M. R. M.; Barros, A. 
S.; Galhano, E.; Pita, C.; Almeida, M. C.; Carreira, I. M.; Gil, A. M. Fetal chromosomal 
disorders impact on maternal metabolome: towards new biomarkers? American 
Journal of Obstectrics & Gynecology 2015, under revision. 
Pinto, J.; Maciel, E.; Melo, T. S.; Domingues, M. R. M.; Galhano, E.; Pita, C.; Almeida, 
M. do C.; Carreira, I. M.; Gil, A. M. Maternal Plasma Phospholipids Are Altered in 
Trisomy 21 Cases and prior to Preeclampsia and Preterm Outcomes. Rapid 
Communications in Mass Spectrometry 2014, 28, 1635–1638. 
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6.1. Analysis of plasma and total lipid extracts by NMR spectroscopy 
Abstract 
Objectives: This study aimed at determining the impact of fetal CD, including T21, on 
1st and 2nd T maternal blood plasma, to identify 1) time course metabolic adaptations to 
the conditions and 2) possible new plasma biomarkers. Furthermore, a definition of a 
joint circulatory (plasma) and excretory (urine) metabolic description of 2nd T CD was 
sought. Study Design: Blood plasma was obtained for 119 pregnant women: 74 
controls and 45 CD cases, including 22 T21 cases. Plasma and lipid extracts were 
analysed by NMR spectroscopy and data was handled by variable selection and MVA. 
Correlation analysis was used on a concatenated plasma/urine matrix descriptive of 2nd 
T CD, based on previously obtained urine data. Results: CD cases were accompanied 
by enhanced lipid -oxidation (increased ketone bodies) and underuse of glucose, 
pyruvate and citrate. Lower circulating HDL levels were noted, along with changes in i) 
proline and methanol in the 1st T, and ii) urea, creatinine and LDL+VLDL in the 2nd T. 
T21 cases were indistinguishable from other CD cases in the 1st T, while in the 2nd T 
increased methanol and albumin may be T21-specific. Furthermore, 1st T lipid extracts 
of T21 showed decreased levels of 18:2 fatty acids, whereas in the 2nd T lower levels of 
20:4 and 22:6 fatty acids were noted, possible indicative of inflammation mechanisms.  
In both trimesters, high classification rates for CD (88-89%) and T21 (85-92%) 
generally relied on variable selection of NMR data. Plasma/urine correlations confirmed 
most metabolic deviations and unveiled possible new ones regarding LDL+VLDL, 
sugar and gut-microflora metabolisms. Conclusions: This work partially confirmed 
previously reported data on 1st T T21 and provided additional information on time 
course metabolic changes accompanying CD and T21, in particular regarding plasma 
lipid composition. These results demonstrate the potential of plasma metabolomics in 
monitoring and characterizing CD cases in the clinic, however, validation in larger 
cohorts and demonstration of putative biochemical hypothesis are required before 
applications may be envisaged.  
 
Brief state of the art 
Current diagnostic methods for CD comprise invasive procedures such as CVS and 
amniocentesis performed at 10-13 g.w. and 15-20 g.w., respectively. These procedures 
involve some risk for mother and fetus (0.5-1% fetal loss rate (Tabor and Alfirevic, 
2010)) and, currently, non-invasive screening tests are used in the 1st and 2nd T based 
on ultrasound and maternal serum biomarkers (β-hCG, PAPP-A, AFP, uE3 or inhibin 
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A) (Nicolaides, 2011). 1st T screening combines maternal age, fetal nuchal 
translucency thickness and serum free -hCG and PAPP-A, with detection and false 
positive rates (FPR) of 85-95% and 5% for T21, and > 90% and 1% for other 
aneuploidies (T18 and T13). In the 2nd T, biomarker combination provides 70-75% 
detection rates and 5% FPR for T21 (Nicolaides, 2011). Analysis of cffDNA in maternal 
blood has a higher performance, with 1st T detection rates of 98.6-100%, 100% and 
91.7% for T21, T18 and T13, respectively, and FPR < 1% (Walsh and Goldberg, 2013). 
However, the high cost of such tests and the relative low detection rates for T13 
presently hinder their use as replacements of either CVS or amniocentesis. Hence, 
there is still a need for biomarkers with improved reliability, as well as for a deeper 
knowledge of how CD impact on pregnancy metabolism, thus enlightening the 
conditions´ mechanisms and interaction between genetic and metabolic traits.  
The metabolic impact of CD on 2nd T amniotic fluid was low, viewed by NMR 
spectroscopy (Graça et al., 2010), but a subsequent HPLC study unveiled amino acid 
changes in T21 cases (Amorini et al., 2012). NMR of 2nd T maternal urine resulted in 
CD classification with 87% sensitivity and 84% specificity, suggesting higher glucose 
excretion and amino acid alterations (Diaz and Pinto et al., 2011). T21 cases were 
distinguished from other CD by possible changes in energy, nucleotide and amino acid 
metabolisms. A subsequent MS study of 1st and 2nd T maternal urine of T21 revealed 
increased dihydrouracil (possibly due to liver abnormalities) and decreased 
progesterone (probably reflecting impairment of placental function due to oxidative 
stress) (Trivedi and Iles, 2014b). Regarding maternal blood, an initial indication of lipid 
changes in 2nd T maternal plasma of T21 (Diaz and Pinto et al., 2011) was later 
confirmed by lipidomics, which revealed changes in LPC and SM, along with ether-
linked PC and PE species related to lipid oxidation (Pinto et al., 2014d). NMR of T21 1st 
T maternal blood reported changes in 11 metabolites, particularly in 3-hydroxybutyrate, 
3-hydroxyisovalerate and 2-hydroxybutyrate (75% sensitivity, 86.2% specificity) 
(Bahado-Singh et al., 2013b). These results were interpreted as reflecting oxidative 
stress, poor myelination and neurotoxicity of the brain in T21 fetuses. A similar study of 
T18 advanced a combination of 2-hydroxybutyrate, glycerol and maternal age for T18 
detection (73% sensitivity, 97% specificity), while trimethylamine, threonine and 
creatine levels seemed to differentiate T18 from T21 (Bahado-Singh et al., 2013c). 
In this work, a NMR metabolomics study of 1st and 2nd T maternal plasma of a 
general CD group and a T21 subgroup is presented in comparison to controls, in order 
to 1) establish the time course adaptations of maternal/fetal metabolism to the 
conditions and 2) unveil dynamic metabolic biomarkers. Furthermore, blood plasma 
and lipid extracts are compared in terms of T21 classification, the latter adding specific 
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information on lipid composition. Finally, the CD-related metabolic changes measured 
in 2nd T maternal plasma are correlated to the corresponding urine samples, thus 
providing a more complete metabolic description of CD in mid-pregnancy. 
6.1.1. Metabolic fingerprinting of CD in the 1st trimester  
The average CPMG 1H NMR spectrum of control 1st T maternal plasma (Figure 
6.1a) is dominated by broad lipoprotein and glucose peaks whereas the corresponding 
lipid extract spectrum (Figure 6.1b) shows additional information on lipid composition, 
namely, several different methylene and methine environments, SM and PC choline 
resonances, TG and PL glyceryl resonances and 18:2, 20:4 and 22:6 FA. PCA of the 
CPMG 1H NMR spectra of 1st T blood plasma of controls and CD samples (not shown) 
revealed no trends and the corresponding PLS-DA model had poor performance (Q2 
0.300) (Table 6.1, Figure 6.2a). Variable selection was applied to the spectra and the 
subsequent PLS-DA 1st T plasma model (Figure 6.3a) was indeed much improved (Q2 
0.700, Table 6.1, Figure 6.2b), the set of variables selected being shown as grey dots 
in Figure 6.1a.  
Table 6.1. MCCV parameters obtained when considering the original (full resolution) 
1
H NMR 
spectra and the NMR spectra after variables selection through the intersection of VIP>1, 
VIP/VIPcvSE > 1 and b/bcvSE > 1. T: trimester; LV: no. of latent variables; Q
2
: most frequent value 
obtained by MCCV; CR: classification rate, Sens: sensitivity and Spec: specificity; %VS: 
percentage of variables selected from the original spectra; values in bold refer to robust PLS-DA 
models. 
T 
Subjects 
group 
Original spectra Spectra after variable selection 
LV Q
2
 CR Sens Spec LV Q
2
 CR Sens Spec % VS 
1
st
 Whole blood plasma           
Controls (n=24) 
/CD (n=15) 
2 0.3 70% 41% 89% 1 0.7 88% 78% 94% 34% 
Controls (n=24) 
/T21 (n=8) 
1 0.2 76% 18% 96% 1 0.7 92% 72% 99% 32% 
Plasma lipid extracts         
Controls (n=15) 
/T21 (n=7) 
- - - - - 1 0.8 87% 78% 91% 25% 
2
nd
 Whole blood plasma           
Controls (n=49) 
/CD (n=30) 
- - - - - 2 0.7 89% 79% 94% 31% 
Controls (n=49) 
/T21 (n=14) 
1 0.3 78% 26% 93% 1 0.7 85% 44% 97% 32% 
Plasma lipid extracts         
Controls (n=15) 
/T21 (n=13) 
2 0.7 94% 94% 94% 2 0.9 98% 100% 97% 33% 
Whole plasma and urine         
Controls (n=22) 
/CD (n=26) 
1 0.3 63% 62% 64% 1 0.6 90% 85% 95% 32% 
Controls (n=22) 
/T21 (n=12) 
- - - - - 1 0.8 95% 85% 100% 32% 
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The fact that some selected variables fall in regions of weak/broad resonances or slight 
baseline nuances (e.g. in the aromatic region) indicates the importance of spectral 
detail for sample classification. Computed metabolite changes (Table 6.2) showed that 
CD samples carry lower amounts of HDL lipoproteins, proline and methanol, and 
increased levels of -hydroxybutyrate and pyruvate (as well as qualitative increases in 
acetate, acetone, citrate, creatine and glucose), as clearly seen in a Volcano plot 
format (Figure 6.3a right). 
 
 
Figure 6.1. a) Average (n=24) 500 MHz CPMG 
1
H NMR spectrum of 1
st
 T plasma of healthy 
pregnant women (controls), with indication of the spectral variables (data points) selected in the 
PLS-DA model controls vs. CD (grey dots under spectrum); b) average (n=15) 500 MHz 
1
H 
NMR spectrum of 1
st
 T plasma lipid extracts of controls, with indication of the spectral variables 
selected in the PLS-DA model of controls vs. T21 (grey dots under spectrum). Assignment: 1- 
CH3 lipids, 2- valine, 3- (CH2)n lipids, 4- lactate, 5- alanine, 6- CH2CH2CH= lipids, 7- CH2CH= 
lipids, 8- N-acetyl glycoproteins, 9- acetone, 10- pyruvate, 11- glutamine, 12- citrate, 13- 
=CHCH2CH= lipids, 14- albumin-lysyl, 15- creatine, 16- creatinine, 17- N(CH3)3 choline PL, 18- 
glucose, 19- HC=CH lipids, 20- urea, 21- tyrosine, 22- histidine, 23- u k  w  1 (δ 7 19-7.38, 
br), 24- C18H3 FC and EC, 25- C26H3 and C27H3 FC and EC, 26- CH3 FA, 27- C21H3 FC and 
EC, 28- C19H3 FC, 29- C19H3 EC, 30- (CH2)n FA, 31- =CHCH2(CH2)n FA, 32- CH2CH= FA, 33- 
CH2CO FA, 34- CH2CO 22:6 FA, 35- =CHCH2CH= 18:2 FA, 36- =CHCH2CH= 20:4 FA, 37- 
N(CH3)3 choline of SM, 38- N(CH3)3 choline of PC, 39- CH2N(CH3)3 PC and SM, 40- glyceryl-
C3H2 PL, 41- glyceryl-C1,3H and -C1,3H’ TG, 42- glyceryl-C1H2 PL, 43- CH2-PO PL, 44- C3H 
EC, 45- glyceryl-C2H PL, 46- glyceryl-C2H TG, 47- HC=CH FA, 48- =CH-CHOH SM, 49- 
U k  w  2 (δ 5 91  b )  50- U k  w  3 (δ 7 12  d   d δ 7 71  m)  *: cu   ff spec   l  eg   s 
corresponding to water and ethanol peaks in a) and chloroform and water peaks in b). 
a) 
b) 
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When comparing T21 cases with controls, the PLS-DA model (after variable 
selection) and metabolite changes noted were very similar to those describing the 
general CD group (Figure 6.3b, Table 6.1 and Table 6.2). Since T21 (n=8) cases 
predominate within the CD group and are indistinguishable from other CD (n=7) in 
multivariate space (results not shown), no specific T21 signature may be advanced at 
this stage. Previous reports on 1st T deproteinized sera of T21 and T18 cases (Bahado-
Singh et al., 2013b, 2013c) also identified increases in -hydroxybutyrate, pyruvate and 
acetone, in addition to other lower abundance metabolites probably made visible by the 
filtration/extraction procedure employed. Here, direct plasma analysis unveils additional 
lipid compositional changes. Considering lipid extract spectra, a distinct subset of 
variables was selected (Figure 6.1b), 1st T extracts being shown to have decreased 
levels of 18:2 FA and PC (Figure 6.3c).  
 
a) Controls 1
st
 T (n=24) vs. CD 1
st
 T (n=15) – CPMG original spectra 
  
b) Controls 1
st
 T (n=24) vs. CD 1
st
 T (n=15) 1T – CPMG spectra after variable selection 
  
Figure 6.2. Q
2
 distributions (left) and ROC plots (right) of true and permuted models obtained 
for a) the original CPMG 
1
H NMR spectra of whole blood plasma of controls 1
st
 T (n=24) vs. CD 
1
st
 T (n=15) and b) corresponding variable selected spectra. 
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Figure 6.3. PLS-DA scores scatter plots for CPMG 
1
H NMR plasma spectra (after variables 
selection) and Volcano plots (effect size vs. –Log (p-value)) representing contributing 
metabolites/resonances for whole blood plasma of controls 1
st
 T (n=24) vs. a) CD 1
st
 T (n=15) 
and b) T21 1
st
 T (n=8); c) plasma lipid extracts of controls 1
st
 T (n=15) vs. T21 1
st
 T (n=7). Ac, 
 ce   e  Ac    ce   e  β-HB  β-hydroxybutyrate; Cit, citrate; Cre, creatine; Glc, glucose; glyc, 
glyceryl; MeOH, methanol; Pro, proline; Pyr, pyruvate. Values in brackets correspond to 
compound chemical shifts. 
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6.1.2. Metabolic fingerprinting of CD in the 2nd trimester  
A similar strategy was employed for comparing 2nd T CD (and T21) cases and 
controls. PLS-DA of variable selected data (Figure 6.4a) and subsequent signal 
integration enabled the identification of a different metabolic profile describing 2nd T CD 
cases (Table 6.2, Figure 6.4a): decreased urea and acetate, and increased creatinine 
and citrate. Additional qualitative differences comprised increasing tendencies for 
LDL+VLDL and alanine, and the absence of changes in creatine and methanol (noted 
in the 1st T). It is important to note that the exact composition of 1st and 2nd T CD 
groups is somewhat different (see Table 2.4, page 66), both groups being dominated 
by T21 (53% and 47% of all cases in 1st and 2nd T respectively) and including small 
numbers of other disorders; therefore, a possible small contribution from under-
represented disorders to the apparent metabolic adaptions/evolution based on average 
CD profiles is possible.  
 
Regarding the 2nd T T21 subgroup, a large similarity to the whole CD group is again 
noted, with significant decreased urea, acetate and HDL (Figure 6.4b). However, an 
increase in glucose becomes clearer (although with high uncertainty, Table 6.2), along 
with apparently T21-specific changes († in Table 6.2): increased lipid CH2CH2CO 
resonance, albumin, methanol and unknown 1 ( 7.19-7.38), and absence of changes 
   β-hydroxybutyrate, proline and creatinine. The spectra of 2nd T extracts produced 
robust PLS-DA models, with or without variable selection (Table 6.2, Figure 6.4c) and 
identified FA methylenes, PC, total choline and PL glyceryl groups as decreased in 
T21, similarly to 1st T plasma. However, some differences are observed, namely the 
now non-significant change in 18:2, decreases in 22:6 and 20:4 FAs, absence of 
change in SM and increase in unknown 3 ( 7.71) (Table 6.2, Figure 6.4c). The 
observation of different metabolic profiles for 2nd T CD and T21 groups, compared to 
the 1st T, suggests that a dynamic metabolic adaptation to CD occurs across 
pregnancy, rather than a simple enhancement of the metabolic impact registered in 
early pregnancy (although a possible contribution of different CD group compositions 
may not be completed ruled out).  
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Figure 6.4. PLS-DA scores scatter plots for CPMG 
1
H NMR plasma spectra (after variables 
selection) and Volcano plots (effect size vs. –Log (p-value)) representing contributing 
metabolites/resonances for whole blood plasma of controls 2
nd
 T (n=49) vs. a) CD 2
nd
 T (n=30) 
and b) vs. T21 (n=14); c) plasma lipid extracts of controls 2
nd
 T (n=15) vs. T21 2
nd
 T (n=13). Ac, 
acetate; Ala, alanine; Alb, albumin-lysyl  β-HB  β-hydroxybutyrate; Cit, citrate; Crn, creatinine; 
FAs, fatty acids; Glc, glucose; glyc, glyceryl; MeOH, methanol; Pyr, pyruvate; Un 1, unknown 1 
(7.19-7.38, br); Un 3, unknown 3 (7.71, m). Values in brackets correspond to compound 
chemical shifts. 
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Table 6.2. List of metabolites/resonances in whole blood plasma and plasma lipid extracts selected by variables selection as important for discrimination of 
CD and T21 from controls, in both 1
st
 and 2
nd
 trimesters. 
a 
Chemical shifts shown correspond to signals used for integration; s: singlet, d: doublet, t: triplet, q: 
quartet, m: multiplet, br: broad. 
b 
E.S.: effect size determined as described in reference (Berben et al., 2012). 
c 
Significance level 95% (p-value < 0.05). Only 
values with statistical relevance or lower uncertainties are specified, otherwise only qualitative information is provided in the form of arrows. *: observations 
noted only in the 2
nd
 T  †:  bse v     s    ed   ly  he T21 subg  up  n.d.: not determined. 
Compound 
Chemical 
shift/ppm
a
 
Variation (E.S.
 b
, p-value
 c
) 
1
st
 trimester 2
nd
 trimester 
CD vs. controls T21 vs. controls CD vs. controls T21 vs. controls 
Whole blood plasma     
CH3 lipids HDL 0.78 -0.86 (br) ↓ -0.86±0.67, 1.3×10
-2
 ↓ -1.10±0.84, 8.8×10
-3
 ↓ ↓ 
(CH2)n lipids HDL 1.20-1.25 (br) ↓ -0.68±0.66, 4.9×10
-2
 ↓ ↓ ↓ -0.56±0.60, 2.2×10
-2
 
CH3 lipids LDL+VLDL 0.86-0.90 (br) - - ↑* ↑ 
(CH2)n lipids LDL+VLDL 1.25-1.30 (br) - - ↑* ↑ 
CH3 HDL/LDL+VLDL  ↓ -0.73±0.67, 4.7×10
-2
 ↓ ↓ ↓ 
Alanine 1.46 (d) - - ↑* ↑ 
CH2CH2CO lipids 1.52-1.60 (br) ↑ ↑ -* ↑† 
Acetate  1.91 (s)  ↑ ↑ ↓ -0.51±0.47, 1.2×10
-2
* ↓ 
Acetone 2.22 (s) ↑ ↑ - - 
-hydroxybutyrate 2.39 (m) ↑ 0 69±0 66  2 6×10
-3
 ↑ 0 70±0 82, 1.8×10
-2
 ↑ -† 
Pyruvate 2.36 (s) ↑ 0 81±0 67  3 0×10
-2
 ↑ 1 22±0 85  4 6×10
-2
 ↑ ↑ 
Citrate 2.51 (d)  ↑ ↑ ↑ 0 51±0 47  3 3×10
-2
 ↑ 
Albumin-lysyl 2.92-3.03 (br) - - - ↑† 
Creatine 3.03 (s) ↑ ↑ -* - 
N(CH3)3 choline HDL 3.20-3.23 (br) ↓ -1.06±0.69, 3.9×10
-3
 ↓ -1.28±0.86, 5.1×10
-3
 ↓ ↓ 
Proline 3.34 (br) ↓ -0.78±0.67, 1.7×10
-2
 ↓ -1.02±0.84, 1.8×10
-2
 ↓ -† 
Methanol 3.36 (s) ↓ -0.98±0.68, 3.0×10
-3
 ↓ -1.01±0.84, 2.3×10
-2
 -* ↑† 
Creatinine  4.05 (s)  - - ↑ 0 60±0 47  1 4×10
-2
* -† 
Glucose 5.23 (d) ↑ ↑ ↑ ↑ 0 47±0 60, 3.0×10
-2
 
Urea 5.77 (br)  - - ↓ -0.81±0.48, 6.7×10
-4
* ↓ -0.87±0.61, 2.6×10
-3
 
Unknown 1 7.19-7.38 (br) - - - ↑† 
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Table 6.2. (cont.) 
Compound 
Chemical 
shift/ppm
a
 
Variation (E.S.
 b
, p-value
 c
) 
1
st
 trimester 2
nd
 trimester 
Controls vs. CD Controls vs. T21 Controls vs. CD Controls vs. T21 
Plasma lipid extracts      
Fatty acids      
CH3 0.89 (t) n.d. ↓ -0.99±0.67, 1.3×10
-2
 n.d. ↓ 
(CH2)n 1.25 (br) n.d. ↓ n.d. ↓ -0.56±0.54 
=CHCH2(CH2)n 1.26-1.40 (br) n.d. ↓ n.d. -* 
CH2CH=  18:2  2.05 (q)  n.d. ↓ -0.86±0.66, 1.7×10
-2
 n.d. -* 
CH2CH=  20:4 2.10 (q) n.d. ↓ n.d. ↓ 
CH2CO  2.28-2.36 (m) n.d. ↓ n.d. ↓ 
CH2CO 22:6  2.37 (t)  n.d. ↑ n.d. ↓ -0.94±0.56, 8.5×10
-4
* 
=CHCH2CH= 18:2 2.77 (t) n.d. ↓ n.d. ↑* 
=CHCH2CH= 20:4 2.79-2.86 (m)  n.d. ↓ n.d. ↓ -0.83±0.55, 3.5×10
-3
 
HC=CH 18:2 5.29-5.35 (m) n.d. ↓ n.d. -* 
HC=CH 20:4 5.35-5.43 (m)  n.d. ↓ n.d. ↓ -0.79±0.55, 6.5×10
-3
 
Phospholipids      
N(CH3)3 choline SM 3.31 (br) n.d. ↓ n.d. -* 
N(CH3)3 choline PC  3.34 (br)  n.d. ↓ -1.36±0.70, 2.1×10
-4
 n.d. ↓ -1.11±0.57, 5.5×10
-5
 
CH2N(CH3)3 choline total 3.78 (br)  n.d. ↓ -1.59±0.72, 8.7×10
-5
 n.d. ↓ -1.30±0.58, 2.5×10
-5
 
Glyceryl-C3H2 3.95 (m)  n.d. ↓ -1.53±0.71, 1.1×10
-4
 n.d. ↓ -1.14±0.57, 1.7×10
-4
 
POCH2 4.34 (br)  n.d. ↓ -0.83±0.66, 6.8×10
-3
 n.d. ↓ -1.36±0.59, 3.0×10
-5
 
Glyceryl-C1H2 4.40 (br)  n.d. ↓ -1.08±0.67, 4.2×10
-3
 n.d. ↓ -0.79±0.55, 6.1×10
-3
 
Unknown 3 7.71 (m)  n.d. - n.d. ↑ 1 08±0 57  3 9×10
-4
* 
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In an attempt to improve samples classification, multivariate analysis was 
performed using a concatenated matrix of 2nd T maternal blood plasma and urine 
collected for common subjects (22 controls, 26 CDs, 12 T21). This led, however, to 
models with comparable robustness as those considering plasma or urine (Diaz et al., 
2013b) alone (Table 6.1), identifying metabolite variations (not shown) in general 
agreement with those provided by single-biofluid models. However, in the smaller 
concatenated matrix (particularly diminished for controls), the urea and creatinine 
variations (shown in plasma-only) were absent, thus demonstrating the importance of 
using larger cohort sizes. Metabolite variations were then used to identify intra- and 
inter-biofluid metabolic correlations describing CD cases in the 2nd T. The resulting 
correlations network (Figure 6.5) identified one correlation cluster within plasma (A) 
and two main clusters in urine (B and C). Cluster A seems to reflect the lipid 
metabolism disturbances, unveiling a negative correlation between plasma creatine 
and lipids and a positive correlation between ketone body acetoacetate and circulating 
lipids. Cluster B links the three excreted ketone bodies, all correlated to acetate; ketone 
bodies also correlate inversely to excreted formate (node 40) and directly to plasma 
acetoacetate (node 9). Cluster C seems to reflect deviations in Krebs cycle 
intermediates (2-ketoglutarate, fumarate), interlinked to glucose, pyruvate and taurine. 
Apparent additional correlations are observed in urine, namely between 1) excreted 
glucose, sucrose and allantoin (nodes 30, 33, 31); 2) excreted 4-hydroxyhippurate, 
indoxyl sulphate and phenylacetylglutamine (nodes 35-37), with the former correlating 
inversely to creatinine (node 29) and this, in turn, to trigonelline (node 41). Notably, the 
relatively large variation in excreted 3-methyl-histidine (node 39) does not show 
relevant correlations.  
 
 
6.1.3. Proposed metabolic interpretation of plasma changes 
In the 1st T, plasma of CD and T21 groups share decreased levels of HDL 
lipoproteins and increased levels of ketone bodies (-hydroxybutyrate and acetone), 
suggesting increased -oxidation. Increases in other metabolites connected to energy 
metabolism (namely glucose, pyruvate and citrate) seem to reflect their underuse in 
glycolysis, pyruvate oxidation and Krebs cycle, respectively, indicating an energy shift 
from glucose to lipids catabolism. In T21 cases, 18:2 FA and PC levels are particularly 
decreased, possibly reflecting their role as HDL constituents. In addition, proline, 
methanol and creatine add to an early CD-specific signature, although no clear 
biochemical interpretation may be advanced at this stage.  
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Figure 6.5. Correlation network of maternal plasma and urine metabolites observed to change 
in 2
nd
    mes e  C  c ses c mp  ed    c     ls  b sed     e  s  ’s c   el      c eff c e  s  
Node colours indicate biofluid type (red for blood plasma and orange for urine) and node size 
reflects effect size of variation in CDs, compared to controls. Green and red lines correspond to 
positive and negative correlations, respectively, and line thickness reflects correlation 
coefficients magnitude. 1- CH3 lipids HDL; 2- CH3 lipids LDL+VLDL; 3- (CH2)n lipids HDL; 4- 
(CH2)n lipids LDL+VLDL; 5- CH2CH2CO lipids; 6- acetate; 7- CH2C=C lipids; 8- CH2CO lipids; 9- 
acetoacetate; 10- citrate; 11- creatine; 12- N(CH3)3 choline HDL; 13- lactate; 14- HC=CH lipids 
LDL+VLDL; 15- acetone; 16- acetate; 17- -hydroxybutyrate; 18- pyruvate; 19- 2-ketoglutarate; 
20- citrate; 21- dimethylamine; 22- scyllo-inositol; 23- acetoacetate; 24- taurine; 25- unknown 5 
(3.48-3.51 ppm, m); 26- guanidoacetate; 27- creatine; 28- unknown 6 (3.96 ppm, s); 29- 
creatinine; 30- glucose; 31- allantoin; 32- fumarate; 33- sucrose; 34- 4-hydroxylphenylacetate; 
35- 4-hydroxyhippurate; 36- indoxyl sulphate; 37- phenylacetylglutamine; 38- histidine; 39- 3-
methyl-histidine; 40- formate; 41- trigonelline; 42- malonate; 43- tartarate; 44- choline. 
 
 
In the 2nd T, the observation of different metabolic profiles for CD and T21 groups, 
compared to 1st T, suggests that a dynamic metabolic evolution occurs in CD cases, 
rather than a simple enhancement of the metabolic impact registered early on. The 
metabolic pattern of enhanced -oxidation is maintained (with the exception of acetone 
variation), however, 2nd T plasma includes novel changes, namely increased 
LDL+VLDL (possibly as compensation for HDL depletion) and decreased urea. The 
latter, together with an increasing (although not statistically correlated) tendency in 
creatinine, may indicate changes in fetal renal function, a condition often observed in 
CD-affected fetuses (Creasy et al., 2009) and here seen to acquire particular emphasis 
in the 2nd T. The lower urea levels may result from up-regulation of creatine 
phosphorylation and/or down regulation of creatine hydrolysis into urea and sarcosine; 
the latter was supported by STOCSY results (not shown) directly correlating urea and 
12
1
3
2
4
5
814
11
7
13
9
20
22
27
10
6
21
31
41
39
29
44
33
28
35
40
23
15
16
17
30
19
25
24
18
32
26
37
36
38
42
34
43
A
B
C
First and second trimester maternal plasma for diagnosis of chromosomal disorders and trisomy 
21 
145 
sarcosine. Second trimester T21 cases show a similar behavior to global CD, with 
additional increasing tendencies for methanol and albumin; the latter may relate to the 
lower HDL levels, since an inverse albumin/HDL relationship was observed in healthy 
pregnancies (Pinto et al., 2014b). Additional apparently T21-specific deviations 
comprised decreases in -3 FA 22:6 and -6 FA 20:4, known for their mediation in 
anti-inflammatory and pro-inflammatory processes (Wall et al., 2010), respectively. The 
somewhat larger depletion in the former may indicate a more significant response to 
inflammation, accompanying 2nd T T21.  
 
6.1.4. Conclusions 
These results partially confirm previously reported changes in deproteinized 1st T 
maternal blood sera of T21 and T18 cases (Bahado-Singh et al., 2013b, 2013c) and 
add information regarding additional metabolites (proline, methanol) and lipid 
metabolism in CD and T21. Other alterations previously observed in T21 cases 
(Bahado-Singh et al., 2013b) were not noted here probably due to metabolite low 
abundance and resonance overlap with macromolecules in whole plasma. In addition, 
a comparison between 1st and 2nd T was performed in this work, enabling a time course 
characterization of CD (and T21) to be carried out and in tandem analysis of plasma 
and lipid extracts unveiled specific changes in lipid metabolism. Indeed, changed 
phospholipid levels had been reported for T21 (Pinto et al., 2014d) and, here, a 
different involvement of HDL and LDL+VLDL lipoproteins in -oxidation was identified, 
in addition to a fine interplay between 18:2, 22:6, 20:4 FA. Plasma/urine correlations 
studies unveiled possible CD-specific intra- and inter-biofluid metabolic relationships, 
confirming main changes noted here for plasma and previously for urine (Diaz et al., 
2013b) and unveiling possible relationships relating to plasma creatine and lipids 
(particularly LDL+VLDL); excreted ketone bodies and acetate/formate; allantoin and 
sugar metabolism; and gut-microflora metabolites (e.g., 4-hydroxyhippurate, 
phenylacetylglutamine, 4-hydroxyphenylace-tate).  
In future work, the putative metabolic signatures advanced for 1st T and 2nd T 
maternal plasma in CD and T21 require validation in larger cohorts and demonstration 
of biochemical explanations, before clinical applications may be envisaged. 
Additionally, the issues of metabolic signature specificity in relation to T21, T18 and 
T13 requires further investigation. 
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6.2. Analysis of plasma phospholipids by Hydrophilic Interaction Liquid 
Chromatography-Mass Spectrometry (HILIC-LC/MS) 
The results presented below were published as part of a short communication with  
reference: Pinto, J.; Maciel, E.; Melo, T. S.; Domingues, M. R. M.; Galhano, E.; Pita, C.; 
Almeida, M. do C.; Carreira, I. M.; Gil, A. M. Maternal Plasma Phospholipids Are 
Altered in Trisomy 21 Cases and prior to Preeclampsia and Preterm Outcomes. Rapid 
Communications in Mass Spectrometry 2014, 28, 1635–1638.  In this subchapter only 
the results obtained for 2nd T T21 will be described. The brief state of the art was 
described in subchapter 6.1. Sample characteristics can be found in Chapter 2 (Table 
2.6). 
 
Abstract 
Rationale: To search for changes in phospholipids in 2nd T maternal plasma, in 
connection to fetal T21, aiming at finding novel markers. Methods: Plasma was 
collected from pregnant women at 16-19 g.w. defining two groups: controls (n=14) and 
T21 (n=5). The PL extracts of the pooled samples were analysed by hydrophilic 
interaction liquid chromatography mass spectrometry (HILIC-LC/MS) and subsequent 
multivariate and univariate analysis. Results: Results showed that T21 has a significant 
impact on 2nd T maternal plasma PL: changes in the levels of LPC, ether-linked PC and 
PE are consistent with previously suggested oxidative processes related to T21. 
Apparent specific features included decreases in two SM and several PC. Conclusions: 
Results indicated that maternal PL metabolism is exquisitely sensitive to fetal T21 and 
the apparent specificity of PL profiles enable future uses for complementary diagnosis 
to be envisaged. 
 
6.2.1. Phospholipid profiling of trisomy 21 in 2nd trimester 
Typical positive-ion HILIC-LC/MS records (Figure 6.6) of pooled 2nd T control 
plasma showed peaks characteristic of different PL classes at average RT 9.5–10.8 
min (PE), 29.5–32.4 min (PC), 34.0–35.9 min (SM) and 38.5–39.8 min (LPC).  
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Figure 6.6. Positive-ion HILIC-LC/MS analysis of a pooled plasma sample from control 
pregnant women. a) Total ion chromatogram (TIC) and b) LC-MS spectra for each PL class: 
region A: phosphatidylethanolamines (PE); region B: phosphatidylcholines (PC); region C: 
sphingomyelins (SM); and region D: lyso PC (LPC). 
 
When visually comparing the corresponding MS records obtained for control and 
disease pools (see Figure 6.7a, for PC species), some differences could be observed 
for T21 (arrows in Figure 6.7a). A more objective analysis of such complex datasets 
requires the use of multivariate analysis, used here to probe for changes to be further 
confirmed rather than for classification (due to the low sample numbers). Preliminary 
PLS-DA (Figure 6.7b, left) showed separation of T21 from controls with a good 
predictive power (Q2= 0.574). Loadings inspection (Figure 6.7b, right) enabled a total of 
34 features to be identified with VIP  1 and p < 0.05 for T21. The most relevant 
features (with higher VIP and lower p value,  
Table 6.3) included significant decreases in SM (d18:1/18:1) (Figure 6.7c) and 
unknown species with m/z 842.3 (unquantifiable in T21 samples).  
 
a) 
b) 
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Figure 6.7. a) MS record of PC TIC region (average RT 29.5 – 32.4 min) of pooled plasma 
samples of pregnant women: healthy throughout pregnancy (control) and carrying fetuses 
affected by trisomy 21; b) PLS-DA scores scatter plot and loadings plot of controls vs. T21; c) 
Bar plot of normalized ion area of a selected PL for control vs. T21 samples pools. * solvent 
impurity. 
a) 
b) 
c) 
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Table 6.3. List of PL species varying most significantly between T21 vs. controls samples. 
Abbreviations: m/z: mass-to-charge ratio; RT: retention time; VIP: variable importance to 
projection. *unknown compound, 
†
 signal observed in more than one disorder (unspecific). 
m/z 
RT 
(min) 
Identification VIP[1] 
p-value 
(<0.05) 
Relative 
variation (%) 
Effect size 
729.4 35.0 SM(d18:1/18:1) 1.64 1.87×10
-5
 -21.2 ± 2.6 -3.23 ± 0.90 
842.3 30.9 Unknown *
 †
 1.44 -  - 
542.3 39.3 LPC(20:5) 
†
 1.42 2.69×10
-4
 -46.8 ± 8.4 -2.23 ± 0.76 
762.5 31.3 PC(34:0) 1.39 1.20×10
-3
 -33.7 ± 7.0 -2.15 ± 0.75 
522.4 39.1 LPC(18:1) 
†
 1.38 4.68×10
-4
 -41.3 ± 7.7 -2.10 ± 0.75 
675.4 35.9 SM(d18:1/14:0) 1.37 5.38×10
-4
 -34.4 ± 6.9 -2.05 ± 0.74 
744.5 31.6 PC(O-34:2) 1.33 6.37×10
-4
 -26.3 ± 5.3 -2.03 ± 0.74 
856.5 29.8 PC(O-42:2) (and PC(42:9)) 1.32 6.97×10
-4
 -33.0 ± 6.9 -1.92 ± 0.73 
752.3 9.7 PE(O-38:5) 1.32 6.24×10
-3
 -24.2 ± 5.8 -1.90 ± 0.72 
832.5 29.9 PC(O-40:0) (and PC(40:7)) 1.32 3.64×10
-2
 -45.3 ± 23.4 -1.91 ± 0.72 
544.4 38.5 LPC(20:4) 
†
 1.29 9.84×10
-4
 -42.6 ± 9.2 -2.06 ± 0.74 
858.5 30.1 PC(O-42:1) (and PC(42:8)) 1.28 1.62×10
-3
 -60.7 ± 15.2 -1.80 ± 0.71 
808.5 30.1 PC(38:5) 1.27 7.92×10
-3
 -23.6 ± 6.1 -1.79 ± 0.71 
808.5 10.7 PE(O- 42:5) 1.25 3.44×10
-3
 -78.1 ± 22.3 -1.76 ± 0.71 
744.4 10.3 PE(36:2) 1.24 1.58×10
-2
 -35.0 ± 10.1 -1.72 ± 0.71 
836.5 29.9 PC(40:5) 1.21 1.47×10
-2
 -33.8 ± 9.8 -1.71 ± 0.70 
520.4 39.4 LPC(18:2) 
†
 1.20 2.05×10
-3
 -28.5 ± 6.7 -1.60 ± 0.69 
 
 
6.2.2. Proposed metabolic interpretation of phospholipid changes 
Our results show, for the first time, that T21 has a significant impact on 2nd T 
maternal plasma PL. The changed LPC, along with ether-linked PC and PE species, 
are known to relate to lipid oxidation processes, seemingly characterizing fetal T21, as 
previously suggested with basis on proteomics (Perluigi et al., 2011). Furthermore, 
decreases in two SM are apparently specific of T21 (compared with pre-PTD and pre-
preeclampsia in Chapter 8, section 8.2), along with a number of decreasing PC. LPC 
species are usually formed due to enzymatic digestion by phospholipase A2, thus 
leading to LPC bearing predominantly saturated fatty acyl chains. Interestingly, in this 
work, although LPC with saturated fatty acyl chains were detected within the plasma 
lipidome (Figure 6.8), the LPC species that showed significant variations between 
controls and T21 were those bearing unsaturated PC. LPC comprising unsaturated 
fatty acyl chains have been identified before in plasma (Quehenberger et al., 2010) and 
may probably arise from the action of phospholipase A1 or to oxidative cleavage by 
metal-catalyzed radical oxidation.  
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Figure 6.8. MS record of LPC TIC region (average RT 38.5–39.8 min) of pooled plasma 
samples of pregnant women: healthy throughout pregnancy (control) and carrying fetuses 
affected by T21. 
 
These results indicated that maternal PL metabolism is exquisitely sensitive to fetal 
T21, although consideration of larger cohorts is necessary for adequate statistical 
validation to be carried out. The PL marker profiles observed seem specific enough to 
enable future uses as complementary diagnosis of T21 to be envisaged, for improved 
prenatal health management. 
 
  
 
Chapter 7. Second trimester maternal plasma for 
prediction of gestational diabetes mellitus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results presented in this chapter were fully submitted for publication in the 
reference below and are here adapted slightly onto the form of a thesis chapter, 
for the sake of clarity: 
Pinto, J.; Almeida, L. M.; Martins, A. S.; Duarte, D.; Barros, A. S.; Galhano, E.; Pita, C.; 
Almeida, M. C.; Carreira, I. M.; Gil, A. M. Prediction of gestational diabetes through 
NMR metabolomics of maternal blood. Journal of Proteome Research 2015, DOI: 
10.1021/acs.jproteome.5b00260. 
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Abstract 
Metabolic biomarkers of pre- and post-diagnosis GDM were sought, using NMR 
metabolomics of maternal plasma and corresponding lipid extracts. Metabolite 
differences between controls and disease were identified through multivariate analysis 
of variable selected 1H NMR spectra. For post-diagnosis GDM, Partial Least Squares 
(PLS) regression identified metabolites with higher dependence on normal gestational 
age evolution. Variable selection of NMR spectra produced good classification models 
for both pre- and post-diagnostic GDM. Pre-diagnosis GDM was accompanied by 
cholesterol increase and minor increases in lipoproteins (plasma), fatty acids and 
triglycerides (extracts). Small metabolite changes comprised variations in glucose (up 
regulated), amino acids, betaine, urea, creatine and metabolites related to gut 
microflora. Most changes were enhanced upon GDM diagnosis, in addition to newly 
observed changes in some small compounds. GDM prediction seems possible 
exploiting multivariate profile changes rather than a set of univariate changes. Post-
diagnosis GDM is successfully classified using a 26-resonance plasma biomarker. 
Plasma and extracts display comparable classification performance, the former 
enabling direct and more rapid analysis. Results and putative biochemical hypotheses 
require further confirmation in larger cohorts of distinct ethnicities. 
 
Brief state of the art  
Given the important risks involved with GDM pregnancies and infants, there is still 
scope for devising earlier and more complete biomarkers of the condition onset and 
development. In recent years, metabolomic studies have searched for metabolic 
biomarkers of GDM by profiling maternal biofluids (blood serum/plasma and urine) and 
fetal/infant samples (amniotic fluid, umbilical cord blood, newborn meconium and 
urine), to obtain fuller descriptions of GDM impact on maternal and fetal metabolisms, 
as reviewed recently (Huynh et al., 2014). Some of these studies have sought 
biomarkers detectable prior to clinical diagnosis, so that women at risk of developing 
GDM may be identified in time to allow improved disease management. A large 
number of studies may be found in relation to post-diagnosis cases, an initial GC-MS 
study revealing an increase in maternal serum total FA and several specific FA (e.g., 
linoleic, arachidonic, docohexaenoic) from controls to slight hyperglycaemia and to 3rd 
trimester GDM, with differences in palmitoleic and docosahexenoic acid levels found 
between hyperglycaemia and GDM (Chen et al., 2010). A subsequent study showed 
higher serum levels of TG, 3-hydroxybutyrate, and Ala, Pro, and branched-chain amino 
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acids (BCAA), and lower 1,5-anhydroglucitol levels, in women with higher fasting 
glucose levels (Scholtens et al., 2014). GDM impact on lipid metabolism was confirmed 
by LC- and GC-MS of maternal plasma, where several lysophospholipids, taurine-bile 
acids and long-chain polyunsaturated FA derivatives were found discriminative of GDM 
and indicative of low-grade inflammation and altered redox-balance (Dudzik et al., 
2014). To our knowledge, no Nuclear Magnetic Resonance (NMR) metabolomics 
characterisation (a more holistic approach, compared to MS) of maternal blood related 
to post-diagnosis GDM has been reported.  
Regarding the search for metabolic alterations in maternal plasma preceding GDM 
diagnosis, NMR of a small cohort detected decreases in TMAO and betaine, 
interpreted as changes in choline-related homocysteine-methionine conversion and 
possible alterations in renal function (Diaz and Pinto et al., 2011). Recently, GC-MS of 
maternal sera unveiled early increases in itaconic acid and cis-aconitate, possibly due 
to inflammation (de Seymour et al., 2014), and a subsequent LC-MS study unveiled 
increases in anthranilic acid, Ala, Glu, Ser and alantoin, and decreased creatinine 
(Bentley-Lewis et al., 2015). The profiling of maternal urine, amniotic fluid, cord serum, 
and newborn urine and meconium has also been performed, a detailed description of 
these studies being found in Chapter 1 (section 1.4.1). 
The present paper presents a NMR metabolomics study of maternal plasma and 
corresponding lipid extracts obtained for a group of pregnant women without clinical 
signs of the disease but who 2-21 g.w. later developed GDM (n=32, pre-diagnosis 
group) and a group of pregnant women at the time of GDM diagnosis (n=12, post-
diagnosis group), in comparison to controls. This adds to a previous smaller cohort 
NMR study of pre-diagnosis GDM (n=14) reported by our own group (Diaz and Pinto et 
al., 2011) and provides a first NMR study of post-diagnosis GDM, to the best of our 
knowledge. In the latter case, GDM and control cases differed in average gestational 
age and, hence, the metabolites related to the normal underlying pregnancy evolution 
were identified prior to determining the post-diagnosis GDM metabolic profile. 
Furthermore, the complementary information provided by whole plasma and lipid 
extract analysis is discussed and sample sensitivity for GDM compared. 
 
7.1. Analysis of whole plasma and lipid extracts 
Figure 7.1 shows the average 1H CPMG NMR spectra of blood plasma for controls, 
pre- and post-diagnosis GDM groups. Some changes are visible for the post-diagnosis 
GDM group, compared to controls (arrows in Figure 7.1c), namely in lipids (CH2)n, Ala, 
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N(CH3)3 choline of PL   d u k  w   es    ce    δ 7 15-7.35, whereas no obvious 
changes are noted for the pre-diagnosis GDM group (Figure 7.1b).  
 
 
 
 
Figure 7.1. Average 500 MHz CPMG 
1
H NMR spectra of plasma of a) controls, b) pre- and c) 
post-diagnosis GDM groups, with indication of spectral variables (data points) selected in the 
corresponding PLS-DA models (grey dots under spectra). 1- CH3 lipids, 2- Val, 3- (CH2)n lipids, 
4- lactate, 5- Ala, 6- CH2C=C lipids, 7- N-acetyl glycoproteins, 8- Gln, 9- pyruvate, 10- citrate, 
11- creatine, 12- creatinine, 13- N(CH3)3 choline of PL, 14- glucose, 15- urea, 16- Tyr, 17- His, 
18- u k  w  (δ 7 15-7.35), 19- formate. Arrows indicate visible alterations. *: cut off spectral 
regions corresponding to water and ethanol peaks. 
Regarding lipid extracts (standard spectra, Figure 7.2), small increases are seen in 
several lipid resonances, from controls to pre-diagnosis and to post-diagnosis GDM 
(Figure 7.2b), the spectra giving a detailed account of the different components of 
plasma lipids and lipoproteins, namely FA (in particular, 18:2 and 20:4), cholesterol 
(free and esterified), TG and PL (in particular, PC and SM). 
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Figure 7.2. a) Average (n=15) 500 MHz 
1
H NMR spectra of plasma lipid extracts of controls 
(top) and post-diagnosis GDM (bottom), with indication of spectral variables selected in the 
corresponding PLS-DA model (grey dots under bottom spectrum); b) spectral expansions of the 
δ 1 23-1 32 (lef )   d δ 5 24-5.44 (right) regions of overlaid average spectra of controls, pre- 
and post-diagnosis GDM. Assignment: 1- C18H3 FC and EC, 2- C26H3 and C27H3 FC and EC, 
3- C19H3 FC, 4- C19H3 EC, 5- (CH2)n FA, 6- =CHCH2(CH2)n FA, 7- CH2CH= FA, 8-CH2CO FA, 
9-CH2CO 22:6 FA, 10- =CHCH2CH= 18:2 FA, 11- =CHCH2CH= 20:4 FA, 12- N(CH3)3 choline 
SM, 13- N(CH3)3 choline PC, 14- CH2N(CH3)3 PC and SM, 15- glyceryl-C3H2 of PL, 16- glyceryl-
C1,3H and –C1,3H’ of TG, 17- glyceryl-C1H2 and CH2-PO PL, 18- C3H EC, 19- glyceryl-C2H 
TG, 20- HC=CH FA, 21- =CH-CHOH SM, 22- Unknow  3 (δ 5 91  b )  
 
Pre-diagnosis GDM vs. controls 
Multivariate analysis was performed for comparison of controls and pre-diagnosis 
GDM groups, matched for gestational age (Table 2.5, Section 2.1.2, page 67). PLS-DA 
of plasma spectra produced non-robust models for both CPMG and diffusion-edited 
spectra (not shown), as revealed by the corresponding low predictive power (Q2), % 
a) 
b) 
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spec. and % sens. given by MCCV (Table 7.1). However, upon variable selection, a 
good model was obtained for CPMG spectra (Figure 7.3a, left), whereas a weaker 
performance was noted when considering the diffusion-edited spectra (Figure 7.3b, left 
and Table 7.1). The lower sensitivities (lower true positive rates, TPR) express the fact 
that several pre-diagnosis GDM cases are, in these models, wrongly classified as 
controls (Figure 7.3a,b left). The grey dots under the CPMG spectrum in Figure 7.1b 
represent the data points selected as main contributors for pre-diagnosis GDM group 
separation from controls in Figure 7.3a. Analysis of the corresponding loadings (Figure 
7.4a) and signal integration enabled peak (and metabolite) variations to be quantified 
and their univariate statistical relevance assessed (Table 7.2).  
 
Table 7.1. MCCV parameters obtained when considering original (full dataset) and variable 
selected 
1
H NMR spectra. LV: no. of latent variables; Q
2
: most frequent value of predictive 
power obtained by MCCV; CR: classification rate; sens: sensitivity; spec: specificity; %VS: 
percentage of variables selected from the original spectra. Values in bold refer to robust PLS-
DA models. 
Subject 
group 
Original spectra Variable selection 
LV Q
2
 CR Sens Spec LV Q
2
 CR Sens Spec % VS 
Controls vs. pre-diagn. GDM         
Whole plasma 
/CPMG 
1 0.1 68% 53% 77% 2 0.5 81% 69% 89% 36% 
Whole plasma 
/Diffusion-ed. 
1 0.3 73% 60% 81% 1 0.2 72% 57% 82% 38% 
Lipid extracts 1 0.3 64% 63% 64% 1 0.5 83% 75% 90% 33% 
Controls vs. post-diagn. GDM         
Whole plasma 
/CPMG 
1 0.4 86% 43% 96% 1 0.6 90% 59% 97% 32% 
Whole plasma 
/Diffusion-ed. 
1 0.5 93% 80% 97% 1 0.7 92% 77% 96% 38% 
Lipid extracts 4 0.6 84% 80% 87% 2 0.7 79% 69% 87% 29% 
 
 
The results show that, several weeks prior to GDM diagnosis (Table 2.5, Section 
2.1.2, page 67), plasma shows a changed profile in low Mw metabolites, comprising 
changes with p < 0.05 for five low Mw compounds (Val↑, Pyr↑, Pro↓, urea↓ and 1,5-
anhydroglucitol↓), in tandem with variation tendencies in Gln (↓), creatine (↓), dimethyl 
sulfone (↓), trimethylamine N-oxide (TMAO) (↓), betaine (↑), lactate (↑) and glucose (↑) 
(Table 7.2).  
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Figure 7.3. PLS-DA scores scatter plots and Volcano plots (effect size vs. – Log (p-value)) of a) 
plasma CPMG 
1
H NMR spectra of controls (, n=49) vs. pre-diagnosis GDM (, n=32) (R2X 
0.29, R
2
Y 0.58), b) plasma diffusion-edited 
1
H NMR spectra of controls (, n=49) vs. pre-
diagnosis GDM (, n=32) (R2X 0.49, R2Y 0.45), and c) lipid extracts 1H NMR spectra of controls 
(, n=15) vs. pre-diagnosis GDM (, n=14) (R2X 0.37, R2Y 0.66). Bet: betaine, FA: fatty acids, 
FC, EC: free and esterified cholesterol, glyc: glyceryl, Lac: lactate, Pyr: pyruvate, TMAO: 
trimethylamine N-oxide, 1,5-AG: 1,5-  hyd  gluc   l  U  3: u k  w  3 (δ 5 91)  3-letter codes 
used for amino acids. 
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Figure 7.4. PLS-DA loading plots of a) CPMG 
1
H NMR spectra of plasma for controls n=49 vs. 
pre-diagnosis GDM n=32, and b) 
1
H NMR spectra of lipid extracts for controls n=15 vs. pre-
diagnosis GDM n=15. 1,5-AG: 1,5-anhydroglucitol, Glyc: glyceryl. 
 
Specific information on lipid changes preceding GDM was obtained considering the 
plasma diffusion-edited spectra and lipid extract spectra (Figure 7.3b,c and Figure 
7.4b), which showed increases in several lipid resonances (cholesterol, HDL and 
LDL+VLDL). Out of the variations listed above, Bonferroni correction of p-values 
identified the increase in the C18H3 cholesterol resonance (measured in diffusion-
edited spectra) as the only statistically relevant change (f in Table 7.2, symbol above 
the p<1.7×10-3 threshold in Figure 7.3b, right), in pre-diagnosis GDM. STOCSY results 
(not shown) determined that this cholesterol resonance originates from free and/or 
esterified forms of HDL and LDL+VLDL cholesterol. The PLS-DA model obtained for 
lipid extracts (Figure 7.3c, Table 7.1) indicated additional small increases in FA and TG 
glyceryl resonances, along with a decrease in unknown 3 ( 5.91) (Table 7.3).  
Notably, when recalculating the CPMG PLS-DA model using the integral values 
found to change significantly (p < 0.05), instead of the full resolution (variable selected) 
spectra, no robust PLS-DA group separation was obtained, which thus indicates that 
spectral detail (often not expressible by discrete peak integrals) seems to hold 
enhanced classification power for pre-diagnosis GDM, compared to a limited set of 
peak integrals, with residual univariate statistical relevance.  
a) 
b) 
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Table 7.2. List of metabolites/resonances selected in the NMR spectra of blood plasma as 
important for discrimination of pre- and post-diagnosis GDM from controls. 
a
 Chemical shifts of 
signals used for integration; s: singlet, d: doublet, dt: doublet of triplets, q: quartet, m: multiplet, 
br: broad. 
b
 E.S.: effect size determined as described in (Berben et al., 2012); values  in 
brackets correspond to  high uncertainties. 
c
 95% significance level (p-value < 0.05); only values 
with statistical relevance are specified. 
d
 Integrals measured in the CPMG spectra and 
e
 in the 
diffusion-edited spectra. 
f
 Alterations remaining significant after Bonferroni correction, with cut-
off p-value of 1.7×10
-3
 (0.05 divided by 29 resonances) and 1.3×10
-3
 (0.05 divided by 38 
resonances) for pre- and post-diagnosis GDM, respectively. † Alterations with a possible 
contribution of normal gestational age evolution. 
Compound 
Chemical 
shift (ppm) 
a
 
Pre-diagn. GDM (n=32) 
vs. controls (n=49) 
Post-diagn. GDM (n=12) 
vs. controls (n=49) 
E.S. 
b
 p-value 
c
 E.S. 
b
 p-value 
c
 
Low Mw compounds 
d
     
Valine 1.03 (d) ↑ (0 38 ± 0 46) 2.6×10
-2
 ↓  4.5×10
-2
 
Alanine 1.47 (d)   ↓ -0.65 ± 0.64  5.0×10
-2
 
Pyruvate 2.36 (s) ↑ 0 49 ± 0 46 4.5×10
-2
 ↓ -0.74 ± 0.65 4.4×10
-3
 
Glutamine 2.44 (m) ↓ >0.05 ↓ -1.27 ± 0.67  2.0×10
-5 f
 
Citrate 2.52 (d)   ↓ >0.05 
Creatine 3.03 (s) ↓ >0.05 ↓ >0.05 
Creatinine 3.04 (s)   ↓ -1.69 ± 0.70  3.5×10
-9 f
 
Dimethylsulfone 3.14 (s) ↓ >0.05 ↓ >0.05 
TMAO 3.27 (s) ↓ >0.05 ↓ -0.86 ± 0.65  4.8×10
-3
 
Betaine 3.29 (s) ↓ >0.05 ↓ -1.40 ± 0.68  3.5×10
-8 f
 
Proline 3.34 (dt) ↓ -0.53 ± 0.46 2.1×10
-2
 ↓ -1.33 ± 0.68  2.0×10
-5 f
 
Methanol 3.36 (s)   ↓ -1.18 ± 0.67  9.4×10
-6 f
 
Glycine 3.55 (s)   ↓  4.6×10
-3
 
1,5-anhydroglucitol 3.95-4.00 (dd) ↓ -0.48 ± 0.46 3.5×10
-2
   
Lactate 4.11 (q) ↑ >0.05 ↓ >0.05 
Glucose 5.23 (d) ↑ >0.05 ↓ -0.96 ± 0.66  1.3×10
-3 f
 
Urea 5.77 (br) ↓ -0.58 ± 0.46 2.1×10
-2
   
Unknown 1 7.15-7.35 (br)   ↑ 1 62 ± 0 70  4.6×10
-5 f
 
High Mw compounds
 e
     
C18H cholesterol 0.67 (br) ↑ 1 23 ± 0 49 1.0×10
-6 f
 ↑ 1 35 ± 0 68  2.2×10
-5 f
 
CH3 lip. HDL 0.79-0.85 (br) ↑ 0 60 ± 0 46 8.5×10
-3
 ↑ 1 47 ± 0 68  1.3×10
-6 f
 
CH3 lip. LDL+VLDL 0.85-0.91 (br) ↑ 0 82 ± 0 47 4.2×10
-3
 ↑ 2 54 ± 0 78  1.1×10
-5 f
 
(CH2)n lip. HDL 1.18-1.25 (br) ↑ 0 60 ± 0 46 8.8×10
-3
 ↑ 1 38 ± 0 68  4.0×10
-5 f
 
(CH2)n lip. LDL+VLDL 1.25-1.37 (br) ↑ 0 69 ± 0 46 3.1×10
-2
 ↑ 1 87 ± 0 71  9.7×10
-4 f
 
CH2CH2CO lip. 1.45-1.62 (br) ↑ 0 56 ± 0 46 2.5×10
-2
 ↑ 1 50 ± 0 68  4.0×10
-5 f
 
CH2CH= lip. 1.90-2.02 (br) ↑ 0 65 ± 0 46 9.2×10
-3
 ↑ 2 37 ± 0 76  4.8×10
-9 f
 
CH2CO lip. 2.17-2.26 (br) ↑ >0.05 ↑ 1 49 ± 0 68  1.1×10
-4 f
 
=CHCH2CH= lip. 2.65-2.84 (br) ↑ >0.05 ↑ 1 29 ± 0 66  5.6×10
-4 f
 
N(CH3)3 chol. HDL 
d,
 
†
 3.19-3.205 (br)   ↓ -1.15 ± 0.67  1.9×10
-3
 
N(CH3)3 chol. LDL+VLDL 3.23-3.26 (br) ↑ >0.05 ↑ 2 24 ± 0 75  1.7×10
-7 f
 
CH2N(CH3)3 chol. 
†
 3.62-3.68 (br)   ↑ 1 29 ± 0 67
 
 2.1×10
-5 f
 
Unknown 2 3.84-3.92 (br)   ↑ 1 72 ± 0 70  1.2×10
-5 f
 
Glyceryl-C1,3H 
†
 4.02-4.10 (br)   ↑ 1 00 ± 0 66  2.3×10
-2
 
Glyceryl-C1 3H’ 4.21-4.32 (br)   ↑ 1 88 ± 0 71  2.8×10
-7 f
 
HC=CH HDL 5.24-5.28 (br) ↑ 0 54 ± 0 46 2.4×10
-2
 ↑ 1 71 ± 0 70  3.8×10
-5 f
 
HC=CH LDL+VLDL 5.28-5.37 (br) ↑ 0 63 ± 0 46 1.0×10
-2
 ↑ 1 55 ± 0 69  1.7×10
-6 f
 
(CH2)n/CH3 lip. HDL  ↑ >0.05 ↑ >0.05 
HC=CH/CH3 lip. HDL  ↑ >0.05 ↑ 1 30 ± 0 67  1.2×10
-3 f
 
(CH2)n/CH3 lip. 
LDL+VLDL 
†
 
 ↑ >0.05 ↑ 0 85 ± 0 65  3.8×10
-2
 
HC=CH/CH3 lip. 
LDL+VLDL 
 ↑ >0.05 ↑ >0.05 
CH3 HDL/CH3 
LDL+VLDL 
 ↓ >0.05 ↓ -1.30 ± 0.67 
 
2.4×10
-3
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Post-diagnosis GDM vs. controls 
Upon GDM diagnosis, separation from controls was clearer in PLS-DA and models 
were good for both CPMG and diffusion-edited spectra of plasma (Figure 7.5a,b), as 
well as for lipid extracts (Figure 7.5c), with or without variable selection (Table 7.1). The 
larger impact of post-diagnosis GDM on plasma composition, compared to that of the 
pre-diagnosis GDM group, is illustrated in the loading plots (Figure 7.6) and in a longer 
list of significant metabolite variations, both in plasma (Table 7.2) and lipid extracts 
(Table 7.3), including upon Bonferroni correction.  
 
Table 7.3. List of metabolites/resonances selected in the NMR spectra of plasma lipid extracts 
as important for discrimination of pre- and post-diagnosis GDM from controls. 
a,b,c 
as defined in 
Table 7.2 caption. 
d
 Alterations remaining significant after Bonferroni correction, cut-off p-value 
of 3.1×10
-3
 (0.05 divided by 16 resonances) and 2.8×10
-3
 (0.05 divided by 18 resonances) for 
pre- and post-diagnosis GDM, respectively. 
Compound 
Chemical 
shift (ppm) 
a
 
Pre-diagn. GDM (n=14) 
vs. controls (n=15) 
Post-diagn. GDM (n=12) vs. 
controls (n=15) 
E.S. 
b
 p-value 
c
 E.S. 
b
 p-value 
c
 
Fatty acids (FAs)      
CH3 0.89 (t)  ↑ 0 69 ± 0 53  1.2×10
-2
 ↑ 1 25 ± 0 59 
d
 8.5×10
-5
 
d
 
(CH2)n 1.20-1.27 (br)  ↑ 0 62 ± 0 53  2.4×10
-2
 ↑ 0 94 ± 0 57  1.6×10
-3 d
 
=CHCH2(CH2)n 1.27-1.40 (br)  ↑ 0 69 ± 0 53  1.1×10
-2
  ↑ 1 21 ± 0 58  4.4×10
-4 d
 
CH2CH2CH=  1.93-2.02 (m)  ↑ 0 55 ± 0 52  4.1×10
-2
  ↑ 1 21 ± 0 58  1.5×10
-4 d
 
CH2CH= 18:2 FA 2.05 (q)    ↑ 0 68 ± 0 55  2.4×10
-2
 
CH2CO 2.28-2.34 (m)  ↑ 0 78 ± 0 53  4.8×10
-3
  ↑ 1 26 ± 0 59  9.7×10
-5 d
 
=CHCH2CH= 18:2 FA  2.77 (t)    ↑ 0 62 ± 0 55  4.0×10
-2
 
HC=CH 18:2 FA  5.29-5.35 (m)  ↑  >0.05  ↑ 0 98 ± 0.57  5.3×10
-3
 
HC=CH 20:4 FA  5.35-5.43 (m)  ↑  >0.05  ↑ 0 74 ± 0 55  5.7×10
-3
 
Free cholesterol (FC) and esterified cholesterol (EC)    
C18H3 FC & EC 0.68 (s)  ↑  >0.05  ↑ 0 73 ± 0 55  2.0×10
-2
 
C26H3 FC & EC 0.86 (d)  ↑  >0.05  ↑ 0 72 ± 0 55  2.1×10
-2
 
C19H3 FC  1.01 (s)  ↑  >0.05  ↑ 0 76 ± 0 56  1.5×10
-2
 
C19H3 EC  1.02 (s)  ↑  >0.05  ↑ 0 69 ± 0 55  2.7×10
-2
 
C4H2 EC  2.26 (t)  ↑  >0.05  ↑ 0 60 ± 0 55  4.8×10
-2
 
C3H EC  4.61 (m)  ↑  >0.05  ↑ (0 42 ± 0.52) >0.05  
Triglycerides (TGs)      
Glyceryl-C1,3H  4.14 (dd)  ↑ 0 56 ± 0 53  3.6×10
-2
  ↑ 1 12 ± 0 58  7.2×10
-5 d
 
Glyceryl-C1,3H’  4.29 (dd)  ↑ 0 61 ± 0 53  4.2×10
-2
  ↑ 1 07 ± 0 57  5.1×10
-4 d
 
Unknown 3 5.91 (br) ↓ -0.69 ± 0.53  1.2×10
-2
  ↓ -0.73 ± 0.55  1.0×10
-2
 
 
 
Variations comprise a general decrease in several low Mw compounds (with the 
exception of unknown 1, at  7.15-7.35, seen to increase) and marked increases in 
lipids (Figure 7.5). However, these changes may have some contribution from the 
gestational age difference between controls (average 17 g.w.) and post-diagnosis GDM 
(average 26 g.w.), so that such dependence needs to be quantified in order for a 
trustworthy profile of GDM alone to be obtained. 
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Figure 7.5. PLS-DA scores scatter plots and Volcano plots (effect size vs. – Log (p-value)) of a) 
plasma CPMG 
1
H NMR spectra of controls (, n=49) vs. post-diagnosis GDM (, n=12) (R2X 
0.35, R
2
Y 0.69), b) plasma diffusion-edited 
1
H NMR spectra of controls (, n=49) vs. post-
diagnosis GDM (, n=12) (R2X 0.47, R2Y 0.73), and c) lipid extracts 1H NMR spectra of controls 
(, n=15) vs. post-diagnosis GDM (, n=12) (R2X 0.28, R2Y 0.72). Bet: betaine, Crn: 
creatinine, EC: esterified cholesterol, FC: free cholesterol, FA: fatty acids, glyc: glyceryl, Glc: 
glucose, MeOH: methanol, Pyr: pyruvate, TG: triglycerides, TMAO: trimethylamine N-oxide, Un 
1: u k  w  1 (δ 7 15-7 35)  U  3: u k  w  3 (δ 5 91)  3-letter codes used for amino acids. 
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Figure 7.6. PLS-DA loading plots of a) CPMG 
1
H NMR spectra of plasma for controls n=49 vs. 
post-diagnosis GDM n=12, and b) 
1
H NMR spectra of lipid extracts for controls n=15 vs. post-
diagnosis GDM n=12. Crn: creatinine, Glc: glucose, Glyc: glyceryl, Lac: lactate, Pyr: pyruvate, 
U  1: u k  w  1 (δ 7 15-7.35). 3-Letter codes used for amino acids. 
 
Therefore, a PLS regression was performed between gestational age and peak 
integrals (with p < 0.05), including lipid ratios HDL/(LDL+VLDL) and average FA chain 
length ((CH2)n/CH3) and unsaturation degree (HC=CH/CH3), since these parameters 
have previously been found to change across pregnancy (Pinto et al., 2014b). The 
resulting low coefficient of determination (R2 0.56) (Figure 7.7a) indicated that the set of 
resonances/ratios correlate poorly with gestational age, in the range considered (16-27 
g.w.), thus rendering this as a low-impact variable. For lipid extracts composition, no 
dependence on gestational age was observed (R2 0.29, results not shown). The 
plasma resonances/ratios having a higher time-dependence, across 16-27 g.w., were 
identified through their b-coefficient values and are situated above the limit of 
│b/bcvSE│= 1 (Figure 7.7b). Among these, a subset of 10 resonances/ratios variations 
had indeed been observed between 2nd and 3rd trimesters of healthy pregnancies(Pinto 
et al., 2014b) (* in Figure 4b). However, some of those resonances (namely, C18H3 
cholesterol; HDL CH3; LDL+VLDL CH3, (CH2)n and N(CH3)3 choline; and CH2C=C of 
FAs) were also seen to change in the matched group of pre-diagnosis GDM (Table 
7.2), which thus shows that their variation, is at least in part, disease dependent. The 
remaining 4 resonances/ratios (two choline resonances at  3.19-3.21 (HDL) and 
b) 
a) 
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3.62-3.68; glyceryl-C1,3H resonance at  4.02-4.10 and average FA chain length of 
LDL+LVDL), not noted to change in the matched group, may indeed have a 
contribution from normal gestational age evolution († Figure 7.7b, Table 7.2), and 
hence will not be considered as part of the GDM profile. Therefore, we interpret 
variations in the remaining resonances listed in Table 7.2 as part of the post-diagnosis 
GDM fingerprint, including those seen to vary due to pregnancy evolution from 16 to 27 
g.w. (with │b/bcvSE│≥ 1 in Figure 7.7b), but as a result of the disease, specifically: 
be    e  Al   TMA   me h   l       c e      e   d u k  w s 1 (δ 7 15-7 35)   d 2 (δ 
3.84-3.92).  
 
 
   
Figure 7.7. PLS regression (LV=2) a) scatter plot of original vs. predicted gestational weeks and 
b) b-coefficients of varying metabolites/resonances, for post-diagnosis GDM compared to 
controls. 
a
 ratio with │b/bcvSE│<1. * Metabolite variations observed from 2
nd
 to 3
rd
 trimesters of 
healthy pregnancies
 
(Pinto et al., 2014b), † resonances/ratios with possible contributions from 
normal gestational age evolution. 
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Finally, PLS-DA recalculation using the integrals of relevant variations only (p < 
0.05) (26 resonances altogether, Table 7.2) provided a model with comparable 
robustness (Q2 0.6, sens 68%, spec 95%) to that of the model obtained with full 
resolution variable selected spectra (Table 7.1), thus indicating that a fingerprint 
composed of such a set of 26 peaks seems sufficiently strong to correctly classify 
diagnosed GDM samples.  
 
7.2. Proposed metabolic interpretation of plasma changes 
This work shows that pre-diagnosis GDM stages (2-21 g.w. prior to diagnosis) 
involve early metabolic variations (blue arrows in Figure 7.8), detectable in both 
maternal plasma and corresponding lipid extracts and showing good predictive power 
when measured through part of the full resolution NMR spectrum, irrespectively of low 
individual metabolite (univariate) statistical relevance. The noted increase in free and/or 
esterified cholesterol in plasma was accompanied by smaller increases in plasma HDL, 
LDL+VLDL lipoproteins and, viewed through lipid extracts, FA (e.g., 18:2 and 20:4) and 
TG, thus evidencing early disturbances in lipid metabolism (Figure 7.8). Lipid 
disturbances in pre-diagnostic GDM have been previously suggested through 
increased TG in serum (dos Santos-Weiss et al., 2013), although other studies have 
noted the absence of significant variations in total cholesterol, HDL, LDL and TG in 
plasma (Emet et al., 2013) and serum (Bentley-Lewis et al., 2015) (the latter study 
reporting, however, a small TG increase). The metabolite profile of pre-diagnosis GDM 
also comprised a small increase in glucose (possibly related to the observed lower 
levels of 1,5-anhydroglucitol (Christensen and Williams, 2009)) and some glycolytic 
and Krebs cycle metabolites (pyruvate, lactate), observed for the first time to our 
knowledge in pre-diagnosis GDM. Additionally, the particular pattern of amino acid 
variations (Gln, Pro and Val) differs from a recent report (Bentley-Lewis et al., 2015) of 
alterations in Ala, Glu and Ser. Other observed changes may stem from deregulation of 
gut microflora (trimethylamine (TMA)/TMAO, dimethyl sulfone and methanol), 
homocysteine-methionine conversion (betaine) and urea cycle (urea and creatine) 
(Figure 7.8). Betaine and TMAO decreases match those observed before in a smaller 
cohort (Diaz and Pinto et al., 2011), the latter metabolite having, in a separate study 
(Wang et al., 2011), been identified as arising from gut microflora. Indeed, a 
contribution from gut microbiota to the development of low-grade inflammation has 
been reported for type 2 diabetes (Everard and Cani, 2013). A recent report detected a 
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decrease in creatinine in pre-diagnosis GDM (Bentley-Lewis et al., 2015) but, to our 
knowledge, no changes in creatine or urea have been observed before.  
 
 
 
Figure 7.8. Schematic representation of the metabolic pathways possibly affected in pre- (blue 
arrows) and post-diagnosis GDM (red arrows). Thicker arrows indicate alterations remaining 
significant after Bonferroni correction. BHMT: betaine homocystein methyltransferase, DMG: 
dimethylglycine, FMOs: flavin-containing monooxygenases, GAA: guanidinoacetate, Hcy: 
homocysteine. 3-letter codes used for amino acids. 
 
Many of the changes observed in the pre-diagnosis GDM group were intensified at 
the time of diagnosis (red arrows in Figure 7.8), whereas new variations were noted for 
Ala, Gly, citrate, creatinine and methanol. Since control and post-diagnosis GDM 
groups presented a small difference in gestational age, evaluation of metabolite 
variations as to their dependence on this parameter revealed that some PL and 
glyceryl resonances may have a stronger influence of normal gestational age evolution 
so these were, hence, left out of a putative GDM profile; the same applied to changes 
seen in average FA chain length of LDL+VLDL lipoproteins. Overall, GDM-related 
metabolite changes were found to be either independent of gestational age or to have 
time-dependences (within 16-27 g.w.) determined by the disease. A surprising 
observation related to the diminished glucose in post-diagnosis GDM subjects, with 
clear reversed impacts on pyruvate and lactate (Figure 7.8). This contradicts previous 
reports on GDM groups (Dudzik et al., 2014; Huynh et al., 2014), although a study has 
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reported no change in glucose (Tarim et al., 2004) and a decrease in this sugar has 
been observed in umbilical cord blood of GDM-born infants (Dani et al., 2014). A 
glucose decrease may be explained by the fact that subjects were informed of GDM 
diagnosis approximately two weeks prior to sample collection having, probably, 
privately adopted lower sugar diets prior to the formal layout of the GDM management 
scheme. Subsequent studies should therefore involve sample collection no later than 
the day of diagnosis, as actually carried out in some studies (Dudzik et al., 2014). The 
impact of glucose reversal seems to affect lactate and pyruvate but other changes, 
namely on lipids, cholesterol, amino acids (with the exception of Val) are maintained 
from pre-diagnosis GDM and, in many cases, intensified thus showing that most of the 
disease effects seem to remain, in spite of the glucose-related adaptation. In fact, the 
marked increases in lipid moieties are consistent with previous reports of increased 
TG, FA and cholesterol (Huynh et al., 2014). Regarding the decreases in amino acids 
which help replenish Krebs cycle substrates (Gln, Pro, Val, Ala and Gly), all have been 
seen to vary in different studies of GDM (Huynh et al., 2014), albeit somewhat 
inconsistently. Furthermore, changes in gut microflora metabolites (including TMA 
conversion to TMAO) are maintained from the early stages of GDM, whereas both 
creatine and creatinine are decreased (the latter having been seen to change 
differently in distinct GDM cohorts (Everard and Cani, 2013; Dudzik et al., 2014; 
Scholtens et al., 2014)), with urea remaining unchanged, contrary to pre-diagnosis 
GDM.  
 
7.3. Conclusions 
This work enabled some considerations to be drawn in relation to possible future 
applications of NMR metabolomics in clinical GDM management. Firstly, analysis of 
plasma seems preferable to lipid extracts, for both pre- and post-diagnosis GDM, since 
classification performance was comparable for both sample types and direct plasma 
analysis avoids time-consuming extraction protocols, with less than ideal 
reproducibility. Furthermore, pre-diagnosis GDM recognition should involve the 
definition of an early biomarker profile as a full resolution subset of the CPMG 1H NMR 
spectra, rather than of a discrete set of metabolites, as shown by the higher 
classification power of the former. This concept of a spectral marker accommodates 
the assumption of metabolite inter-dependence and multivariate nature of the 
metabolite profile used to recognize the early stages of GDM. On the other hand, for 
post-diagnosis GDM, a robust profile of 26 resonances (corresponding to 10 
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metabolites and lipids) may be defined to describe the condition, as viewed by NMR, 
thus advancing the possibility of using a multi-metabolite biomarker of GDM as a 
complementary tool in the clinical management of the disease. In the follow-up of this 
work, it is important that the putative metabolic disturbances hereby suggested to relate 
to pre- and post-diagnosis GDM may be demonstrated in larger cohorts and by 
complementary biochemical methods. In addition, issues such as improving inter-
laboratory consistency of experimental design and data handling protocols, as well as 
considering populations of different ethnicity, would greatly contribute to resolving 
apparent discrepancies between existing studies and understanding possible cohort-
dependent responses to GDM.  
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Part of the results presented in this chapter were published in the article below 
and are here adapted slightly onto the form of a thesis chapter, for the sake of 
clarity:  
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Trisomy 21 Cases and prior to Preeclampsia and Preterm Outcomes. Rapid 
Communications in Mass Spectrometry 2014, 28, 1635–1638. 
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8.1. Fetal malformations  
The work presented in this subchapter aims to explore the potential of 2nd T 
maternal plasma to detect metabolic deviations due to fetal malformations (FM) using 
the whole 1H NMR blood metabolome. Samples metadata is shown in Chapter 2 
(Section 2.1.2, Table 2.6  and Table 2.7). The results shown here were not subjected to 
publication. 
8.1.1. Analysis of whole plasma by NMR spectroscopy 
Figure 8.1 shows the average CPMG 1H NMR spectra of controls and FM samples. 
The visual comparison of these spectra revealed subtle changes (arrows in Figure 
8.1b) mainly in acetone, acetoacetate, citrate and formate. PCA of the CPMG 1H NMR 
spectra of 2nd T blood plasma of controls vs. FM samples (not shown) unveiled no 
trends and the corresponding PLS-DA model had poor performance (Q2 0.1, CR 70%, 
sens. 55%, spec. 79%). In addition, PCA and PLS-DA of the standard and diffusion-
edited spectra unveiled no trends. 
 
Figure 8.1. Average 500 MHz CPMG 
1
H NMR spectra of 2
nd
 T plasma of a) controls and b) FM, 
with indication of spectral variables (data points) selected in the corresponding PLS-DA models 
(grey dots under spectra). 1- CH3 lipids, 2- valine, 3- (CH2)n lipids, 4- lactate, 5- alanine, 6- N-
acetyl glycoproteins, 7- acetone, 8- acetoacetate, 9- pyruvate, 10- glutamine, 11- citrate, 12- 
albumin-lysyl, 13- creatine, 14- creatinine, 15- glucose, 16- urea, 17- histidine, 18- tyrosine, 19- 
unknown 1 ( 7.20-7.39), 20- formate. *: cut off spectral region corresponding to water. Arrows 
indicate visible alterations. 
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Variable selection was applied to the CPMG 1H NMR spectra and the subsequent PLS-
DA model (Figure 8.2a left) was indeed much improved (Q2 0.5, CR 81%, sens. 72%, 
spec. 87%, Figure 8.3a). The grey dots under the CPMG spectrum in Figure 8.1a 
represent the data points selected as main contributors for FM group separation from 
controls in Figure 8.2a. Computed metabolite changes (Table 8.1) showed that FM 
samples carry lower amounts of urea and N(CH3)3 choline of LDL+VLDL, and 
increased levels of -hydroxybutyrate, citrate and acetoacetate, as well as qualitative 
decrease in methanol and increases in N-acetyl glycoproteins, acetone, albumin-lysyl, 
pyruvate, CH3 lipids of LDL+VLDL and lactate, as clearly seen in the Volcano plot 
(Figure 8.2a right). 
 
  
 
 
 
 
Figure 8.2. PLS-DA scores scatter plots and Volcano plots (effect size vs. – Log (p-value)) of 
plasma CPMG 
1
H NMR spectra of a) controls (, n=47) vs. FM (, n=37) (R2X 0.14, R2Y 0.77), 
and b) CNS (, n=13) vs. other FM (, n=24) (R
2
X 0.23, R
2
Y 0.87). AcAc: acetoacetate, Alb: 
albumin-lysyl, Act: acetone, cit: citrate, For: formate, N-ac. glycop: N-acetyl glycoproteins, -HB: 
-hydoxybutyrate, Lac: lactate, Pyr: pyruvate, Un1: unknown 1 ( 7.20-7.39). 3-letter codes 
used for amino acids. 
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When comparing CNS cases with other FM cases, the PCA of CPMG 1H NMR 
spectra revealed no trends (not shown) and the corresponding PLS-DA model had 
poor performance (Q2 0.1, CR 62%, sens. 79%, spec. 32%). The PLS-DA model 
(Figure 8.2b left) obtained after variable selection was much improved (Q2 0.5, CR 
84%, sens. 94%, spec. 66%, Figure 8.3b). The other FM group includes different 
malformation types (as described in Chapter 2, section 2.1.2, Table 2.7), namely 
cardiac (n=7), polimalformations (n=6), limbs (n=4), urogenital (n=3) and other types 
(n=4). Subsequent loadings inspection (not shown) and signal integration unveiled that 
CNS malformations have a distinct profile compared with other FM comprising changes 
with statistical relevance (p < 0.05) in glycerol (↓) and N-acetyl glycoproteins (↓), 
tandem with variation tendencies in pyruvate (↓), acetate (↓), CH3 and choline HDL (↑), 
valine (↑), alanine (↑) and lactate (↑) (Figure 8.2b right).   
a) Controls (n=47) vs. FM (n=36) – CPMG spectra after variable selection 
  
b) CNS (n=13) vs. other FM (n=24) – CPMG spectra after variable selection 
  
Figure 8.3. Q
2
 distributions (left) and ROC plots (right) of true and permuted models obtained 
for CPMG 
1
H NMR spectra of whole blood plasma after variable selection of a) controls (n=47) 
vs. FM (n=37) and b) CNS (n=13) vs. other FM (n=24). 
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Table 8.1. List of metabolites/resonances selected in the 
1
H CPMG NMR spectra of blood 
plasma as important for discrimination of FM from controls and CNS from other FM. 
a
 Chemical 
shifts of signals used for integration; s: singlet, d: doublet, dd: doublet of doublets, q: quartet, br: 
broad. 
b
 E.S.: effect size determined as described in (Berben et al., 2012). 
c
 95% significance 
level (p < 0.05); only values with statistical relevance are specified. 
Compound 
Chemical 
shift (ppm) 
a
 
FM (n=36) vs.  
controls (n=47) 
CNS (n=13) vs.  
other FM (n=24) 
E.S. 
b
 p-value 
c
 E.S. 
b
 p-value 
c
 
CH3 HDL 0.79-0.86 (br)   ↑ > 0.05 
CH3 LDL+VLDL 0.86-0.91 (br) ↑ > 0.05   
Valine 1.03 (d)   ↑ > 0.05 
-hydroxybutyrate 1.19 (d) ↑ 0 76 ± 0 45  1.50×10
-3
   
Alanine 1.45 (d)   ↑ > 0.05 
N-acetyl glycoproteins 2.03 (s)   ↓ -0.77 ± 0.70 4.27×10
-2
 
Acetone  2.22 (s) ↑ > 0.05 ↓ > 0.05 
Acetoacetate 2.27 (s) ↑ 0 55 ± 0 45 3.01×10
-2
   
Pyruvate 2.36 (s) ↑ > 0.05 ↓ > 0.05 
Citrate 2.52 (d) ↑ 0 62 ± 0 45 3.63×10
-3
   
Albumin-lysyl 2.92-3.03 (br) ↑ > 0.05   
N(CH3)3 cho. HDL 3.18-3.22 (br)   ↑ > 0.05 
N(CH3)3 cho. LDL+VLDL 3.22-3.24 (br) ↓ -0.47 ± 0.44 4.44×10
-2
   
Methanol 3.36 (s) ↓ > 0.05   
Glycerol 3.65 (dd)   ↓ -0.98 ± 0.71 2.01×10
-3
 
Lactate 4.11 (q) ↑ > 0.05 ↑ > 0.05 
Urea  5.77 (br) ↓ -0.55 ± 0.45 1.66×10
-2
 ↑ > 0.05 
Unknown 7.20-7.39 (br) ↑ > 0.05 ↑ > 0.05 
Formate 8.45 (s) ↑ > 0.05 ↓ > 0.05 
 
When recalculating the CPMG PLS-DA model using the integral values found to 
change significantly (p < 0.05), instead of the full resolution (variable selected) spectra, 
no reliable PLS-DA group separation was achieved for both controls vs. FM and CNS 
vs. other FM. This finding indicates that spectral detail (full spectral resolution) needs to 
be taken into account in order to achieve enhanced classification power, compared to a 
limited set of peak integrals, as previously observed for other disorders.  
 
8.1.2. Proposed metabolic interpretation of plasma changes  
The metabolic alterations found in 2nd T maternal plasma of pregnant women 
carrying malformed fetuses were consistent with previously observed changes in a 
lower cohort (25 controls and 26 FM) (Diaz and Pinto et al., 2011), namely in increased 
levels of CH3 of lipids, ketone bodies (-hydroxybutyrate, acetone and acetoacetate) 
and a decreased tendency for methanol. The increased levels of ketone bodies may 
reflect an increased oxidation of fatty acids in liver and ketone bodies transfer through 
blood for conversion to acetyl-CoA and oxidation in the TCA cycle for energy 
production in extra-hepatic tissues. Alterations in ketone bodies consistent with lipid 
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oxidation were also found for 2nd T maternal urine of FM cases (Diaz et al., 2013b), 
along with changes in carnitine and other metabolites in 2nd T amniotic fluid (Graça et 
al., 2012b). Interestingly in this work, two resonances from LDL+VLDL were seen to 
change in FM cases but in opposite directions, while the CH3 resonance from total fatty 
acids tended to increase, the N(CH3)3 resonance from phospholipids showed a 
decrease tendency. This suggests a depletion of phospholipids in LDL+VLDL particles, 
seen here for the first time to our knowledge. For congenital heart defects, lower levels 
of phospholipids (including several PC, LPC and SM) have been reported for 1st T 
maternal deproteinized serum by LC-MS/MS (Bahado-Singh et al., 2014). Regarding 
the decreasing tendency of methanol, consistent with our previous report (Diaz and 
Pinto et al., 2011), a possible explanation may be related with alterations in gut 
microflora (Komarova et al., 2014).  
Novel alterations in 2nd T maternal plasma of FM cases comprised the increase in 
pyruvate, lactate, formate, citrate, albumin, and the unknown resonance at  7.20-7.39, 
as well as the decrease in urea levels. The increasing tendency of pyruvate, lactate 
and formate suggests enhanced glycolysis consistent with the glucose depletion 
observed in amniotic fluid (Graça et al., 2010). In addition, increased levels of citrate 
seem to reflect its underuse in TCA cycle. Alterations in pyruvate and lactate levels in 
1st and 2nd T maternal sera were observed before for NTD cases but in the opposite 
direction suggesting a reduction in glycolysis activity (Zheng et al., 2011). An increased 
tendency for albumin may suggest increased protein biosynthesis, which has also been 
previously found in amniotic fluid (Graça et al., 2010).  Relevant changes were also 
observed for urea levels (lower), possibly reflecting alterations in urea cycle and/or in 
renal function. Alterations in renal function were found before in 2nd T amniotic fluid of 
FM cases (Graça et al., 2010), whereas for 2nd T maternal urine no changes were 
reported . 
CNS malformations showed a distinct plasma metabolic profile when compared to 
other FM types. Statistically significant changes comprise the decrease in glycerol and 
N-acetyl glycoproteins, while only qualitative changes were observed for HDL (CH3 and 
N(CH3)3 choline resonances), valine, alanine, acetone, pyruvate, lactate, urea, formate 
and unknown resonance at  7.20-7.39. Changes in valine and lipid profile in CNS, 
compared with the remaining malformations, are consistent with our previous report 
(Diaz and Pinto et al., 2011). Novel alterations include the lower levels of glycerol, 
possibly reflecting enhanced glycerolipid metabolism with glycerol utilization to form TG 
and other glycerolipids. Other significant change found in this work is the decrease in 
N-acetyl glycoproteins metabolism suggesting a decrease in synthesis of a number of 
p   e  s (α1- c d glyc p   e    α1-antitrypsin and haptoglobulin (Torri et al., 1999)), not 
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previously observed for CNS malformations. Furthermore, reversed variations were 
seen for acetone, pyruvate, formate and urea in CNS vs. other FM compared with 
controls vs. FM, suggesting a possible lower contribution of CNS cases for ketone body 
synthesis, enhanced glycolysis and alterations in urea cycle or renal function.    
 
8.2. Pre-premature rupture of membranes (pre-PROM) 
In this subchapter, the possibility of predicting PROM (here named pre-PROM), 
occurring after the 37th g.w., through 2nd T maternal plasma was attempted by 
comparing samples collected 19-24 g.w. before the PROM diagnosis with controls. A 
more complete description of samples is shown in Chapter 2 (Section 2.1.2., Table 
2.6). The results shown here were not published. 
8.2.1. Analysis of whole plasma by NMR spectroscopy 
Figure 8.4 shows the average CPMG 1H NMR spectra of controls and pre-
diagnosis PROM (pre-PROM) where no visible changes are noted for pre-PROM 
group. A strong impact of pre-PROM on maternal plasma metabolome is not expected 
since this condition is an integral part of the normal parturition process at term without 
posing significant risks for mother and fetus.  
 
Figure 8.4. Average 500 MHz CPMG 
1
H NMR spectra of 2
nd
 T plasma of a) controls and b) pre-
PROM, with indication of spectral variables (data points) selected in the corresponding PLS-DA 
models (grey dots under spectra). 1- CH3 lipids, 2- valine, 3- (CH2)n lipids, 4- lactate, 5- alanine, 
6- CH2CH2CO lipids, 7- CH2CH2CH= lipids, 8- CH2CH= lipids, 9- N-acetyl glycoproteins, 10- 
acetone superimposed on CH2CO lipids, 11- =CHCH2CH= lipids, 12- N(CH3)3 choline of PL, 13- 
glucose, 14- urea, 15- histidine, 16- tyrosine. *: cut off spectral region corresponding to water. 
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Multivariate analysis of standard and diffusion-edited spectra produced models with 
no trends between controls and pre-PROM. PLS-DA of full resolution CPMG 1H NMR 
spectra produced a poor model with low predictive power and robustness (Q2 0.1, CR 
71%, sens. 58%, spec. 81%). After variable selection, an improved model was 
obtained (Figure 8.5) (Q2 0.5, CR 82%, sens. 73%, spec. 89%) with a separation trend 
between the two groups although with 8 pre-PROM samples overlapped with controls, 
thus justifying the low sensitivity.  Loadings inspection and spectral integration unveiled 
four statistical significant alterations (p < 0.05) and ten qualitative changes in plasma 
resonances of pre-PROM compared to controls, as listed in Table 8.2.  
   
 
 
Figure 8.5. a) PLS-DA scores scatter plot (left) and Volcano plots (effect size vs. – Log (p-
value)) (right) and b) Q
2
 distributions (left) and ROC plots (right) of true and permuted models 
obtained for plasma CPMG 
1
H NMR spectra of a) controls (, n=47) vs. pre-PROM (, n=37) 
(R
2
X 0.26, R
2
Y 0.62). Act: acetone, Pyr:pyruvate and 3-letter code for amino acids. 
 
Significant alterations included a small increase in CH3 lipids (total), N-acetyl 
glycoproteins and acetone, and decrease in an unknown resonance at  3.98-4.04 
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possibly arising from H resonances of amino acids. Qualitative changes included 
several lipidic resonances ((CH2)n, CH2CH2CO, CH2CH=, CH2CO, =CHCH2CH= and 
N(CH3)3 choline), glycine and urea. 
Table 8.2. List of metabolites/resonances selected in the 
1
H CPMG NMR spectra of blood 
plasma as important for discrimination of pre-PROM from controls. 
a
 Chemical shifts of signals 
used for integration; s: singlet, d: doublet, m: multiplet, br: broad. 
b
 E.S.: effect size determined 
as described in (Berben et al., 2012). 
c
 95% significance level (p-value < 0.05); only values with 
statistical relevance are specified. 
Compound 
Chemical 
shift (ppm) 
a
 
Pre-PROM (n=36) vs. controls (n=49) 
E.S. 
b
 p-value 
c
 
CH3 lipids  0.66-0.91 (br)  0.51  0.44 3.09×10
-2
 
Valine 1.03 (d)  > 0.05 
(CH2)n lipids  1.21-1.29 (br)  > 0.05 
CH2CH2CO lipids 1.52-1.62 (br)  > 0.05 
CH2CH= lipids 1.93-2.02 (br)  > 0.05 
N-acetyl glycoproteins 2.03 (s)  0.58  0.44 1.34×10
-2
 
Acetone 2.22 (s)  0.53  0.44 2.93×10
-2
 
CH2CO lipids 2.18-2.23 (br)  > 0.05 
Pyruvate 2.36 (s)  > 0.05 
=CHCH2CH= lipids 2.70-2.83 (br)  > 0.05 
N(CH3)3 choline  3.18-3.21 (br)  > 0.05 
Glycine 3.55 (s)  > 0.05 
Unknown 3.98-4.04 (m)   -0.72  0.44 2.54×10
-3
 
Urea 5.77 (br)  > 0.05 
 
Finally, when recalculating the CPMG PLS-DA model using the integral values 
found to change significantly (p < 0.05), no robust PLS-DA group separation was 
obtained indicating that the full resolution spectra is important for pre-PROM 
discrimination. Besides, the altered metabolic profile found for pre-PROM is very weak 
but any impact is surprising due to the large time between collection and PROM event. 
Thus, the results found in this work really need confirmation in larger cohorts. 
 
8.2.2. Proposed metabolic interpretation of plasma changes 
The impact of pre-PROM on 2nd T maternal plasma metabolome was firstly study 
considering a lower sample cohort (20 controls and 18 pre-PROM) unveiling only faint 
alterations in some samples for acetate, glutamine, citrate and albumin (Diaz and Pinto 
et al., 2011). Considering the larger cohort presented here, none of the previously 
observed alterations were confirmed. Results obtained included relevant changes in N-
acetyl glycoproteins, acetone and unknown resonance at  3.98-4.04, along with 
qualitative changes in several lipidic resonances, valine, pyruvate, glycine and urea. A 
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higher level of N-acetyl glycoproteins possibly suggests an increased biosynthesis of 
these proteins seen here for the first time to our knowledge. Indeed, the fetal 
membrane weakening involved in PROM event has been related with biochemical 
p  cesses   clud  g deg  d       f memb   e’s c ll ge  w  h   v lveme    f 
proteolytic enzymes (Moore et al., 2006).  For 2nd T amniotic fluid, a possible increase 
of proteins was found for pre-PROM by MIR (Graça et al., 2013), whilst for maternal 
urine no alterations were observed in NMR metabolic profile. Regarding the significant 
decrease of the unknown resonance at  3.98-4.04 (possible arising from amino acid 
H resonances) and the increase in acetone, no possible metabolic interpretation may 
be advanced at this stage. Qualitative alterations suggest subtle alterations in lipid 
metabolism, amino acid catabolism (glycine, valine and pyruvate) and urea cycle. 
These results showed an apparently specific metabolic signature of 2nd T maternal 
plasma possible useful for prediction of PROM cases 19-24 g.w. before diagnosis. The 
complementary use of more sensitive techniques and proteomic approaches could 
provide more knowledge about the small alterations detected here. 
 
8.3. Pre-diagnostic preterm delivery and preeclampsia  
The work presented in this subchapter shows the results obtained for plasma 
phospholipid profile of pre-diagnostic preterm delivery and preeclampsia by HILIC-
LC/MS. Regarding NMR plasma metabolome, no separation trends were obtained for 
pre-diagnostic preterm delivery (n=16) while for preeclampsia the number of samples 
(n=4) was insufficient for multivariate analysis. The metabolic alterations obtained for 
these disorders through phospholipid profiling by HILIC-LC/MS were published as a 
short communication with reference: Pinto, J.; Maciel, E.; Melo, T. S.; Domingues, M. 
R. M.; Galhano, E.; Pita, C.; Almeida, M. do C.; Carreira, I. M.; Gil, A. M. Maternal 
Plasma Phospholipids Are Altered in Trisomy 21 Cases and prior to Preeclampsia and 
Preterm Outcomes. Rapid Communications in Mass Spectrometry 2014, 28, 1635–
1638. The results concerning the T21 group were described before in Chapter 6 
(section 6.2), and here only the results obtained for pre-diagnostic preterm delivery and 
preeclampsia will be presented. Samples metadata can be found in Chapter 2 (Table 
2.6). 
Abstract 
Rationale: To search for changes in phospholipids in 2nd T maternal plasma, in 
connection to pre-diagnostic preterm and preeclampsia, aiming at finding predictive 
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markers of these conditions. Methods: Plasma was collected from pregnant women at 
16-19 g.w. defining three groups: controls (n=14), pre-diagnostic preterm delivery (n=5) 
and pre-diagnostic preeclampsia (n=4). The PL extracts of the pooled samples were 
analysed by hydrophilic interaction liquid chromatography mass spectrometry (HILIC-
LC/MS) and subsequent multivariate and univariate analysis. Results: A measurable 
impact on maternal PL was noted for pre-diagnostic preterm and preeclampsia. Pre-
diagnostic preterm samples comprised changes in unsaturated PC and a PC oxidation 
product, possibly due to non-enzymatic oxidative processes. PL sensitivity to pre-
diagnostic preeclampsia was confirmed by a newly observed LPC changes (common 
to T21, possibly reflecting a common oxidative mechanism) and specific changes in a 
PE and an ether-linked PC. Conclusions: Results indicated that maternal PL 
metabolism is exquisitely sensitive to pre-diagnostic preterm and preeclampsia. The 
apparent specificity of PL profiles enables future uses for predictive diagnosis to be 
envisaged, for improved prenatal health management. 
 
Brief state of the art 
Lipid changes are known to accompany the onset and evolution of many diseases. 
In pregnancy, maternal blood lipids naturally undergo extensive changes and their 
deregulation has been associated with some prenatal disorders. For preeclampsia for 
instance, changes have been noted in the levels of TG and specific PL, both at 
diagnosis and at pre-diagnostic stages (10-20 g.w.) (Wiznitzer et al., 2009; Kenny et 
al., 2010; De Oliveira et al., 2012; Gallos et al., 2013). Furthermore, increased risk of 
spontaneous preterm birth has been suggested for women with high total cholesterol, 
LDL-cholesterol and TG (Mudd et al., 2012), whereas altered levels of glycerolipids, 
PL, sterol lipids and sphingolipids have been found in pregnancies with poor outcomes 
(stillbirth, preterm, small for gestational age) (Heazell et al., 2012). Preeclampsia and 
preterm usually pose significant risks in pregnancy and, hence, the discovery of 
predictive biomarkers at the pre-diagnostic stages could be of great usefulness in 
prenatal health management.  
 
8.3.1. Phospholipid profiling of pre-diagnostic preterm delivery and 
preeclampsia by HILIC-LC/MS 
Typical positive-ion HILIC-LC/MS records of pooled 2nd T control plasma showed 
peaks characteristic of different PL classes at average RT 9.5–10.8 min (PE), 29.5–
32.4 min (PC), 34.0–35.9 min (SM) and 38.5–39.8 min (LPC), as shown previously in 
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Figure 6.6 (Chapter 6). When visually comparing the corresponding MS records 
obtained for control and disease pools (see Figure 8.6, for PC species), only small 
changes were suggested for the pre-diagnostic stages of preterm and preeclampsia 
(arrows in Figure 1a, middle and bottom). A more objective analysis of such complex 
datasets requires the use of multivariate analysis, used here to probe for changes to be 
further confirmed rather than for classification (due to the low sample numbers).  
 
Figure 8.6. a) MS record of PC TIC region (average RT 29.5 – 32.4 min) of pooled plasma 
samples of pregnant women: healthy throughout pregnancy (control), pre-PTD and pre-PEC. * 
solvent impurity. 
Preliminary PLS-DA (not shown) indicated that each disorder separated from each 
other (reflecting PL profile specificity) and from controls. Pair-wise PLS-DA (Figure 8.7) 
produced preliminary models for pre-diagnostic preterm (Q2 0.70, Figure 8.7a) and 
preeclampsia (Q2 0.82, Figure 8.7b). For these disorders, the challenge to find PL 
markers is raised due to the absence of clinical symptoms, at collection. Loadings 
(Figure 8.7a and b) inspection revealed lesser numbers of changing features compared 
to T21 (in Chapter 6, section 6.2). In pre-diagnostic preterm plasma, out of a total of 23 
features with VIP  1 and p < 0.05, 4 PCs and the m/z 842.3 unknown were 
significantly decreased, along with an increased oxidation product: 1-palmitoyl-2-(9-
oxo-nonanoyl)-sn-glycero-3-phosphocholine (PONPC) (Table 8.3, Figure 8.7c left). For 
pre-diagnostic preeclampsia, decreases were observed for PE(O-36:4) and 4 LPCs (in 
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common with T21 samples), along with increases in PC(O-40:2) and/or PC(40:9) 
(Table 8.3, Figure 8.7c right).  
 
 
  
  
  
Figure 8.7. PLS-DA scores and loadings plot of pooled plasma samples of a) controls vs. pre-
diagnostic preterm and b) controls vs. pre-diagnostic preeclampsia; c) bar plots of normalized 
ion area of selected PL for controls vs. pre-diagnostic preterm and vs. pre-diagnostic 
preeclampsia. PONPC: 1-Palmitoyl-2-(9-oxo-nonanoyl)-sn-glycero-3-phosphocholine (short 
chain oxidation product of PC(16:0/18:2). 
 
a) 
b) 
c) 
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Table 8.3. List of PL species varying most significantly between pre-PTD vs. control and pre-
PEC vs. control samples. Abbreviations: m/z: mass-to-charge ratio; RT: retention time; VIP: 
variable importance to projection, PONPC: 1-Palmitoyl-2-(9-oxo-nonanoyl)-sn-glycero-3-
phosphocholine (short chain oxidation product of PC(16:0/18:2)). *unknown compound, 
†
 signal 
observed in more than one disorder (unspecific). 
Disease  m/z 
RT 
(min) 
Identification VIP[1] 
p-value 
(<0.05) 
Relative 
variation (%) 
Effect size 
P
re
-p
re
te
rm
 650.4 34.4 PONPC 2.35 2.9×10
-3
 78.5 ± 10.8 2.84 ± 0.84 
842.3 30.9 Unknown * 
†
 1.85 2.5×10
-2
 -80.3 ± 27.8 -1.72 ± 0.70 
756.5 31.2 PC(34:3) 1.80 2.0×10
-3
 -24.5 ± 5.8 -1.61 ± 0.69 
784.5 30.8 PC(36:3) 1.71 3.2×10
-3
 -20.1 ± 5.0 -1.50 ± 0.68 
754.5 31.6 PC(34:4) 1.69 3.8×10
-3
 -54.5 ± 15.5 -1.47 ± 0.68 
730.5 31.7 PC(32:2) 1.68 6.4×10
-3
 -37.0 ± 10.7 -1.46 ± 0.68 
P
re
-
p
re
e
c
la
m
p
s
ia
 726.4 9.8 PE(O-36:4) 2.52 1.82×10
-2
 -54.0 ± 19.2 -2.50 ± 0.80 
522.4 39.1 LPC(18:1) 
†
 2.20 3.26×10
-3
 -37.3 ± 9.1 -1.81 ± 0.71 
520.4 39.4 LPC(18:2) 
†
 2.19 6.77×10
-3
 -32.8 ± 8.4 -1.80 ± 0.71 
544.4 38.5 LPC(20:4) 
†
 2.09 1.45×10
-2
 -40.7 ± 11.9 -1.67 ± 0.70 
828.5 30.0 PC(O-40:2) (and PC(40:9)) 2.05 8.47×10
-3
 32.0 ± 7.6 1.61 ± 0.69 
542.3 39.3 LPC(20:5) 
†
 2.04 7.69×10
-3
 -34.9 ± 9.8 -1.60 ± 0.69 
 
 
8.3.2. Proposed metabolic interpretation of phospholipid changes 
Our results show, for the first time, that the impact on maternal PL is much 
diminished for the pre-diagnostic stages of preterm and preeclampsia. For pre-
diagnostic preterm, unsaturated PC seem particularly affected (decreased), probably 
due to their high susceptibility to oxidation. The concomitant increase in PONPC, an 
oxidation product of PC(16:0/18:2), the most abundant PC (m/z 758.5 in Figure 8.6), 
further supports the hypothesis that enhanced oxidation (most probably via a radical 
mechanism (Levitan et al., 2010)) seems also related to a PTD outcome. However, the 
absence of LPC variations suggests that radical non-enzymatic oxidation may take 
place, rather than an enzymatic mechanism. Finally, PL sensitivity to pre-diagnostic 
preeclampsia is confirmed by a number of LPC changes common to T21 (Chapter 6, 
section 6.2) (possibly reflecting a common oxidative mechanism, a condition suggested 
before for preeclampsia (Genc et al., 2011)), with specific changes in PE(O-36:4) and 
an ether-linked PC. Again, although LPC with saturated fatty acyl chains were detected 
within the plasma lipidome (Figure 8.8), the LPC species that showed significant 
variations between controls and pre-preeclampsia were those bearing unsaturated PC. 
LPC comprising unsaturated fatty acyl chains may probably arise from the action of 
phospholipase A1 or to oxidative cleavage by metal-catalyzed radical oxidation.  
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Figure 8.8. MS record of LPC TIC region (average RT 38.5–39.8 min) of pooled plasma 
samples of pregnant women: healthy throughout pregnancy (control), pre-PTD and pre-PEC. 
 
These results indicated that maternal PL metabolism is exquisitely sensitive to the 
pre-diagnostic stages of preterm and preeclampsia, although consideration of larger 
cohorts is necessary for adequate statistical validation to be carried out. The PL marker 
profiles observed seem specific enough to enable future uses as predictive diagnosis 
of preterm and preeclampsia to be envisaged, for improved prenatal health 
management. 
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The work presented in this thesis represents a contribution to the study of 1st and 
2nd T maternal plasma metabolome and lipidome in order to obtain insight into the 
biochemistry and pathophysiological alterations occurring in healthy pregnancies and 
prenatal disorders, mainly using NMR spectroscopy but also MS in selected instances. 
Since the fundamental role of blood is to maintain body homeostasis, even the smaller 
alterations found in this work may be of central importance to clinical biochemistry.   
Firstly, the human plasma metabolome was characterized by 1D and 2D NMR 
spectroscopy enabling the identification of 31 low Mw metabolites (including 1,5-
anhydroglucitol, here detected for the first time to our knowledge) in addition to lipids 
and proteins (albumin and N-acetyl glycoproteins). The characterization of plasma 
lipidome by NMR spectroscopy has been less explored in literature, and here the 
assignment of plasma lipid extracts by 1D and 2D NMR enabled the identification of 
four distinct unsaturated fatty acids, total saturated fatty acids, free cholesterol, 
esterified cholesterol, total phospholipids, phosphatidylcholines, sphingomyelins and 
triglycerides, confirming previous reports. Furthermore, STOCSY analysis gave 
additional information mainly in the identification of different CH3 environments arising 
from distinct unsaturated FA. MQ NMR spectroscopy was explored in this work for 
assignment of complex lipid mixtures for the first time to our knowledge. This technique 
showed simpler spectral profiles than single quantum 2D NMR experiments, however 
the molecules elected to test this methodology showed a similar fingerprint with high 
overlap of protons from fatty acyl chain and from cholesterol part of EC in the aliphatic 
region. The application of MQ to plasma lipid extracts unveiled a similar profile when 
compared to the lipid mixture. In future, the combination of MQ with diffusion ordered 
spectroscopy (DOSY) may allow the discrimination of similar lipid molecules by 
separation of the MQ fingerprint as a consequence of molecular size.  
The identification of the effects of handling and storage conditions on plasma NMR 
metabolome was of paramount importance for the proposed metabolic profiling studies 
of healthy pregnancy and prenatal disorders. EDTA and heparin tubes seem equally 
suitable for plasma collection for NMR analysis, however EDTA signals overlap with 
some resonances that are not easily studied in other spectral regions (choline 
containing compounds PC, LPC and SM). Room temperature stability studies showed 
that plasma samples should not be kept at room temperature for  2.5 hours, since 
metabolic changes alter the plasma composition, particularly in relation to lipoprotein 
profile. Short term (up to 1 month) storage stability revealed that plasma samples can 
be stored at -20ºC up to 7 days, but for longer periods they should be stored at -80ºC. 
Long term storage at -80ºC showed almost negligible alterations up to 30 months with 
only a small increase in cholesterol having been noted after 20 months storage. The 
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effects of up to 5 freeze-thaw cycles were found to be strongly sample-dependent with 
most alterations seen to take place upon cycle 4 and thereafter, hence no more than 3 
freeze-thaw cycles are recommended. Finally, the particular non-fasting conditions 
characterizing samples collection for the pregnant women in this work (2 hours after 
ingestion of uncontrolled breakfast) were evaluated in a group of healthy non-pregnant 
women, showing that non-fasting conditions do not affect the overall metabolic 
characteristics of the sample group. 
The second study aimed at defining and characterizing the metabolic adaptations 
reflected in plasma metabolome throughout healthy pregnancies, constituting an 
important step towards the identification of disease-related deviations in subsequent 
studies. Results showed the expected decrease in circulating amino acids early in 
pregnancy, suggesting a larger requirement by the fetus. Newly observed changes 
included early adjustments in energy and gut microflora metabolisms. In addition, 
alterations in glomerular filtration rate were observed, along with HDL and LDL+VLDL 
increases throughout pregnancy in different extents and accompanied by increases in 
fatty acid chain length and degree of unsaturation. Plasma and urine metabolite 
correlation studies provided further understanding of healthy pregnancy metabolism, 
namely unveiling specific lipoprotein/protein plasma metabolic correlations with 
excreted metabolites.    
NMR metabolomics of 1st and 2nd trimester maternal plasma of a general CD group 
and a T21 subgroup, compared to controls, showed additional information 
accompanying these disorders. A different plasma metabolic profile of CD and T21 was 
observed in the 2nd trimester compared to 1st, suggesting a dynamic metabolic 
evolution in CD cases. The metabolic pattern of enhanced -oxidation observed 
previously in the 1st trimester was maintained in the 2nd trimester, novel changes 
including abnormalities in plasma lipoprotein profile and its involvement in -oxidation, 
along with possible changes in fetal renal function. Additionally, plasma lipid extracts 
gave valuable insight into the mediation of anti-inflammatory and pro-inflammatory 
processes indicating a more significant response to inflammation for 2nd trimester T21 
cases. Plasma/urine correlation studies confirmed main changes previously noted for 
each biofluid, unveiling possible relationships relating to plasma creatine and lipids 
(particularly LDL+VLDL); excreted ketone bodies and acetate/formate; allantoin and 
sugar metabolism; and gut microflora metabolites. Furthermore, HILIC-LC/MS analysis 
of phospholipid extracts of 2nd trimester T21 cases showed alterations in levels of LPC, 
ether-linked PC and PE consistent with a possible oxidative stress accompanying T21. 
These results demonstrate the potential of plasma metabolomics in monitoring and 
characterizing CD and T21 cases, however, validation in larger cohorts and 
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demonstration of putative biochemical hypothesis are required before clinical 
applications may be envisaged. In addition, the metabolic signatures of T18 and T13 
require investigation in order to define a specific metabolic signature capable to 
discriminate each trisomy type. 
The possible application of NMR plasma metabolomics for GDM management was 
investigated considering 2nd trimester maternal plasma and corresponding lipid extracts 
obtained for a group of pregnant women without clinical signs but who later developed 
GDM (pre-diagnosis group) and a group of pregnant women at the time of GDM 
diagnosis (post-diagnosis group), in comparison to controls. Plasma and lipid extracts 
displayed comparable classification performance, the former enabling direct and more 
rapid analysis. Metabolic variations detectable in pre-diagnosis GDM included an 
increase in free and/or esterified cholesterol in plasma, accompanied by smaller 
increases in plasma HDL, LDL+VLDL lipoproteins, and changes in FA (e.g., 18:2 and 
20:4) and TG levels viewed through lipid extracts. Novel alterations were observed for 
glucose (small increase), some glycolytic and TCA cycle metabolites, along with a 
possible deregulation of gut microflora, homocysteine-methionine conversion and urea 
cycle. Many of the changes observed in the pre-diagnosis GDM were intensified at the 
time of diagnosis, whereas new variations were noted for some small metabolites. In 
addition, for post-diagnosis GDM, PLS regression identified metabolites with higher 
dependence of normal gestational age evolution whose were also compared with the 
metabolic trajectory previously defined for healthy pregnancies. After exclusion of 
plasma metabolic changes with a possible contribution of gestational age, a robust 
profile of 26 resonances may be used to discriminate GDM. This work advances the 
possibility of predicting GDM with basis on the full resolution NMR spectra of plasma 
and using a multi-metabolite biomarker of GDM as a complementary tool in the clinical 
management of the disease. In future studies, the putative metabolic disturbances 
hereby suggested to relate to pre- and post-diagnosis GDM may be demonstrated in 
larger cohorts of distinct ethnicities and by complementary biochemical methods.  
Prenatal disorders with less impact on 2nd T maternal plasma metabolome included 
FM and pre-diagnosis PROM, preterm delivery and preeclampsia. Metabolic alterations 
found for maternal plasma of pregnant women carrying malformed fetuses were 
consistent with a previous report with some novel alterations found, namely LDL+VLDL 
lipid composition, some low Mw metabolites and albumin. Overall these changes 
suggested increased -oxidation of fatty acids, depletion of phospholipids in 
LDL+VLDL particles, enhanced glycolysis and protein biosynthesis and possible 
alterations in urea cycle and gut microflora. CNS malformations showed a distinct 
metabolic profile when compared to other FM types suggesting enhanced glycerolipid 
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metabolism, decreased N-acetyl glycoproteins metabolism and a possible lower 
contribution of CNS for the -oxidation, enhanced glycolysis and urea cycle alterations 
found for general FM cases.  
The possibility of predicting the occurrence of PROM, occurring after 37th g.w., was 
attempted 19-24 g.w. before PROM diagnosis by NMR metabolomics. This unveiled a 
specific metabolic signature characterized by an increased biosynthesis of N-acetyl 
glycoproteins, along with subtle alterations in lipid profile, amino acid catabolism and 
urea cycle. Despite some detected alterations, any impact of this disorder on plasma 
profile is surprising due to the large time (19-24 g.w.) between sample collection and 
PROM event. Thus, the results obtained really need confirmation in larger cohorts. 
NMR metabolomics of pre-diagnostic preterm delivery unveiled no impact of this 
disorder on plasma metabolome detectable by NMR, while for preeclampsia, an 
insuffient number of samples was available. The HILIC-LC/MS phospholipid profile of 
2nd T maternal plasma showed apparent specific alterations for prediction of preterm 
delivery and preeclampsia. Pre-diagnostic preterm delivery showed alterations in 
unsaturated PC and a PC oxidation product, possible due to non-enzymatic oxidative 
processes, while phospholipid sensitivity was confirmed for pre-diagnostic 
preeclampsia by changes in LPC (common to T21, possibly reflecting a common 
oxidative mechanism) and novel changes in PE and an ether-linked PC. These results 
indicated that 2nd T maternal plasma is sensitive to FM and pre-diagnosis PROM by 
NMR, and to preterm delivery and preeclampsia by HILIC-LC/MS profiling of 
phospholipids. The apparent specificity of metabolic profiles requires further 
investigation in larger cohorts before future use for complementary or predictive 
diagnosis may be advanced.  
 
The results presented in this thesis give new insights into the development of new 
prenatal diagnosis and prognosis methods through maternal plasma metabolome. 
Future work will entail the study of other important prenatal disorders, not studied in 
this work due the low number of samples available, namely IUGR, SGA and 
macrosomia. Furthermore, larger cohorts and samples from different ethnicities will be 
required to confirm the changes found in this work, especially for the most serious 
disorders namely trissomies, and prediction of GDM, preeclampsia and preterm 
delivery. Another future work of paramount importance includes external validation by 
classification of new samples using the previously developed MVA models in order to 
advance a possible clinical application of maternal plasma biomarkers. Finally, the 
search for potential biomarkers for diagnosis and prediction of prenatal disorders will 
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necessarily entail blood samples collected early, in the 1st trimester, in order to more 
significantly reduce the adverse risks caused to mother and fetus. 
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Annex: Informed consents and questionnaires used in this study 
 
Figure A.1. Informed consent given to pregnant women before sample collection at the time of 
amniocentesis. 
 212 
 Figure A.1. Informed consent given to pregnant women before sample collection at each 
pregnancy trimester. 
